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1 INTRODUCTION 
As the initial focus, to modify livestock for agricultural purpose, such as growth 
performance, feed efficiency and body composition (Pursel, 1998), lactation 
performance (Zuelke, 1998), reproduction, disease resistance and immune 
responsiveness (Muller et al., 1998) does not meet the expectations, large animals 
came in a tighter focus for alternative areas. Especially the pig, due to indications 
like physique, the ability to standardize the environmental situation (housing, 
feeding, and sanitation standard), the well established reproductive technology 
and advanced techniques of genetic modification of the porcine genome, 
represents an ideal model organism for both, human diseases and 
xenotransplantation (Aigner et al., 2010). Several different technologies to 
produce transgenic animals, primarily developed in the mouse, such as pronuclear 
microinjection (PMI) (Gordon et al., 1980), sperm-mediated gene transfer 
(SMGT) (Lavitrano et al., 1989) or viral gene transfer (Jaenisch et al., 1976), 
were later on adapted to livestock (Brem et al., 1985; Hofmann et al., 2003; 
Kurome et al., 2006). In mice the main disadvantages arising from those methods, 
reported as random, partially multicopy integration of the transgene, insertional 
mutagenesis, positional effects, oncogene activation, low integration efficiencies 
or offspring mosaicism (Wheeler, 2003) have been partially bypassed with the 
establishment of murine embryonic stem cells (ESCs) (Evans et al., 1981; Martin, 
1981) and the development of strategies to genetically modify them (Kuehn et al., 
1987). In order to circumvent the lack of porcine ESCs, an alternative method, 
termed somatic cell nuclear transfer (SCNT), has become an indispensable tool to 
generate large animal models from genetically modified somatic cells (Campbell 
et al., 1996; Wilmut et al., 1997). Different strategies to engineer primary somatic 
donor cells by the introduction of DNA or RNA have been developed, achieved 
by viral or non-viral, in turn subdivided in physical and chemical methods 
(Kobayashi et al., 2005). Viral transgenesis is most frequently performed using 
retroviral, especially lentiviral, or adeno-associated viruses (AAV) (Park, 2007). 
Non-viral DNA delivery methods are grouped in chemical (Azzam et al., 2004) 
and physical (Magin-Lachmann et al., 2004) systems. The most common methods 
among them are reported to be lipofection (Felgner et al., 1987), electroporation 
(Neumann et al., 1982) and nucleofection (Martinet et al., 2003) as an advanced 
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method of electroporation. With SCNT the possibility to produce even tailored 
porcine animal models arose. Site directed mutagenesis is achieved by 
homologous recombination (HR) of constructed targeting vectors with the target 
locus. It is reported that the frequency of targeted HR events is much lower 
compared to random integrations of the vector construct throughout the genome in 
most mammalian cell lines, necessitating strategies to increase the frequency of 
HR events in somatic cell gene targeting (Wang et al., 2003). Several parameters 
obviously influence the frequency of HR events, such as a positive correlation of 
the efficiency with the increased length of the homologous regions of the targeting 
vector (Hasty et al., 1991; Deng et al., 1992), the need of an isogenic vector 
construction (te Riele et al., 1992) and locus dependency of the absolute targeting 
efficiency (Wang and Zhou, 2003). Additionally, enrichment of the targeted 
clones by positive and negative marker selection (Izant et al., 1985; Mansour et 
al., 1988), promoter- or polyadenylation-trap experiments or artificially 
introduced double strand breaks (DSB) by site-directed nucleases inducing repair 
mechanisms, can increase the targeting efficiency remarkably (Karreman, 1998).  
Different targeted porcine animal models, including a disease model for cystic 
fibrosis targeting the CFTR (cystic fibrosis transmembrane conductance regulator) 
gene (Rogers et al., 2008) and animals containing targeted deletion of the GGTA1 
(α-1,3-galactosyltransferase) gene, making them interesting as organ sources for 
the xenotransplantation research (Lai et al., 2002), have already been developed. 
The aim of this doctoral thesis is to demonstrate whether the establishment of two 
different porcine animal models (CFTR and GGTA1), utilizing the extended 
homologous regions provided by the respective bacterial artificial chromosome 
(BAC)-based targeting vectors to increase the targeting efficiency in primary 
porcine kidney cells as nuclear donor cells for SCNT, is feasible.  
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2 OVERVIEW OF LITERATURE 
2.1 Transgenic large animals 
2.1.1 Background 
Ever since domestic animals played an important role in maintaining human 
wellbeing, as they provide basic materials like food and clothing. As a matter of 
fact, one tried to improve phenotypical amenities by classical breeding, although 
these processes act very slowly and the alteration of many genes often happens in 
an unregulated manner (Laible et al., 2009). In farm animals originally a special 
focus lies on the optimization of production characteristics like growth 
performance, feed efficiency and body composition (Pursel, 1998), lactation 
performance (Zuelke, 1998), reproduction, disease resistance and immune 
responsiveness (Muller and Brem, 1998). The benefit of transgenic farm animals 
for their agricultural use is on the decline due to decreasing demand and 
insufficient implementation of scientific issues. In this context, one point of 
interest to improve the conversion of feed to body weight gain in comparison to 
sibling controls was examined by the generation of transgenic pigs, carrying 
structural genes for human or bovine growth hormone (hGH or bGH) ligated to a 
mouse metallothionein-I (MT) promoter, driven by the idea to mimic the mouse 
model, in which the introduction of a growth hormone gene markedly increased 
the growth rate and final size of the animals (Palmiter et al., 1982). Though, the 
resulting persistent excess of hGH and bGH led to health effects in modified pigs 
like lameness, lethargy, gastric ulcers and anestrous gilts (Pursel et al., 1990). 
Attempts to improve transgenic livestock resistance to viral infection were also 
not promising (Muller et al., 1992). Nowadays, the Western civilization aspires 
towards incomparable health awareness, opening an additional niche for 
transgenic farm animals bringing up the term ‘functional food’. Transgenic pigs 
were generated, which express a humanized Caenorhabditis elegans gene, fat-1, 
encoding an omega-3 (n-3) fatty acid desaturase. The hfat-1 transgenic pigs 
produce high levels of n-3 fatty acids, usually mainly contained in fish-oil, which 
are known to improve heart function and help to reduce the risks for heart disease 
(Dai et al., 2002).  
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Especially the pig is reflecting many beneficial properties used as large animal 
model for selected human diseases and as a source for donor organs in 
xenotransplantation (Platt, 1998; Bendixen et al., 2010). With its domestication, 
about 9000 years ago, accompanied by the rise of agriculture, the pig underwent 
rapid evolution all over the world through artificial phenotypical selection, as for 
example resulting in a decreased skeletal size (Giuffra et al., 2000). Due to the 
long history of the pig meeting agricultural demands also the sanitation standards, 
housing and feeding are well established to date. Its reproductive characteristics 
are favorable to other large animals reflecting a relatively short gestation period of 
around 114 days, an early sexual maturity with six to eight months of age and 
large litter sizes ranging from eight to twelve piglets. With the theoretical 
potential of three deliveries per year, also not depending on season, one single 
sow is able to produce 24-36 pigs per year, compared to two to four in general in 
sheep (Newman et al., 1995) and one to two in cattle (reviewed in Wolf et al., 
2000). Similarities in size, physiology, anatomy, metabolism, pathology, organ 
development and disease progression to human, even without any genetic 
alterations, make the pig an interesting model organism, being established in 
reasonable periods and with acceptable costs (Lunney, 2007). Furthermore, the 
ethical issues concerning a porcine model organism are not that critical, at least 
compared to primate animal models, keeping in mind that in 2010 almost 
59 million pigs were slaughtered for meat production in Germany, anticipating 
that these numbers are going to increase with every year (evaluated by 
Statistisches Bundesamt Deutschland, 2010). The importance of the pig as model 
organism was underlined in 2006, when the pig whole genome sequencing project 
has been launched and was initiated by the Swine Genome Sequencing 
Consortium (SGSC) (Archibald et al., 2010). Evidently, the porcine genome, 
comprised of 18 autosomes and 2 sex chromosomes, exhibits tight similarity in 
size and also complexity to the human genome. Unlimited access to a wide range 
of porcine genomic and expressed sequence tag (EST) sequences, extensive trait 
loci, linkage and physical maps, single nucleotide polymorphisms (SNPs) and 
expression data via GeneBank and other databases have been provided over the 
years (Chen et al., 2007). An additional benefit is the possibility to genetically 
modify the porcine genome quite effectively to reflect particular human diseases 
or enable xenotransplantation (reviewed in Aigner et al., 2010). Taken all those 
facts together led to the generation of several different porcine disease models, 
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including cardiovascular diseases (Hao et al., 2006), obesity or hypertension 
(Dyson et al., 2006), diabetes (Renner et al., 2010), alcoholism (Wallock-
Montelius et al., 2007), skin physiology (Simon et al., 2000), lipoprotein 
metabolism (Ginsberg et al., 1997), intestinal function (Domeneghini et al., 
2006), nutrition (Mitchell, 2007), injury and repair (Winter, 2006), 
neurodegenerative diseases (Uchida et al., 2001; Kragh et al., 2009), retinitis 
pigmentosa (Ross et al., 2012) and cystic fibrosis (Rogers et al., 2008; Klymiuk et 
al., 2011) and contributes to manifest the idea to swap pigs for non-human 
primates as donor animals in xenotransplantation (Klymiuk et al., 2010). In 
conclusion, its body composition, the possibility of the environmental 
standardization (housing, feeding, and sanitation standard), the well established 
reproductive technology and advanced techniques of genetic modification of the 
porcine genome combine prerequisites pointing the pig out as an ideal model 
organism for both, human diseases and xenotransplantation. 
2.1.2 General methods for the establishment of transgenic pigs 
One of the major advantages of pigs as animal models is the ability to modify the 
porcine genome by several different techniques of genetic engineering. In 1971 
Brackett and co-workers first were able to demonstrate that mammalian 
spermatozoa show an ability to act as shuttle vectors for foreign DNA, also 
described as sperm mediated gene transfer (SMGT) (Brackett et al., 1971). The 
technique was described with high efficiency in the mouse (Lavitrano et al., 
1989), subsequently successfully adapted for use in farm animals, such as for the 
generation of human decay accelerating factor (hDAF) transgenic pigs (Lavitrano 
et al., 1999), as well as pigs multitransgenic for three reporter genes: enhanced 
green and blue fluorescence protein (eGFP and eBFP) and red fluorescent protein 
(DsRed2) (Webster et al., 2005). Since the integration sites are unknown and the 
number of inserts may fluctuate between individual embryos and experiments 
(Habermann et al., 2007) up to now, SMGT cannot be considered as a routine and 
effective application to mammalian livestock species. Viral transgenesis aims at 
the introduction of foreign DNA into preimplantation embryos by using virus 
shuttles. Lentiviruses, as members of the family Retroviridae, are characterized by 
their ability to reversely transcribe their viral genome into double stranded DNA 
by an enzyme called reverse transcriptase and subsequently integrate it into the 
host genome as a so called provirus (Guo et al., 2008). This retroviral infection 
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method was first described to generate transgenic mice by Jaenisch and colleagues 
in 1976. The lentiviral gene transfer was successfully adapted using human 
immunodeficiency virus (HIV-1) based vectors (Hofmann et al., 2006) or an 
equine infectious anaemia virus (EIAV) (Whitelaw et al., 2004) vector to 
establish eGFP transgenic pigs. The major advantage of this method is the 
relatively low technical effort of presenting a virus to embryos in various 
developmental stages. In contrast, the application of this system may be 
influenced by its capacity limitation (< 10 kb DNA) (Pfeifer, 2004). Finally, in 
1980 Gordon and colleagues were able to show, that DNA injected into the 
pronuclei of single-cell embryos is incorporated, expressed and transmitted to the 
offspring of transgenic mice. (Gordon et al., 1980). The same method, also known 
as pronuclear microinjection (PMI) has been used to generate transgenic livestock 
(Brem and Springmann K, 1985; Hammer et al., 1985; Klose et al., 2005), mainly 
for agricultural and reproductive purpose (Galli et al., 2008). However, in this 
method the integration pattern is reported to be mosaic, the DNA integration 
efficiency is often very low (< 1%), making it also quite costly especially for large 
animal approaches, and the technique is restricted to additive gene transfer (Wolf 
et al., 2000). In mice, those disadvantages have been partially bypassed with the 
development of murine embryonic stem cells (ESCs) (Evans and Kaufman, 1981; 
Martin, 1981) and the establishment of strategies for their modification (Kuehn et 
al., 1987; Ramirez-Solis et al., 1995). Due to the lack of porcine ESCs, somatic 
cell nuclear transfer (SCNT) has become the leading tool for generating animals 
from genetically engineered somatic cells.  
2.1.3 Somatic cell nuclear transfer 
Initial nuclear transfer experiments using blastomeres of 16-cell-embryos as 
nuclear donors resulted in the generation of cloned sheep (Willadsen, 1986). In 
1996, Campbell and co-workers showed that an expansion of ovine embryonic 
cells before using them for nuclear transfer is possible in cell culture (Campbell et 
al., 1996). The first successful approach via SCNT using not only embryonic but 
adult somatic cells as nuclear donor cells was Dolly the sheep (Wilmut et al., 
1997), followed by many more species resulting in live birth with the most 
prominent among them like mice (Wakayama et al., 1998), cattle (Zakhartchenko 
et al., 1999), goats (Baguisi et al., 1999), pigs (Betthauser et al., 2000; Polejaeva 
et al., 2000) and rabbits (Challah-Jacques et al., 2003).  
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In brief, donor nuclei obtained from various tissues are transferred to the 
cytoplasm of a zygote or a metaphase II oocyte, from which its genetic material 
previously had been removed (reviewed in Wolf et al., 1998). After membrane 
fusion by an electric current and activation, either chemically or by an electric 
pulse, cells are allowed to reprogram using medium that arrests the cell cycle, and 
cultured in vitro (Niemann et al., 2003). This technology bears several 
advantageous characteristics, such as the possibility to pre-select donor cells 
concerning gender or transgene expression. Even a single cell can be expanded 
and used for SCNT. Additionally, the production of mosaic animals is out of the 
question, since a cloned transgenic animal originates from a single, stably 
transfected cell (Aigner et al., 2010). Though, only a small number of cloned 
embryos are able to develop normally as a result of unpredictable epigenetic 
reprogramming impacts (Hochedlinger et al., 2003). Initial nuclear transfer 
experiments were performed to clone animals by the use of embryonic or later of 
somatic cells, but to introduce modifications into the genome of the individual of 
interest, somatic primary cells have to be genetically engineered. This opens the 
opportunity to introduce a transgene of interest into a mature cell, by viral or non-
viral, in turn distinguishable between physical and chemical methods.   
2.1.3.1 Genetic engineering of primary somatic cells 
SCNT as a tool for the generation of transgenic animal models necessitates the 
genetic modification of the somatic primary donor cells through the introduction 
of DNA or RNA by different ways. Viral transgenesis mainly includes the use of 
retroviral vectors and adeno-associated viruses (AAV). So far, two types of 
retroviral vectors have been established to generate transgenic animals: prototypic 
retroviruses such as murine leukemia virus (MLV) and lentiviruses such as human 
immunodeficiency virus (HIV). One main difference between those two groups of 
retroviruses is the ability of the lentivirus genome to be directly transported to the 
nucleus, enabling the transduction of non-dividing cells as well. They offer a large 
spectrum of different host cells to be infected at different cycle stages, 
subsequently used for the generation of transgenic animals (Lois et al., 2002; 
Pfeifer et al., 2002). Also transgenic pigs could be generated with high efficiency 
by lentiviral vectors (Hofmann et al., 2003; Whitelaw et al., 2004). AAVs, 
described as single stranded DNA viruses, enable site-directed mutagenesis of the 
host genome. It was reported that adeno-associated virus-mediated gene targeting 
Overview of Literature     8 
has been used to deliver targeting vectors to cell lines and primary cells (Inoue et 
al., 1999; Porteus et al., 2003). Up to now porcine disease models for cystic 
fibrosis were generated by Rogers and co-workers using AAVs in concert with 
SCNT (Rogers et al., 2008). Viral vectors represent a powerful transduction tool, 
but also exhibit several drawbacks such as their immunogenicity, oncogenic 
properties, vector inactivation and the need for a relatively large-scale 
environment for their production, which leads to additional expenditure for the 
improvement of non-viral gene transfer systems. 
Non-viral DNA delivery methods are subdivided in chemical systems, such as 
lipofection, calcium phosphate precipitation, cationic polymers or molecular 
conjugates (Azzam and Domb, 2004; Kulkarni et al., 2006) and physical systems, 
such as gene guns, also known as particle bombardment technique, 
microinjection, electroporation, sonoporation, laser assisted delivery and 
magnetofection, (Magin-Lachmann et al., 2004; Andre et al., 2010). Out of these 
two groups, lipofection and electroporation are the most common techniques used 
for the transfection of primary cells. In the late 1970s the possibility of a passive 
encapsulation of DNA into liposomes, preventing its degradation by plasma 
nucleases, was reported (Hoffman et al., 1978). Felgner and colleagues described 
the use of cationic liposomes as efficient carriers for intracellular DNA delivery, 
in which the transfection is mediated by a spontaneous electrostatic interaction 
between the liposome (positive) and the DNA (negative), resulting in an efficient 
condensation of the nucleic acids. The liposome/DNA complex (net positive 
charge) associates with the cell surface (negative charge). Fusogenic properties, 
accumulated during cationic liposome formulation, enable fusion and/or 
destabilization of the plasma membrane, alleviating the intracellular release of the 
complexed DNA (Felgner et al., 1987). Advantages of lipofection over viral 
transduction are simplicity of production, low toxicity and low immunogenicity 
(Iversen et al., 2005). Electroporation means the reversible permeabilization of 
the cell membrane to exogenous DNA in the surrounding media by an exposure of 
the cell to an electrical field, increasing the efficacy of gene transfer with 
proliferating cells. Adherent cells have to be detached from their substratum, 
resulting in unwanted physiological effects undermining cell viability (Neumann 
et al., 1982). Nucleofection, as advancement of the physical electroporation, is 
favorable for the transfection of primary cells and mammalian cells, so far 
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considered to be difficult or even impossible to transfect, due to the fact that the 
substrate is transferred directly into the nucleus, independent from cell division 
accompanied by nuclear envelope breakdown (Hamm et al., 2002; Maasho et al., 
2004). It represents a combination of electrical parameters with cell type specific 
reagents. Optimal nucleofection conditions are not depending on the transfected 
substrate but on the cell type to be transfected. This means, as a main advantage, 
that identical conditions are used for the nucleofection of DNA including BACs, 
RNA, siRNAs or other biologically active molecules (Maurisse et al., 2010). 
Comparing the efficiencies of those non-viral DNA delivery methods, of course 
also depending on cell-type and transfection conditions, stated nucleofection prior 
to electroporation, followed by lipofection. Nevertheless, cytotoxicity is reported 
to be higher with nucleofection compared to lipofection (Yanez et al., 1999; 
Iversen et al., 2005; Jacobsen et al., 2006).  
2.1.3.2 Type of modification 
The development of SCNT and the different possibilities of introducing DNA into 
primary cells or preimplantation embryos push the generation of large animal 
models. The objective of transgenic technology to generate animals exhibiting 
stable integration of foreign DNA in their germline is achieved, depending on the 
requirements, by additive or targeted gene transfer. Mice produced by injection of 
retroviral Simian virus 40 (SV40) DNA were the first animals carrying 
experimentally inserted genes, although germline transmission, later on shown by 
transduction of mouse embryos with a Moloney leukemia virus (Jaenisch, 1976) 
was not achieved with this mouse model (Jaenisch et al., 1974). Viral transduction 
was also adapted for the production of transgenic pigs (Hofmann et al., 2003; 
Whitelaw et al., 2004), although the first transgenic pigs were produced by PMI 
(Brem and Springmann K, 1985; Hammer et al., 1985). In general, the efficiency 
of PMI is very low, also accompanied by effects of random integration, such as 
insertional inactivation, varying expression levels due to positional effects or 
mosaicism of the founder (reviewed in Wolf et al., 2000). By then, genetic 
modification of domestic animals depend on coincidental events for incorporating 
exogenous DNA randomly into the genome regarding both, number of integrated 
copies and location of their integration. Therefore, it is not possible to accurately 
predict the phenotype of the resulting animals, nor a specific inactivation or 
modification of genes is feasible (Piedrahita et al., 1999). In 1985, the first 
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‘planned’ modification of the human β-globin gene in murine erythroleukemia 
cells was achieved (Smithies et al., 1985). Since then, the most examples for 
targeted modifications of the genome represent an inactivation of specific genes. 
New findings like selectable markers, enrichment protocols and site-directed 
recombination systems open a broad range of modification possibilities for 
specific genes, starting with single base-pair substitutions, conditional and tissue-
specific inactivation and gene replacement (Cohen-Tannoudji et al., 1998). The 
site-directed modification of animal genomes is accomplished either by 
homologous recombination (HR) events or by non-homologous end joining 
(NHEJ) using site-directed nucleases (Zinc finger nucleases; ZFNs and 
transcription activator-like effector nucleases; TALENs) as a tool for the 
introduction of double-strand breaks (DSBs). In general, HR can be described as a 
fundamental, regenerative process within living organisms, mostly occurring very 
rare, requiring a complex set of reactions and extensive homology. HR usually 
occurs in mammals during the meiotic cleavage of germ cells or can be described 
as a process driven by the attempt of the endogenous DNA repair machinery to 
mend DSBs. Furthermore, this mechanism opens the possibility to introduce 
defined modifications (replacements or deletions) into the genome (Ellis et al., 
1989; Court et al., 2002). The regions of homology, necessary for HR, are DNA 
stretches shared by the two molecules supposed to recombine. Those regions are 
freely selectable, making it possible to specifically alter any position on a target 
molecule (Muyrers et al., 1999). For the most cells an up to 1000-fold higher 
frequency of random (nonhomologous) integrations, mediated by NHEJ occurs 
(Merrihew et al., 1996; Sargent et al., 1997). Therefore, several strategies to 
improve the ratio of targeted integrants compared to random integrants came in a 
tighter focus. 
2.2 Increasing the targeting efficiency: vectors for gene 
targeting 
The introduction of defined mutations necessitates the construction of targeting 
vectors, containing the engineered DNA, as well as DNA sequences up- and 
downstream of the modification cassette homologous to the target locus. Those 
stretches of homology enable the tailored integration of the vector construct into 
the locus of interest by HR. Nevertheless, the frequency of targeted HR events is 
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much lower compared to random integrations of the vector construct throughout 
the genome in most mammalian cell lines (beyond mouse ESCs), which can 
necessitate screening thousands of clones representing a very time- and cost-
intensive method to find a biallelic targeted gene knock-out (Colosimo et al., 
2000; Vasquez et al., 2001). Accumulated evidence indicates that mouse 
embryonic stem cells exhibit a higher recombinogenic potential compared to 
somatic cells, whereas the absolute targeting efficiency in mESCs varies from 
1 x 10
-5
 to 1 x 10
-6
 per electroporated cell compared to a two orders of magnitude 
lower frequency in somatic cells, for example 2.8 x 10
-7
 to 2.75 x 10
-7
 in sheep 
(Denning et al., 2001). Apparently, this makes it important to trace strategies to 
increase the frequency of HR events in somatic cell gene targeting (Wang and 
Zhou, 2003). Comparing experiences using mouse embryonic stem cells for gene 
targeting emerged several parameters influencing the frequency of HR events. It 
was stated that an increase of the HR frequency is correlated with the length of the 
homologous regions of the used targeting vector, mediated by the use of large 
vector vehicles, such as yeast artificial chromosomes (YACs), P1 artificial 
chromosomes (PACs) or bacterial artificial chromosomes (BACs) (Hasty et al., 
1991; Deng and Capecchi, 1992). Base pair heterologies between vector and 
target DNA negatively influence the frequency of HR, favoring an isogenic vector 
construction (te Riele et al., 1992). Additionally, enrichment of the clones by 
positive and negative marker selection (Izant and Weintraub, 1985; Mansour et 
al., 1988) optionally combined with Cre/loxP or FLP/FRT systems (Baer et al., 
2001) and promoter- or polyadenylation-trap experiments can increase the 
targeting efficiency remarkably (Karreman, 1998).  
2.2.1 Positive and/or negative selection 
Targeting vectors generally are classified in two groups: replacement and 
insertion vectors. The replacement vector is linearized, resulting in a colinearity of 
the vector sequence with the target sequence. Mediated by the flanking 
homologous regions a double crossover facilitates the replacement of the 
chromosomal DNA by the vector sequence. In contrast, the insertion vector is 
linearized within the homologous region, resulting in a duplication of the genomic 
sequence after HR. Both vector types were tested targeting hprt with the result 
that the insertion vector targeted up to ninefold more frequently than the 
replacement vector, with equal length of the homologous sequence (Hasty et al., 
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1991). Nevertheless, the most widely used targeting vectors are replacement 
vectors, based on a previous report that the recombination frequencies were 
comparable to those using insertion vectors (Thomas et al., 1987). Additionally, 
positive/negative selection is possible using this kind of vector (Mansour et al., 
1988). The most common positive selection marker is the aminoglycoside 
phosphotransferase gene, providing resistance to antibiotics such as kanamycin, 
geneticin (G418) and neomycin (neo
R
). In addition, genes encoding for the 
hygromycin B phosphotransferase, xanthine-guanine phosphoribosyl transferase, 
blasticidin-S deaminase or puromycin-N-acetyl-transferase have been applied as 
well. Most frequently a cassette containing neo
R
 under the control of a strong 
promoter, such as the phosphoglycerate kinase (PGK) promoter, is used (Santerre 
et al., 1984; von Melchner et al., 1992; Ramirez-Solis et al., 1995; Cheah et al., 
2001). Superiorly, selection cassettes providing the possibility to be removed by 
site-specific recombinases, such as Cre, FLPe or ФC31 (Voigt et al., 2008), after 
successful integration, are favorable (Birling et al., 2009; Tuntufye et al., 2011). 
Otherwise the selection cassette might interfere with the expression of 
surrounding genes, as an example reported by Fiering and co-workers in 1995. A 
targeted deletion of the 5’-DNase hypersensitive site 2 of the locus control region 
of the β-globin locus, subsequently replaced by a PGK-neo
R
 cassette resulted in a 
markedly reduced globin expression, leading to fetal death of homozygous mutant 
mice. FLP-mediated excision of the selection cassette restored viability and 
maintained normal globin expression (Fiering et al., 1995). Positively selected 
cells reflect the integration of the desired transgene, but not if random or site-
directed integration took place. A combined strategy termed ‘positive/negative’ 
selection (PNS) was developed in the group of Capecchi to enrich clones which 
undergone HR, therefore being targeted. A thymidine kinase (tk) gene from the 
herpes simplex virus was inserted at one end of the linearized targeting construct, 
already carrying a positive selection marker. After treatment with a toxic 
nucleoside analogue (e.g. gancyclovir) randomly transfected cells were 
eliminated, whereas correctly targeted cells, that have undergone HR, have lost 
the tk gene. Typically, those strategies result in 3- to 10-fold targeting enrichment 
(Mansour et al., 1988; Karreman, 1998). The diphteria toxin A (DT-A) fragment 
and immunotoxin-mediated cell killing have successfully been applied as negative 
selection (Yagi et al., 1990; Kobayashi et al., 1996). 
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2.2.2 Gene trapping 
Gene trapping is described as a type of insertional mutagenesis through vectors, 
which render to simultaneously disrupt and report the expression of the 
endogenous gene. First generation vectors were used to trap actively transcribed 
genes in undifferentiated ESCs and are subdivided, according to their integration 
area, in promoter trap and gene trap vectors. The promoter trap strategy enriches 
intragenic integration events by the use of vectors containing a promoterless 
selectable marker (e.g. neo
R
 or β-geo; a fusion of neomycin phosphotransferase 
and β-galactosidase), which have to be integrated into an exon of a 
transcriptionally active locus, capturing the promoter of the target cell, to be 
selectable for neomycin or lacZ staining. Though, silent gene loci are missed by 
this strategy (Skarnes et al., 1992; Friedrich et al., 1993). Gene trap vectors are 
able to integrate into intronic sequences. At the 5’-end of the reporter gene they 
carry a splice acceptor (SA) site, which enables the vector to be spliced to the 
endogenous gene resulting in a fusion transcript. Improving this strategy led to the 
introduction of an internal ribosomal re-entry site (IRES) between the SA and the 
reporter gene. On that account, the reporter gene can be translated even without 
being fused to the trapped gene (Lako et al., 2000). Second generation vectors 
trap silent loci. Those vectors still carry a promoterless reporter gene with a 5’-SA 
site, but the antibiotic resistance gene is controlled by a constitutive promoter. As 
a result, the reporter gene expression is still regulated by the endogenous 
promoter, whereas the antibiotic selection is independent of the trapped gene 
(Niwa et al., 1993). Hanson and colleagues reported that a promoterless vector 
system targeting the c-myc gene in a rat fibroblast cell line led to a 5000 to 10000 
fold targeting increase (Hanson et al., 1995). Targeted knock-out of the α-1,3- 
galactosyltransferase gene (GGTA1) by a promoterless vector in porcine 
fibroblasts resulted in an increase in the targeting efficiency compared to PNS 
(Harrison et al., 2002). An additional strategy to select for intragenic vector 
integration, applied in mESCs, is indicated by polyadenylation (poly A) trap, in 
which the mRNA of a selectable marker gene lacking a poly A signal in a gene 
trap vector is only stabilized when the vector gets a cellular poly A signal 
(Salminen et al., 1998). 
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2.2.3 BAC vectors 
Beside the possibility to increase the frequency of HR events by selection systems 
and gene trapping, the increase of the homology regions of the targeting vector 
represents a promising alternative (Hasty et al., 1991). Facing this task, large 
vector vehicles for targeting approaches, such as YACs, PACs and BACs came 
into a tighter focus. Previous studies turned towards the use of modified BACs as 
targeting vectors for the transfection of murine ESCs (Testa et al., 2003; Yang et 
al., 2003; Testa et al., 2004; Yang et al., 2005), later on also for human ESCs 
(Song et al., 2010). Barakat and co-workers developed a new BAC-targeting 
strategy in mice. The use of a RFLP (restriction fragment length polymorphism) 
present in genetically polymorphic ES hybrid cell lines, generated by crossing 
C57BL/6 female mice with Cast/Ei male mice, provide a convenient readout for 
proper targeting. Rnf12, encoding a nuclear factor involved in X chromosome 
inactivation, was used as the target gene of interest to evaluate the new targeting 
method. As a result, this strategy is feasible for the introduction of genetic 
alterations in murine ESCs via BAC-targeting cassettes coupled with a reliable 
readout method based on allele specific PCR (Barakat et al., 2011). 
The BAC system is based on the F (fertility)-factor known from E. coli and its 
replication is strictly controlled (Mori et al., 1986). Usually, BACs are maintained 
in one or two copies in the bacterial host and are, in contrast to YACs, resistant to 
mechanical shearing. Additionally, as an advantage in time and costs, it is 
possible to use conventional plasmid purification protocols for their isolation 
(Yang et al., 1997; Warming et al., 2005). Compared to conventional targeting 
vectors, able to carry up to 20 kb genomic inserts, BACs are described as circular 
molecules that are capable to carry large, regularly 200 to 300 kb, genomic 
regions of interest (Shizuya et al., 1992). The stability and the large insert 
capacity opens a broader application range of BACs, such as tools for high-
resolution physical mapping, making them the cloning system of choice for 
constructing physical maps of the human, mouse and pig genome sequencing 
projects (Anderson et al., 2000; Chung et al., 2004; Humphray et al., 2007). In 
conclusion, the application area of BACs ranges from the establishment of long-
range physical maps to positional cloning disease genes to whole-genome 
sequencing, as BAC libraries were used for the human genome project (Lander et 
al., 2001). They are taken as a source of substrates in shotgun sequencing 
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projects, enabling the setup of an end sequence database (Mahairas et al., 1999). 
Additionally, overlapping clone sets, contigs, are generated by restriction 
fingerprints (Marra et al., 1997). Those sequence contigs, containing scaffolding 
information, are mapped to a localized genomic region after a direct genomic 
shotgun sequencing approach (Hoskins et al., 2000). Finally, BACs are used to 
increase the HR frequency in targeting approaches using ESCs to establish 
various mouse models (Valenzuela et al., 2003; Yang and Gong, 2005; Barakat et 
al., 2011). Effective targeting efficacies of up to 28% have been observed (Yang 
and Seed, 2003). 
Furthermore, to enable the use of BACs in gene targeting approaches, novel 
recombination tools using bacterial enzymes have been established. Those 
facilitate the modification of any DNA region of interest, allowing the 
introduction of desired mutations into BACs independently of restriction sites for 
cloning (Wang et al., 2009). The conventional method of construct design, using 
restriction enzymes and DNA ligase to cut and rejoin DNA, is often limited by the 
availability of the appropriate restriction enzyme sites for the respective cloning 
steps. This problem appears in the vector construct as well as in the genomic 
DNA quite frequently, since the vector and the genomic target site contain 
hundreds of kilobases, as present in BACs. Additionally, the PCR amplification of 
DNA fragments for cloning, prevalently used in traditional approaches, proved to 
be relatively fault-prone also limited by the length of the desired amplificate 
(Zhang et al., 1998; Muyrers et al., 1999; Copeland et al., 2001; Muyrers et al., 
2001). In E. coli, the endogenous recombination mechanisms are initiated by the 
cooperation between RecA (strand invasion protein) and RecBCD (exonuclease) 
and need linear dsDNA to start the recombination machinery (Murphy, 1998). An 
alternative recombineering approach was developed independent of RecA, instead 
using phage-derived, functionally and operationally equivalent, protein pairs: 
RecE/RecT from the Rac phage or Redα/Redβ from λ-phage. This 
recombinogenic engineering strategy was also termed ET recombination (ET 
cloning) (Zhang et al., 1998), λ-mediated recombination (Yu et al., 2000) or GET 
recombination (Nefedov et al., 2000). The interaction between RecE/Redα, 
encoding 5‘-3‘ exonucleases, and RecT/Redβ, representing DNA annealing 
proteins, is necessary for the initiation of HR (Kolodner et al., 1994). The need of 
using linear targeting DNAs in ET recombination requires the endogenous 
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RecBCD endonuclease activity to be absent or silenced (Murphy, 1991). It was 
reported that in ET cloning only short homology regions of 35-60 nucleotides are 
sufficient for HR events, simply amplified by oligonucleotide synthesis. 
Combining those regions of homology with a selectable gene, there is even no 
need for the construction of targeting plasmids, because linear PCR products can 
be used (Narayanan et al., 1999). In comparison to RecA approaches, it was noted 
that the recombination efficiencies using the RecE/RecT and Redα/Redβ protein 
pairs are higher, indicated by 80% correctly modified candidates. The 
identification of correct clones can be performed by employing antibiotically 
selectable genes, or even more simply, by conventional PCR screening (Muyrers 
et al., 2000). Those strategies, of course, open the way to easily modify any DNA 
of interest. Moreover, it represents a time-saving and easy-to-handle methodology 
to modify BACs, subsequently used as targeting vectors to establish animal 
models. 
However, there is still one important point to be kept in mind. Targeting vectors in 
their simplest form consist of a gene for drug selection flanked by homologous 
arms enabling HR in the target sequence. If BAC vectors are used for targeting 
approaches, conventional screening methods such as long-range PCR, utilizing 
one primer outside of the construct in conjugation with one primer present on the 
selectable marker (Lay et al., 1998), or Southern blotting, which usually identifies 
correctly targeted clones and permits the verification of a single-copy insertion of 
the construct, are not feasible. To bypass these problems alternative screening 
methods are necessary. These include: (i) to permit Southern blotting, one short 
arm on the targeting construct has to be designed (Testa et al., 2003), (ii) to detect 
the number as well as the chromosomal localization of integrated BAC sequences, 
fluorescent in-situ hybridization (FISH) is used (Yang and Seed, 2003) and (iii) 
via quantitative real-time PCR it is possible to screen for the loss of sequences, 
deleted in the targeting construct (Valenzuela et al., 2003) also described as the 
‘loss of wild-type allele’ (LOWA) assay (Frendewey et al., 2010). 
2.2.4 Site-directed nucleases 
DNA double strand breaks (DSB) in mammalian cells can be repaired via two 
distinct mechanisms: (i) homologous recombination (HR) and (ii) nonhomologous 
end-joining (NHEJ). Both pathways are highly conserved from yeast to 
vertebrates. However, HR plays a major role in any DSB repair in yeast, whereas 
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in vertebrates NHEJ contributes more frequently to DSB repair, resulting in an 
imperfect repair process often leading to changes to the DNA sequence at the site 
of DSB (Sonoda et al., 2006). In mammalian systems, as represented in Chinese 
hamster ovary cells, a 9:13 ratio between HR and NHEJ has been reported 
(Santiago et al., 2008). An additional possibility to increase the targeting 
efficiency is represented by the volitional introduction of artificial DSBs at a 
desired locus to be targeted by site-directed nucleases, inducing HR.   
Initial experiments in mouse ESCs, using the homing nuclease I-SceI to induce 
DSB, stimulates the gene targeting at a selectable neo locus enormously (at least 
50-fold). But due to the fact that a specific recognition sequence for I-SceI has to 
be introduced to the target locus to facilitate its function, other nuclease types 
were favored for gene targeting approaches (Smih et al., 1995; Taghian et al., 
1997). Zinc-finger nucleases, first reported in 1996 by Kim and colleagues (Kim 
et al., 1996), are described as hybrid molecules composed of a specifically 
designed polymeric zinc finger domain, recognizing the desired DNA target 
sequence, and a FokI nuclease cleaving domain (Carroll, 2011). This newly 
developed technology enables the design of Zn-finger proteins theoretically 
recognizing any 18 bp target sequence, which is long enough to address a unique 
target within the mammalian genome (Mani et al., 2005; Remy et al., 2010). The 
endonuclease activity of FokI is dependent of DNA binding, which is only 
achieved by dimerization of the FokI domain. During cleavage of double-stranded 
DNA, a pair of hybrids, consisting of a Zn-finger and nuclease domain bind 
simultaneously to the DNA. The subsequent DNA scission by the dimeric FokI 
nuclease occurs without any site-specificity. A transient expression of ZFNs in 
cells leads to a site-specific DSB in the endogenous target gene. This DSB is most 
likely repaired via NHEJ, creating not predetermined mutations that might cause 
gene disruptions (Santiago et al., 2008; Katada et al., 2009). Additionally, it was 
recently reported by Olsen and colleagues that the formation of site-specific DSB 
by ZFN increases the rate of HR between a specific genomic target and a donor 
plasmid (Yan et al., 2009) opening the possibility of gene correction indicating 
one more step towards gene therapy (Olsen et al., 2010). 
Recently, several groups described possibilities to engineer DNA-binding 
specificities based upon transcription activator-like effector (TALE) proteins from 
Xanthomonas plant pathogens (Moscou et al., 2009; Boch et al., 2010). Within 
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their structure, a central repeat domain is required for DNA recognition. This 
domain consists of repeat units with 33-35 amino acids each specifying one target 
base. Two critical, adjacent amino acids within one repeat, called ‘repeat variable 
di-residue’ (RVD), mediate the base preference of each unit. Due to the 
appearance of the preferred binding site of the TALE and its specific RVD, it is 
possible to predict some kind of code, in which each repeat is specifying its 
targeted base (Boch et al., 2009). These investigations led to the establishment of 
TALE-nuclease chimeras (TALENs) as site-specific endonucleases for selective 
genome cleavage (Bogdanove et al., 2011). Those truncated TALE variants linked 
to the catalytic domain of FokI, were able to modify the endogenous human genes 
NTF3 and CCR5, indicating that TALEN architectures are able to efficiently 
modify the genome of mammalian cells at an endogenous locus by NHEJ (Miller 
et al., 2011).  
2.3 Site-directed modification of two different porcine loci 
The techniques for targeted modifications of desired genes were established in the 
mouse during the 1980s (reviewed in Capecchi, 1989), including gene knock-outs 
in specific tissues (Chapman et al., 1999) and single-base pair introductions into 
specific genes (Dickinson et al., 2000). It was possible to target endogenous genes 
by HR in pluripotent ESCs. After reimplantation into the early embryo, chimeric 
animals have been generated, some of which exhibited germline transmission of 
the modification, subsequently used to generate mouse strains carrying the knock-
out allele by breeding. Until now this technology is still not transferable to 
livestock due to the lack of germ line-competent ESCs (Stice et al., 1998) or other 
pluripotent stem cells. In the first transgenic livestock, produced by SCNT as an 
alternative strategy to ESCs, the ovine collagen gene was replaced by an 
expression cassette, targeting the expression of human factor IX to the mammary 
gland (McCreath et al., 2000). More recently, pigs with an engineered deletion of 
the α-1,3-galactosyltransferase (GGTA1) gene, determining a cell-surface 
xenoepitope, have been generated (Denning et al., 2001; Lai et al., 2002). This 
epitope plays a key role in hyperacute rejection (HAR). Organs and tissues of pigs 
lacking the GGTA1 gene, not expressing this epitope have a reduced HAR 
response after transplantation to humans, making these animals an interesting 
source for xenotransplantation. In 2008 Rogers and co-workers reported the 
production of porcine animal models for cystic fibrosis, by targeting the CFTR 
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(cystic fibrosis transmembrane conductance regulator) gene. Those animals 
represent expedient tools for a better understanding of this hereditary disease and 
to develop new prevention and treatment strategies (Rogers et al., 2008).  
2.3.1 Targeted knock-out of CFTR: a disease model for cystic fibrosis  
2.3.1.1 Cystic fibrosis 
Cystic fibrosis (CF) is one of the most common, genetically inherited disorders 
with recessive outcome among Caucasians (Ren, 2008). It was first described as 
an independent disease in 1938 by Andersen and colleagues, who investigated 
autopsy studies from malnourished infants (Andersen, 1938). In her publication 
‘Cystic fibrosis of the pancreas and its relation to celiac diseases’ she was able to 
distinguish a disease, developing mucus plugging of the glandular ducts, termed 
‘cystic fibrosis of the pancreas’, from other celiac syndromes (Davis, 2006). 
Additionally, the disease also was known as ‘generalized exocrinopathy’ because 
many exocrine glands were affected. This syndrome was characterized by fat and 
protein malabsorption due to pancreatic damage and a lack of pancreatic enzyme 
secretion, steatorrhea, growth failure and pulmonary infection, often representing 
the terminal event (Kreindler, 2010). Studies on the basic defect, at that time, 
usually focused on the abnormalities of mucus. One decade later, in 1951, Kessler 
and Anderson developed the connection between salt transport and cystic fibrosis 
of the pancreas and supported the hypothesis that ‘fibrocystic disease is associated 
with widespread abnormality of epithelial glands’ (Kessler et al., 1951). In 1953, 
di Sant’Agnese postulated that Na
+
 and Cl
-
 levels in the sweat of CF patients were 
markedly elevated, not representing the consequences of pancreatic dysfunction, 
pulmonary disease adrenal dysfunction or renal disease, but the elevated 
susceptibility to dehydration in CF was due to increased salt loss from the sweat 
glands (Di Sant'Agnese et al., 1953). These findings resulted in the development 
of a diagnostic tool for CF, the sweat test (Gibson et al., 1959). In the 1980s, by 
investigating sweat glands, pancreas and pulmonary tract, it became more and 
more obvious, that CF was a disease of altered anion transport. In 1988 Kopelman 
and co-workers reported that abnormal pancreatic secretion in CF could mainly be 
attributed to an altered Cl
-
 secretion, opening the door for researchers to find the 
affected gene (Kopelman et al., 1988). In 1985, it was possible to localize the 
gene by linkage analysis to the long arm of chromosome 7 (Knowlton et al., 
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1985). Furthermore, more than 20 years ago, in 1989, Kerem and colleagues were 
able to identify the causative gene for CF called CF transmembrane conductance 
regulator (CFTR) (Kerem et al., 1989).  
2.3.1.2 CFTR: genetic structure and function 
The CFTR gene encodes a 250 kb long, consisting of 1480 AA, protein with a 
molecular weight of 168 kDa, which acts as an apically localized chloride 
channel, mainly anchored to the outer membrane of epithelial cells of the sweat 
glands, pancreatic duct, airway, skin, intestine, biliary tree and vas deferens. 
Defects in the causative gene for CF lead to consequences like elevated sweat 
chloride concentration, lung disease, pancreatic insufficiency, intestinal 
obstruction, biliary cirrhosis, and congenital bilateral absence of the vas deferens 
(Davis, 2006). However, the most severe impacts caused by a defective CFTR 
protein are observed in the lung and the pancreas. The main function of the 
cAMP-mediated chloride channel, encoded by the CFTR gene, is the regulation of 
the ion and water homeostasis across epithelia. CFTR is a member of the ATP-
binding cassette superfamily of proteins. Those transporters usually consist of two 
highly hydrophobic transmembrane domains, each of them containing six 
membrane-spanning segments, and two hydrophilic nucleotide binding domains. 
CFTR contains one additional, highly charged, so called regulatory domain (R-
domain), responsible for the regulation of the channels function (Higgins, 1992).  
2.3.1.3 CFTR mutations 
Up to now 1900 mutations (according to the Cystic Fibrosis Mutation Database; 
CFMDB, 2011) are known, which proved to be responsible for the development 
of this monogenic disease. The most common among them is a deletion of a 
nucleotide triplet encoding a phenylalanine, called ΔF508. It accounts for almost 
70% of all mutant CFTR alleles (Riordan, 2008). Based on their influence on the 
CFTR protein the different mutations are grouped in five distinct mutation classes 
including (i) the presence of large deletions and STOP-codons, both mostly 
leading to truncated and non-functional protein, (ii) mutations (e.g. ΔF508) 
affecting the post-translational folding of CFTR, (iii) mutations resulting in full-
length protein, being incorporated into the cell membrane, but presenting a 
defective regulation impairing the channel gating function (iv) mutations leading 
to defective chloride conductance and (v) transcription dysregulations, ending in 
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decreased amounts of functional CFTR (Proesmans et al., 2008). Focusing on the 
pulmonary phenotype, a non-functional protein leads to an imbalance of the ion 
and water regulation in epithelia, resulting in increasing viscosity of the exocrine 
secretion with the consequences of ciliary dysfunction, mucus impaction and 
chronic endobronchial infections in the lung, representing the most common and 
severe phenotype of CF (Ren, 2008; Widdicombe, 2010).    
2.3.1.4 CF animal models 
For the development of curative therapies for CF, making one step towards the 
establishment of gene therapy approaches, it is inevitable to focus on the 
generation of expedient animal models. Carvalho-Oliveira and colleagues (2007) 
showed an overview of mouse models for CF, reflecting different mutation 
strategies. Surprisingly, all of those models lack the prominent lung phenotype 
(referring to Davidson et al., 2001; Carvalho-Oliveira et al., 2007). Guilbault and 
colleagues (2007) explained this fact by the decreased amount of mucous glands 
generally contained in mouse airways (Guilbault et al., 2007). The differential 
expression of CFTR and CaCCs (Ca
2+
-activated chloride channel) as well as the 
longevity, size of airways and immunology, may contribute to the differences in 
the lung disease characteristics between mice and humans. As a consequence, 
other animal models, which are able to reflect all aspects of this very complex 
disease were required, leading to the generation of CFTR-deficient ferrets (Sun et 
al., 2008) and pigs (Rogers et al., 2008), at least exhibiting a similar airway gland 
situation compared to human. The group around M. J. Welsh and R. S. Prather 
generated CFTR-null and CFTR-ΔF508 hetero- and homozygous pigs by using 
adeno-associated virus gene targeting in combination with SCNT (Rogers et al., 
2008; Welsh et al., 2009). The CFTR-null and CFTR-ΔF508 heterozygous piglets 
were generated by integration of a neomycin-resistance cassette via homologous 
recombination to disrupt exon 10 of the porcine CFTR gene. The insertion of the 
cassette also introduced a premature STOP-codon at position 508, whereby the 
production of a functional protein is inhibited. Using a similar strategy, the 
ΔF508-mutation was mimicked by eliminating 3 bp, encoding Phe508 in the 
porcine exon 10. In humans, this mutation disrupts processing of the protein, 
resulting in the retention of nearly all human CFTR-ΔF508 in the ER 
(endoplasmic reticulum) followed by its degradation. Surprisingly, some porcine 
CFTR-ΔF508 is able to escape the ER retention, traffics to the Golgi apparatus, 
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meaning there is still some CFTR activity left in contrast to human CFTR carrying 
the ΔF508 mutation (Rogers et al., 2008). All CFTR
-/-
 newborn piglets exhibited 
the earliest manifestation of CF in humans, a meconium ileus. In humans, around 
15% of all CF infants exhibit this intestinal obstruction, whereas the penetrance of 
meconium ileus in CFTR
-/- 
piglets was 100%. The occurrence of pancreatic 
insufficiency in CFTR
-/-
 piglets was comparable to the human phenotype (Wine, 
2010). Further studies showed other significant aberrations present at birth, 
including degenerative changes of the pancreas, focal biliary cirrhosis in the liver 
and gall bladders smaller than usual and often filled with mucus and congealed 
bile (Rogers et al., 2008). Additional studies revealed an increase in mucus cells 
in the pancreas, liver, gall bladder, intestine and cystic duct (Meyerholz et al., 
2010). In another study, CFTR
ΔF508/ΔF508
 pigs developed lung disease exceedingly 
similar to the human phenotype, indicating that the limited CFTR activity is not 
sufficient to prevent lung as well as gastrointestinal disease in CF (Ostedgaard et 
al., 2011). Stoltz and colleagues investigated the progress of CF lung disease in 
CFTR
-/-
 pigs, which were generated by breeding. They reported that homozygous 
knock-out pigs spontaneously develop the pulmonary CF phenotype, largely 
replicating that observed in human, reflecting the main features of inflammation, 
remodeling, mucus accumulation and infection (Stoltz et al., 2010). Although it is 
not obvious whether homozygous CFTR knock-out pigs or humans develop more 
severe lung disease, the characteristic hallmarks of lung disease in both species 
are comparable and differ from the mouse. Those results also indicate that the 
pulmonary consequences of CFTR loss are not unique to primates (Welsh et al., 
2009). 
The fact that the targeted disruption of the porcine CFTR gene reflected several of 
the major phenotypes known from CF-patients in pigs, opens the door for 
investigators to better understand this hereditary disease and to develop new 
prevention and treatment strategies (Mogayzel et al., 2010).  
2.3.2 Targeting of GGTA1: organ resources for xenotransplantation 
2.3.2.1 Xenotransplantation: background 
Currently, 11594 patients (evaluated by the Eurotransplant-International-
Foundation, 2010) are registered on the active waiting list for donor transplants 
(including kidney, heart, liver, lung, pancreas), facing the lack of improvement in 
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the number of deceased human organs that become available each year and 
restrict allotransplantation. Therefore, cross-species transplantation would offer 
the prospect of an unlimited supply of organs, tissue and cells for clinical 
transplantation. The pig as a main candidate for xenotransplantation of solid 
organs will only ever become reality in clinical application with genetic 
modifications of the porcine genome, to overcome hyperacute, acute antibody-
mediated or cellular rejection (reviewed in Pierson et al., 2009). Additionally, 
other issues also have become very prominent, such as development of thrombotic 
microangiopathy in the graft or systemic consumptive coagulopathy in the 
recipient (Bach et al., 1994; Gollackner et al., 2004). Hence, to address these 
problems, pigs that express one or more human thromboregulatory or anti-
inflammatory genes, such as human thrombomodulin or human CD39 are being 
established (Petersen et al., 2009; Le Bas-Bernardet et al., 2011). Nevertheless, 
the results of preclinical transplantation of porcine cells, such as pancreatic islets 
(van der Windt et al., 2009), neuronal cells (Lim et al., 2010), hepatocytes (He et 
al., 2011), or corneas (Choi et al., 2011) are as well very encouraging, with 
survival times greater than one year in all cases.  
Xenotransplantation (XT) is described as the transplantation of living cells, tissue 
or organs (so called xenografts or xenotransplants) from one species to another. 
One major obstacle in this field of research is the lack of a readily available 
source of such xenografts for transplantation, which would decrease the 
availability imbalance of donated human organs and the demand for 
transplantation (reviewed in Cooper, 2012). In general, although non-human 
primates are phylogenetically closely related to humans, they exhibit several 
disadvantages when used as organ source for xenotransplantation: (i) there is still 
little experience in breeding these animals in captivity, (ii) breeding would be 
cost-intensive, (iii) they have a relatively long generation period accompanied by 
small litter sizes, (iv) many considerable species are known as endangered, (v) 
there is little knowledge about the possibility to genetically modify these species 
and (vi) the very close relation between non-human primates and human, brings 
up moral and ethical concerns and the transmission of inter-species infections may 
arise more likely (reviewed in Dooldeniya et al., 2003). 
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2.3.2.2 The pig as a donor animal for xenotransplantation 
The pig represents a suitable source as xenograft donor, due to its similarities in 
size, physiology, anatomy, metabolism, pathology, organ development and 
disease progression to human (Rieben et al., 2005; Sachs et al., 2009), not to 
forget that SCNT works quite well in pigs (Lagutina et al., 2007). The main focus 
of porcine organs used for XT lies on pancreatic islets (Hering et al., 2006), 
kidneys (Yamada et al., 2005), heart (Kuwaki et al., 2005) and liver (Nagata et 
al., 2007). It just has to be taken into account that there indeed is a risk of 
transmission of infectious agents from pig to humans. The use of designated 
pathogen-free (DPF) animals counteracts the impact of exogenous agents. In 
contrast, porcine endogenous retroviruses (PERVs), known as vertically 
transmitted proviruses, are present in all pig breeds, and they have the potential to 
infect human cells (Dieckhoff et al., 2009). Hence, several approaches to compass 
this infectious risk were developed, including introduction of siRNAs/shRNAs 
targeting highly conserved PERV sequence regions (Dieckhoff et al., 2008). 
2.3.2.3 Xenograft rejection and GGTA1 
The major problem of immunological xenograft rejection still remains. There are 
different types of rejection mechanisms known, following the generally accepted 
nomenclature including HAR (hyperacute rejection), AVR (acute vascular 
rejection) with its major component AHXR (acute humoral xenograft rejection) 
and chronic rejection (Schuurman et al., 2002). An important step forward to 
circumvent this problem was the finding that the rejection mechanism is started by 
HAR and AHXR, which attack vascularized organs from pigs, after 
transplantation to primates, within minutes or days, respectively (Miyagawa et al., 
2010). HAR is mediated by ‘natural’ antibodies directed against a carbohydrate 
epitope, Galα1-3Galβ1-4GlcNAc (α-1,3-Gal), synthesized by the enzyme α-1,3-
galactosyltransferase (α-1,3GalT), encoded by GGTA1 (Yang et al., 2007). 
GGTA1 encodes a 371 amino acid protein, belonging to the family of 
glycosyltransferases 6, which catalyzes the terminal step in biosynthesis of the 
α-Gal-epitope. This epitope is expressed on the cell surface of all mammalian 
species, including pigs, but not in catarrhine primates, as Old World monkeys and 
Apes (including human). Those species produce high concentrations of anti-αGal 
antibodies, subsequently mediating HAR by the activation of the complement 
system and the coagulation cascade, when organs from α-Gal-positive species are 
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transferred to α-Gal-negative species (Koike et al., 2007; Puga Yung et al., 2009). 
Therefore, the major focus in XT-research lies on the development of strategies to 
prevent HAR in a first step. Thus, absorbing α-1,3-Gal-specific antibodies from 
the recipients’ blood with α-1,3-Gal antigen, the depletion or total inactivation of 
the complement, as well as the overexpression of α-2,3-siasyltransferase or α-1,2-
fucosyltransferase to compete with GGTA1 (Dai et al., 2002), are taken into 
account to overcome this hurdle. As a self-evident solution, genetically modified 
pigs lacking a functional GGTA1 expression have been generated (Lai et al., 
2002; Phelps et al., 2003). The elimination of GGTA1 prevented HAR after 
transplantation of pig hearts into baboons and extended the survival of the graft up 
to 2-6 months (Kuwaki et al., 2005). Additionally, pigs deficient for GGTA1 in 
combination with the overexpression of complement regulatory proteins, e.g. 
human decay-accelerating factor (hDAF) (Zaidi et al., 1998) or CD59 (protectin) 
(Niemann et al., 2001) have been developed. A promising strategy for the 
generation of GGTA1 knock-out pigs, resulting in a very low level of inbreeding 
is achieved by the combination of SCNT with heterozygous somatic cells for αGal 
and crossbreeding of the resulting animals (Nottle et al., 2007). This genetic 
background subsequently can be used to be combined with other candidate 
transgenes to develop multi-transgenic pigs required for clinical 
xenotransplantation (Klymiuk et al., 2010). 
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3 MATERIAL AND METHODS 
3.1 Material 
3.1.1 Apparatuses 
Accu-jet
®
 pro pipette controller   Brand, Wertheim 
Agarose gel electrophoresis chamber  MWG Biotech, Ebersberg 
Analytical balance     Sartorius, Göttingen 
Gel documentation system    BioRad, Munich 
Heating plate with magnetic stirrer   KA-processequipment, Staufen 
Hybridization oven     H. Saur, Reutlingen 
Microwave      Severin, Sundern 
MS1 minishaker  IKA-process equipment,                                                                    
Staufen 
Pipetman (1000, 200, 20)    Gilsen, Middleton 
Pipettes (1000, 200, 100, 20, 10)   Eppendorf, Hamburg 
pH-meter      WTW, Weilheim 
Rolling device     Heidolph, Schwabach 
Shaking-incubator 3031    GFL, Burgwedel 
Thermomixer 5436     Eppendorf, Hamburg 
UV-crosslinker     Biometra, Göttingen 
Waterbath WB6 Medingen    Störk-Tronic, Stuttgart 
 
Centrifuges  
Sorvall RC5C plus     Thermo Scientific, Dreieich 
Table centrifuge 5415D    Eppendorf, Hamburg  
Table centrifuge 5810R (cooling)    Eppendorf, Hamburg 
 
Thermocycler 
ABIPrism 7000  Applied Biosystems, 
Weiterstadt 
Biometra Uno Thermoblock    Biometra, Göttingen 
GeneAmp PCR System 9700  Applied Biosystems, 
Weiterstadt 
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3.1.2 Consumables 
Centrifugation tubes     Herolab, Wiesloch   
Micro Amp
TM
 optical adhesive film   Applied Biosystems, USA 
Micro Amp
TM
 optical 96-well reaction plate Applied Biosystems, USA 
Parafilm®   American Can Company,     
  Greenwich 
PCR reaction tubes (0.2 ml)    Life Science Brand, Wertheim 
Pipettetips      Eppendorf, Hamburg 
Pipette filter tips     Axygen, California, USA 
Reaction tubes     Eppendorf, Hamburg 
Tubes (50 ml, 15 ml)     Greiner, Frickenhausen 
 
3.1.3 Chemicals 
Acetic acid (glacial acetic acid)   Roth, Karlsruhe 
Adenosine triphosphate    Sigma-Aldrich, Deisenhofen 
Agar, granulated     Difco, Detroit, USA 
Agarose      Invitrogen, Karlsruhe 
Agarose ultra pure     Invitrogen, Karlsruhe 
Ampicillin      ApliChem, Darmstadt 
Bacto
TM
 Trypton     BD, Heidelberg 
Bacto
TM
 Yeast Extract    Difco, Detroit, USA 
Calcium chloride     Sigma-Aldrich, Deisenhofen 
Chloramphenicol     Sigma-Aldrich, Deisenhofen 
Chloroform      Merck, Darmstadt 
Dithiothreitol (1 M)     Invitrogen, Karlsruhe 
EDTA       Merck, Darmstadt 
Ethanol      Roth, Karlsruhe 
Ethidiumbromide (solution: 1%)   Merck, Darmstadt 
D-(+)-Glucose     Sigma-Aldrich, Deisenhofen 
Glycerol      Roth, Karlsruhe 
Hydrochloric acid     Roth, Karlsruhe 
IPTG (Isopropyl-beta-thio galactopyranoside) Invitrogen, Karlsruhe  
Kanamycin      Roth, Karlsruhe 
Magnesium chloride (15 mM)   Qiagen, Hilden 
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Potassium acetate     Roth, Karlsruhe 
Potassium chloride     Merck, Darmstadt 
Potassium hydrogen phosphate   Merck, Darmstadt 
2-Propanol      Merck, Darmstadt 
Saccharose      Roth, Karlsruhe 
Sodium chloride     Merck, Darmstadt 
Sodium dodecyl sulphate    Roth, Karlsruhe 
Sodium hydroxide (platelets)    Roth, Karlsruhe 
Tris       Roth, Karlsruhe 
X-gal (5-bromo-4-chloro-3-indolyl-β-D-  Invitrogen, Karlsruhe  
galactoside) 
 
3.1.4 Enzymes, kits and other reagents 
dNTPs (dATP, dCTP, dGTP, dTTP)   Fermentas, St. Leon-Rot 
E.Z.N.A. Tissue DNA Mini Kit  Omega bio-tek, Norcross, 
USA 
Gene Ruler
TM
 (1 kb DNA ladder)   Fermentas, St- Leon-Rot 
Geneticin (G418)     Invitrogen, Karlsruhe 
Gentra Puregene Cell Kit    Qiagen, Hilden 
MAXWELL
®
16 Cell LEV DNA    Promega, Mannheim 
Purification Kit 
nexttec
TM
 DNA Isolation clean columns  nexttec, Leverkusen 
Nucleospin
®
 Tissue Kit    Macherey-Nagel, Dueren 
peqGOLD MicroSpin Tissue DNA Kit  Peqlab, Erlangen 
Proteinase K (20 mg/ml)    Roche, Mannheim 
pUC mix marker 8     Fermentas, St. Leon-Rot 
QIAamp DNA Micro Kit    Qiagen, Hilden 
QIAgen DNA Maxi Kit    Qiagen, Hilden 
QIAexII Gel Extraction Kit    Qiagen, Hilden 
QIAgen DNeasy
®
 Blood & Tissue Kit  Qiagen, Hilden 
Restrictionenzymes and -buffers   Fermentas, St. Leon-Rot 
Restrictionenzymes and -buffers  New England Biolabs, Boston, 
USA 
Ribonuclease A (RNase A; 0.2 U/µl)  Applied Biosystems, 
Weiterstadt 
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Spermidine      Sigma-Aldrich, Taufkirchen 
SYBR
®
 Green PCR Master Mix   Applied Biosystems, 
Weiterstadt 
Taq Polymerase     Agrobiogen, Hilgertshausen 
T4 DNA Ligase (2000 U/µl)    Fermentas, St. Leon-Rot 
UNG (uracil-N-glycosylase)  Applied Biosystems, 
Weiterstadt 
Wizard® genomic DNA-Purification Kit  Promega, Mannheim 
10x ligation buffer     Fermentas, St. Leon-Rot 
10x PCR buffer     Agrobiogen, Hilgertshauesen 
 
3.1.5 Buffers, media and solutions 
Unless otherwise noted, in a Millipore machine deionized water termed aqua 
bidest was used as solvent. 
Chloroform-isoamylalcohol (CiA) 
 96 ml chloroform 
 4 ml isoamylalcohol 
Stored at 4°C protected from light 
 
DNA loading buffer (10x)   
 10% glycerol in aqua bidest 
 1 spatula tip of bromophenolblue (BPB) 
 Add 0.5 M NaOH until color turns blue 
 Stored at 4°C 
 
DNA molecular weight standards 
 100 µl of 1 kb DNA ladder standard 
 100 µl 6x loading dye 
 400 µl aqua bidest 
 Stored at -20°C 
 
dNTP-mix 
 2 mM dATP, dCTP, dGTP, dTTP 
In aqua bidest 
 Stored at -20°C in suitable aliquots 
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Kawasaki buffer   
20 mM Tris-HCl (pH 8.3)  
1.5 mM MgCl2    
 25 mM KCl    
 0.05% Tween 20 
Aqua bidest    
 
LB medium   
5 g yeast extract 
 10 g peptone/tryptone 
 5 g NaCl 
 Ad 1000 ml aqua bidest 
pH 7.0  (adjust with 5 M NaOH) 
Autoclave  
Medium was stored at room temperature 
 
LB-Agar   
2.5 g yeast extract 
 5 g peptone/tryptone 
 2.5 g NaCl 
 Ad 500 ml aqua bidest 
 pH 7.0 (adjust with 5 M NaOH) 
 7.5 g agar-agar 
 Autoclave 
Keep liquid at 60°C 
Add 500 µl respective antibiotic (ampicillin 50 mg/ml, chloramphenicol 
12.5 mg/ml, kanamycin 25 mg/ml) 
Pour into sterile 10 cm culture dishes (afterwards stored at 4°C) 
 
Lysisbuffer for DNA isolation (high-salt precipitation) 
 100 µl PK buffer (10x) 
 10 µl 10% (w/v) SDS  
4.4 µl DTT (1M) 
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Lysisbuffer for DNA isolation (PCiA extraction) 
160 mM saccharose 
80 mM EDTA pH 8.0 
100 mM Tris/HCl pH 8.0 
0.5% (w/v) SDS 
 
Lysisbuffer for DNA isolation (spermidine-method; cutting buffer)  
 2.5 ml 1 M Tris/HCl pH 8.0 
 5.0 ml 0.5 M EDTA 
 1.0 ml 5 M NaCl 
 250 µl 1 M DTT 
 127 µl spermidine (500 mg/ml) 
 Ad 50 ml aqua bidest 
 Stored at 4°C 
 
Phenol-chloroform-isoamylalcohol (PCiA) 
 25 ml phenol 
 25 ml CiA 
 Stored at 4°C protected from light 
 
PEG-MgCl2    
40% (w/v) PEG 8000 
 30 mM MgCl2 
 Stored at room temperature 
 
PK Buffer (10x)   
200 mM Tris 
 1 M NaCl 
 40 mM EDTA 
 Stored at room temperature 
 
Plasmid A    
50 mM glucose 
 25 mM Tris/HCl pH 8.0 
 10 mM EDTA/NaOH pH 8.0 
 Stored at room temperature 
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Plasmid B 
 0.1 M NaOH 
 0.5% (w/v) SDS 
 Prepared freshly before use 
 
Plasmid C 
 3 M KOAc 
 pH 4.8 (adjust with 9 M HOAc) 
 Autoclave 
 Stored at room temperature 
 
Proteinase K (20mg/ml) 
 Stored at 4°C 
 
RNaseA (20mg/ml) 
 Stored at -20°C 
 
SOC medium (500 ml)    
2.5 g yeast extract 
 10 g peptone/tryptone 
 0.25 g NaCl 
 9.32 g KCl 
 pH 7.0 (adjust with 5 M NaOH) 
 Autoclave  
add 2 M MgCl2 (final conc. 10 mM) 
 add 1 M glucose, (final conc. 20 mM) 
 Stored at room temperature 
 
STE     
10 mM Tris/HCl pH 8.0 
 100 mM NaCl 
 1 mM EDTA/NaOH pH 8.0 
 Stored at room temperature 
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TAE (50x) 
 242g Tris 
 100 ml 0.5 M EDTA (pH 8.0) 
 57 ml AcOH conc. 
 Ad 1000 ml aqua bidest 
 
T-buffer 
 10 mM Tris/HCl 
Adjust to pH 8.0 with HCl 
Stored at room temperature 
 
Tbf I (250ml)    
30 mM KOAc pH 6.0 
 100 mM CaCl2 
 15% (w/v) glycerol 
 Autoclave  
Add 1 M MnCl2 (final conc. 50 mM) 
 Stored at 4°C 
 
Tbf II (20ml) 
 10 mM MOPS pH 7.0 
 75 mM CaCl2 
 10 mM KCl 
 15% (w/v) glycerol 
 Autoclave 
 Stored at 4°C 
 
TYM medium  
 5 g yeast extract 
 20 g peptone/tryptone 
0.1 M NaCl 
Autoclave 
 Add 2 M MgCl2 (final conc. 10 mM) 
Ad 1000 ml aqua bidest 
Stored at room temperature 
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3.1.6 Plasmids and BACs 
3.1.6.1 Plasmids 
pGEM® T-Easy Vector System  Promega, Mannheim 
CloneJET
TM
 PCR Cloning Kit  Fermentas, St. Leon-Rot 
pSV-β-galactosidase Control Vector  Promega, Mannheim 
pBluescript KSII    Stratagene, La Jolla, USA 
pBS302     kindly provided by Brian Saur 
PL452  kindly provided by Neil Copeland 
pPNTlox
2
     kindly provided by Ingeborg Klymiuk 
pPNT4     Conrad M. et al. (2003) 
bGHpA     kindly provided by Marlon Schneider 
 
3.1.6.2 BACs  
CH242-248P18    BACPAC Resource, Chori, USA 
CH242-21F3     BACPAC Resource, Chori, USA 
CH242-372F22    BACPAC Resource, Chori, USA 
PigI-170I3     BACPAC Resource, Chori, USA 
 
3.1.7 Bacterial strains 
DH10B     New England Biolabs, USA 
SW106     NCI Frederick, USA 
TOP10     Invitrogen, Karlsruhe 
 
3.1.8 Software 
Abi Prism 7000    Applied Biosystems, Weiterstadt 
BioEdit Sequence Alignment Editor  Ibis Bioscience, USA 
Double Digest 
TM
    Thermo Fisher Scientific, USA 
FinchTV Version 1.3.1   Geospiza Inc., USA 
Macromedia  Freehand MX   Adobe, USA 
NEBcutter V2.0    New England Biolabs, USA 
Primer Express
®
 Software v2.0  Applied Biosystems, Weiterstadt  
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3.1.9 Oligonucleotides 
Oligonucleotides were either designed by hand or with the Primer Express
®
 
Software v2.0. 
3.1.9.1 Oligonucleotides for qPCR 
ACTB1059fw  5’-CCACAGCGGAAGCTCAGTC-3’ 
ACTB1219rev 5’-CTGGGTACATGGTGGTGCC-3’ 
ACTB237fw  5’-TCTCCTTTGGAACTCTGCC-3’ 
ACTB390rev  5’-TTTACGGCAGCCTCGTCG-3’ 
pACTB129f  5’-CCCAGGTCAGTGGCCCACTG-3’ 
pACTB1686r  5’-CGCCCTAGATGCATGCTCGA-3’ 
pACTB100f  5’-GAACCCCAAAGCCAACCGTG-3’ 
pACTB1760r  5’-CGCACACCGGCCTTATTCCA-3’ 
CFTR1772f  5’-GACAGTACTGCTTAGTGGTCAG-3’ 
CFTR2060r  5’-GGTACAGGGAGTTGTAAAGACTG-3’ 
CFTR986f  5’-CCACCGAATCAGCATACTTAGG-3’ 
CFTR1132r  5’-TTAGCACCTGAGCTCTATCC-3’ 
CFTR6752fw  5’-AAGGGAGGCTCGGGACTG-3’ 
CFTR7118rev  5’-GAGAAGATGCTGGCCTTTTCC-3’ 
CFTR6822fw  5’-GGAGAAAGCCGCTAGAGCAA-3’ 
CFTR7199rev  5’-TTTCCACCCCAAACGCAG-3’ 
CFTR46f  5’-TTCAGGTGAGAGGGTGTCTA-3’ 
CFTR172r  5’-ACCCTCATTCTCGTCCAT-3’ 
CFTR402fw  5’-GGCGCCGAGAAGAGTAGGG-3’ 
CFTR621rev  5’-TTTCCACCCCAAACGCAG-3’ 
CFTR359fw  5’-CAAATGACATCACCGCAGGTC-3’ 
CFTR564rev  5’-TCCAAAGCTCAGCTAGACACCCT-3’ 
CFTR696f  5’-TGTGAAGCCATGGGAATAG-3’ 
CFTR853r  5’-CACTTTGCCTAAGACTCTGAAC-3’ 
GGTA10f  5’-GGAAGAGTGGTTCTGTCAATGC-3’ 
GGTA149r  5’-GGTGACTTGGCTGATAACTAGGAG-3’ 
GGTA126f  5’-CTCCTAGTTATCAGCCAAGTCACC-3’ 
GGTA492r  5’-CGGTATTTAAGGGCTCAGGGATAC-3’ 
GGTA2377fw 5’-CACTCCTTAGCGCTCGTTGAC-3’ 
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GGTA2758rev 5’-ATTGGGTTTGCTGCCCCT-3’ 
GGTA3423fw 5’-TCATCAGTGGATTCACCCCAA-3’ 
GGTA3640rev 5’-CACCACGGGAATGCCTTC-3’ 
GGTA3323fw 5’-GCTGGTGATTCATTTGTGCCT-3’ 
GGTA 3516rev 5’-CTGTCAGAAGCGTCTCCAGCT-3’ 
GGTA131f  5’-CCTCGTTATCAGCCAAGTCACC-3’ 
GGTA297r  5’-CGGATCCTTAAGCCAAAGAG-3’ 
GGTA232f  5’-CCAATTAGGATCCAAGAGGAGG-3’ 
GGTA424r  5’-GCAAGTGTGGGATATGGAAG-3’ 
HPRT781i2fw 5’-GAGCTACAGTTGCCGGCCT-3’ 
HPRT943i2rev 5’-AGCGGAAACAAATCCAACTAGG-3’ 
HPRT834i2fw 5’-TGTCTGCGACCCACACCA-3’ 
HPRT987i2rev 5’-GCATGCATCAGTAAGGAACTGG-3’ 
HPRT3133i4fw 5’-CGAATCAGAGCTGTAGCCGC-3’ 
HPRT3297i4rev 5’-TGACGAATCCAACTAGGAACCA-3’ 
HPRT374i5fw 5’-GAGGGCTTAGGCAGTGGCA-3’ 
HPRT528i5rev 5’-AAACAGCGTAGGTCAGACCAGG-3’ 
HPRT3088f  5’-GTTCTACATGCTGATCCTGACC-3’ 
HPRT3425r  5’-CTCTGCCTAGCTACTCTGATGATG-3’ 
HPRT4152f  5’-CCTTATCCCTTCTCACTACTCAGG-3’ 
HPRT4478r  5’-CCCACTTCCACGAATCAATGCTAC-3’ 
HPRT4578f  5’-GTGCTTATTGCCTCTCACTC-3’ 
HPRT4744r  5’-GGCTCCAACAATAAGACTCC-3’ 
HPRT657f  5’-CATCTAGCCTCTCTGGAGTTAG-3’ 
HPRT788r  5’-CGACATGCTAATGCTCTTGC-3’ 
lepR1452fw  5’-GCATCCCATATCTGAACCCAAA-3’ 
lepR1616rev  5’-ACGGAATCAGGAATGACACATG-3’ 
pLEPR3119rev 5’-GCCTGGGTTTCTATCTCCCATG-3’ 
pLEPR3059fw 5’-GCAGCAATTCCCTACCGAAAG-3’ 
pLEPR3360fw 5’-CCTCCAGGAGAGCTGTTCACAC-3’   
pLEPR2944rev 5’-CATCCTCACGAGTTATCTCCATGC-3’ 
pLEPR2834fw 5’-CTCTACTCTTGACAACTCCGGACC-3’ 
pLEPR3517rev 5’-GAACTTAGACGGTTAGGTCATACATCTTG-3 
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pLEPR3068fw 5’-CCCTACCGAAAGAGTCTTTCTCG-3’ 
MYC41f  5’-TACCGCTTTCAATCCGCGATGAGT-3’ 
MYC307r  5’-CCGAGGTCAGCGTTCATCTACATT-3’ 
MYC633f  5’-CTTGGTCCTCGGAGATGTTAAG-3’ 
MYC761r  5’-GCGGAGATTTGTCCTCGTTT-3’ 
MYC286f  5’-TGTAGATGAACGCTGACCTC-3’ 
MYC425r  5’-CTTACTCATAGGAGCTCAGGAC-3’ 
MYC949f  5’-TACTGGGTGTTGCAAGGA-3’ 
MYC1051r  5’-GGGTAGAGAGCTCAGTCTT-3’ 
pTM1966f  5’-GGACCATTTCATAGGGACAGACT-3’ 
pTM2106r  5’-CTTGGACATTATCCACCAGTGAA-3’ 
 
3.1.9.2 Oligonucleotides for vector constructs 
CFTR-3armf  5’-ATGACATGCATGTCATGGGATCCATACCAG-3’  
CFTR-3armr  5’-TACTTGCGGCCGCAAGTCCAAGTGATCAGTCC-3’  
CFTR-5armf  5’-CTGGTTGGTACCTTCTGTCCTCGAGTGTC-3’ 
CFTR-5armr  5’-CACAAAACCCTCATTCTCGTC-3’ 
CFTR-lacZf  5’-CGGTTCCCCCAGAGACCATGGTCGTTTTACAA                               
   CGTCGTGAC-3’ 
CFTR-lacZr  5’-GTCACGACGTTGTAAAACGACCATGGTCTCTG                             
   GGGGAACCG-3’ 
CFTR-STOPf 5’-CGGTTCCCCCAGAGACCATGCCTCGGGGACAC                                        
CAAATATGG-3’ 
CFTR-STOPr  5’-CCATATTTGGTGTCCCCGAGGCATGGTCTCTGG                                   
   GGGAACCG-3’ 
GGTA-3armf  5’-TGCCTTGGAGATTCCAGCTG-3’ 
GGTA-3armr  5’-ATGATTGCGGCCGCCATCATCCTGAACTTGAG-3’ 
GGTA-5armf  5’-AGATTGGGTACCGAATCTCTATATGCTGTG-3’ 
GGTA-5armr  5’-GATAACTAGGAGATTAGAG-3’ 
GGTA-STOPf 5’-CCTTTTCTTTTCCCAGGAGAAAATAATGCCTCG                                   
   GGGACACCAAATATGG-3’ 
GGTA-STOPr 5’-CCATATTTGGTGTCCCCGAGGCATTATTTTCTCC                                  
   TGGGAAAAGAAAAGG-3’ 
GGTA-sf  5’- CAG TGG GTT AAG GAT CTG-3’ 
lacZr   5’-GTTCGGATAATGCGAACAG-3’ 
STOPr   5’-CCAATTATGTCACACAG-3’ 
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3.2 Methods 
3.2.1 DNA amplification 
3.2.1.1 End-point PCR 
The PCR amplification of desired DNA-fragments was performed according to 
the given cycling protocol using the reaction mix with a total volume of 25 µl as 
noted below (table 3.1). The amplifications were carried out using the GeneAmp 
PCR System 9700 (Applied Biosystems, Weiterstadt) thermocycler. 
Table 3.1: Mastermix and cycling protocol for end-point PCR. 
PCR-mastermix (total volume 25µl) 
 
PCR cycling protocol   
2.5 µl 10x PCR buffer 
 
denaturation 95°C 3 min   
2.5 µl MgCl2 (15 mM stock)  
denaturation 95°C 30 sec   
2.5 µl dNTPs (2 mM stock) 
 
annealing** xx°C 30 sec 32 x 
0.5 µl forward primer (10 mM stock) 
 
elongation*** 72°C xx min   
0.5 µl reverse primer (10 mM stock) 
 
final elongation 72°C 10 min   
0.2 µl Taq-polymerase (5 U/µl) 
 
cooling step 4°C 15 min   
1.0 µl DNA-template* 
     
16.3 µl A.dest. 
     
 
* genomic DNA 50-200 ng/µl, plasmid 1-100 ng/µl, BAC 10-200 ng/µl; ** annealing temperature 
depends on the used primer pair; is calculated by primer designing software or can be estimated by 
the ‘4+2’-rule -5°C (2°C for A/T, 4°C for C/G); *** elongation time depends on the length of the 
desired PCR-amplicon; if Agrobiogen-Taq-Polymerase is used, 1 min correlates with 2 kb DNA; 
 
A specific 2-step fusion PCR shown in table 3.2 was developed for the 
construction of the modification vectors pCFTR-STOP/lacZ and pGGTA-
STOP/lacZ described in 4.1.2.  
Table 3.2:  Cycling protocol for the 2-step fusion PCR used for STOP-box and lacZ 
introduction 
2-step-fusion-PCR  
denaturation 95°C  2 min 
  denaturation 95°C  45 sec   
pre-amplification annealing 68°C 1 min 3x 
elongation 72°C 2 min   
denaturation 95°C  45 sec     
annealing 58°C 30 sec 32x amplification 
elongation 72°C 2 min     
cooling step 4°C 15 min  
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3.2.1.2 qPCR (quantitative real-time PCR) 
The qPCR-amplifications were carried out with the ABIPrism 7000 Detection 
System (Applied Biosystems, Weiterstadt) using the SYBR
®
 Green PCR Master 
Mix (Applied Biosystems, Weiterstadt). Table 3.3 shows the standard qPCR-
mastermix components for target and reference genes (CFTR, GGTA1, HPRT) 
calculated for a total volume of 12.5 µl per sample. A standard curve using DNA 
of Niere m cells isolated via PCiA purification (read 3.2.9.1), with the assigned 
values of 10000, 7500, 5000, 2500, 500, 250, 50 and 25 copies, was prepared for 
each targeting approach, where it was assumed that 15000 copies is equivalent to 
100 ng of DNA. Calibrators, reflecting copy numbers of approximately 5000, 
were prepared for each standard curve, using the same initial Niere m DNA. 
Sample DNA for the screening procedure was isolated according to the high-salt 
precipitation protocol further described in 3.2.9.1. Samples, standard curve, 
including the calibrator, and reaction components, except UNG, usually stored 
at -20°C and held on ice during the whole procedure, were pre-warmed in the 
water bath to room temperature. All components were gently stirred before the 
reaction was, pipetted on ice, applied to Microamp
TM
 optical 96-well reaction 
plates. After charging, the plates were covered using a Microamp
TM
 optical 
adhesive film and used either immediately or stored at -20°C. 
Table 3.3:  Standard mastermix for qPCR approaches. 
qPCR standard mastermix 
6.25 µl SYBR
®
 Green I 
0.075 µl UNG 
0.2-0.6 µM primer fw 
0.2-0.6 µM primer rev 
ad 12.5 µl A.dest. 
 
The standard thermal profile of the qPCR performance consists of (i) an initial 
activation step (for UNG) at 50°C for 2 min, followed by (ii) an initial 
denaturation step at 95°C for 10 min completed by (iii) a 40 cycle repeat of 
denaturation at 95°C for 15sec and primer annealing and extension at 60°C/63°C 
for 1.5 min. Finally, the plates were again heated from 60°C to 95°C to obtain a 
dissociation curve of the PCR products. 
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3.2.2 Agarose gel electrophoresis 
The agarose gel electrophoresis allows separation of DNA fragments according to 
their size. For separation of DNA, TAE-agarose gels (0.7-3.0%) were used. After 
boiling the gel-solution in the microwave until the agarose was completely 
dissolved and cooling down of the suspension to approximately 60°C, ethidium 
bromide (1 mg/ml) was added (9 µl/100 ml). Samples were mixed with 10x BPB 
loading dye to observe the progress of the electrophoresis and were applied to the 
slots of the electrophoresis gel as well as a DNA molecular standard (1 kb DNA 
ladder or pUC8 marker) for estimating the gel band sizes. Ethidium bromide 
fluoresces under UV light, when intercalated into double stranded DNA, enabling 
the detection of the DNA bands by a gel electrophoresis documentation system 
(BioRad). Depending on the experiment, for fragments which were further 
processed agarose UltraPure
TM
 was used and fragments were excised under UV-
light. For standard detection approaches Universal agarose was used. 
3.2.3 Gel elution 
The elution of DNA out of agarose gels was carried out according to the modified 
QIAex
®
II Gel Extraction Kit (Qiagen, Hilden) protocol. 
The gel bands of interest were excised and put into a 1.5 ml reaction tube. The gel 
slices were weighed. Three times the volume of buffer QX I was added to the 
tube, which then was placed onto a heating block at 50°C until the agarose had 
dissolved completely. Subsequently, 8 µl of QIAEX II were added to the tube, 
getting mixed by inverting the tube several times. To ensure an adequate DNA 
binding to the gel matrix, the tube was hold for 10 more minutes on the heating 
block. The sample then was centrifuged for 30 sec at 5400 g, the supernatant was 
removed and the pellet washed with 500 µl QX I solution. After an additional 
centrifugation for 30 sec at 5400 g the supernatant was removed again and the 
pellet was washed twice with 500 µl of PE buffer. The pellet then was air-dried 
for approximately 10 min and was afterwards resuspended in 20 µl T-buffer. Gel 
electrophoresis is used to estimate the concentration of the eluted DNA. 
3.2.4 Restriction digest 
The utilized amount of DNA was incubated for 90 minutes (for large amounts of 
DNA the restriction digest was performed overnight) with the appropriate 
restriction endonuclease, its recommended buffer at the recommended 
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temperature in a total volume of 20 to 50 µl. In general 0.25 units of the 
restriction enzyme per µg DNA were used. Respective restriction enzyme 
recognition sites were determined using NEBcutter V2.0, appropriate restriction 
conditions for enzyme combinations are suggested by DoubleDigest
TM
. 
Depending of the experiment different amounts of DNA have been digested. In 
term of analysis approximately 1 µg, for subsequent ligations 2 µg of DNA were 
digested. Restriction digests, unless otherwise noted by the supplier, were 
incubated o/N at 37°C. 
Testing the integrity of BAC-DNA, a restriction digest of 10/20 µg BAC-DNA 
with the appropriate enzyme (e.g. EcoRI, XbaI, NsiI, PvuII) was performed 
overnight. The digest total volume was loaded onto a 0.7/1.0% agarose gel and 
run overnight at 0.5/2V/cm.  
3.2.5 PCiA purification of restriction digests 
PCiA-extraction was used to achieve the required purity of the digested DNA-
fragments (e.g. if they were further used for ligations). 
After the restriction digest volume was adjusted to 150 µl with A. dest., 100 µl of 
PCiA were added. The mixture was shaken for at least 2 minutes and then 
centrifuged for 3 minutes at RT and 16100 g. The supernatant was transferred to a 
new reaction tube, 15 µl NaOAc (3 M) and 400 µl EtOH (100% and ice cold) 
were added, mixed and the tubes then were maintained at -80°C for 30-60 
minutes. Afterwards the tubes were centrifuged again for 30-45 minutes at 4°C 
and 16100 g. The precipitated pellet was washed once with 70% EtOH, air-dried 
for 5 minutes and dissolved in an appropriate volume of T-buffer. 
3.2.6 Ligation 
In general, an appropriate amount of vector was ligated with a 3 times 
stoichiometric excess of insert in the presence of 1 µl ligase and 2 µl of 10x ligase 
buffer. The ligation mix was adjusted with A. dest. to a total volume of 20 µl. The 
mix then was incubated at RT for at least 1.5 hours, but ideally overnight. For 
further applications the ligase was inactivated by a heating step at 65°C for 15 
min. 
3.2.7 Heat shock and electro-transformation  
Two different methods, heat-shock-based transformation and electroporation, to 
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introduce foreign DNA into different strands of E. coli bacterial cells have been 
used. The E. coli cells were prepared to make them competent for DNA uptake, 
according to the following protocols.  
Heat shock-competent cells 
The protocol for heat shock competent E. coli TOP10 cells was adapted from the 
protocol used at the Gene Center, LMU-Munich. 
A 5 ml overnight culture TOP 10 cells was cultivated in LB medium at 37°C. On 
the next day 250 ml TYM medium were inoculated and incubated while shaking 
until this daily culture reaches an OD600 between 0.7 and 0.8 (approx. 2-4 hours). 
This bacterial suspension then was divided in 6 x 40 ml. Those reaction tubes 
were cooled down in an ice water bath for 5 to 10 min and then were centrifuged 
for 10 min at 3700 g and 4°C. After discarding the supernatant, each pellet was 
resuspended in 12 ml Tbf I solution, incubated for 10 min at 4°C and then 
centrifuged again for 10 min at 2500 g and 4°C. The supernatant was discarded, 
each pellet was resuspended in 1.6 ml Tbf II solution and the bacterial suspension 
subsequently was split into aliquots of 30-60 µl per Eppendorf cup. The ready to 
use aliquots were stored at -80°C. 
Competent cells for electroporation (including recombineering) 
The protocol to produce competent cells for electroporation was adapted from Liu 
and colleagues (or http://recombineering.ncifcrf.gov). For the general uptake of 
DNA by electroporation, the E. coli strain DH10B (Invitrogen, Karlsruhe) was 
used. Two other E. coli strains, SW106 for recombineering and SW 106 for Cre-
mediated recombination, have been identically prepared (table 3.4). 
Table 3.4:  Protocols for competent cells. 
competent cells for electroporation 
DH10B                          
(general procedure) 
SW106 
(recombineering) 
SW106 
(Cre-recombination) 
 
5 ml o/N culture in LB 
 
5 ml o/N culture in LB 
 
5 ml o/N culture in LB 
1 ml o/N culture
*
 1 ml o/N culture
*
 1 ml o/N culture
*
 
OD600 = 0.6/0.8 OD600 = 0.4/0.5 OD600 = 0.3/0.4 
 
15 min at 42°C water bath add 1 ml arabinose
**
 
  
shake 1 h at 32°C 
* per 100 ml LB  ** conc. 100 mg/ml; 1 ml per 100 ml o/N 
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General washing procedure 
For this general step, the cells should be kept at 4°C at any time. The cell 
suspension was cooled down with occasional shaking for 10 min. Then the cells 
were harvested by centrifuging the suspension for 10 min at 5000 g and 4°C. 
After carefully removing the supernatant with a pipette, the pellet was 
resuspended in 50 ml ice-cold A. dest. Following a centrifugation for 10 min at 
5000 g and 4°C, the supernatant was removed and the pellet was resuspended in 
20 ml ice-cold A. dest. The centrifugation was repeated and the pellet resuspended 
in 1 ml ice-cold 10% glycerol/A.dest. Subsequently 50-80 µl aliquots of this 
suspension have been prepared. Preferentially, those cells should be used freshly 
for electroporation (1.75 kV), but can be stored at -80°C for several months. 
3.2.7.1 Heat shock transformation 
An aliquot (30-60 µl) of chemically-competent E. coli TOP10 cells, usually stored 
at -80°C, was slowly thawed. Up to 10 µl of the inactivated ligation batch were 
added to the bacteria solution, gently mixed and incubated on ice for 20 minutes. 
Applying a heat shock for 45 sec at 42°C in the water bath was followed by an 
incubation step of  2-3 minutes on ice. Subsequently 1 ml of SOC (or LB) 
medium was added to the suspension, gently mixed and incubated for 45 minutes 
at 37°C. The bacterial suspension then was centrifuged for 5 minutes at RT and 
2300 g. The pellet was resuspended in 100-200 µl of the supernatant and plated on 
LB-agar plates containing the appropriate antibiotic (ampicillin 50 μg/ml, 
kanamycin 25 μg/ml and chloramphenicol 12.5 μg/ml). Optionally, if 
pGEM
®
Teasy vector was used the LB agar plates were pre-treated with 40 µl 
IPTG (100 mM) in combination with X-Gal (20 mg/ml) enabling the 
differentiation between positive and negative plasmid colonies (also termed ‘blue-
white-selection’). The plates were incubated at 37°C overnight. After counting the 
grown colonies, plates were conserved by wrapping them with Parafilm
®
 and 
stored at 4°C. 
3.2.7.2 Electroporation 
Electro-competent cells were used to transfer DNA by applying an external 
electrical field, increasing the electrical conductivity and permeability of the cell 
membrane. This process is known to be approximately 10 times as efficient as 
chemical transformation. The procedure was performed using the BioRad Pulser. 
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Cuvettes were pre-cooled on ice and 1 ml LB aliquots in 1.5 ml reaction tubes on 
RT were prepared. The DNA was mixed with one aliquot of electro-competent 
cells (Plasmid: 1 ng, BAC: 20-100 ng). After transferring this mixture to a cuvette 
and pulsing it with 1.75 kV (the resulting time constant should range between 4.0 
and 5.0), 1 ml LB medium was added to the cuvette, was resuspended and 
transferred to a reaction tube. 
The cells then were stored in the incubator: 
 DH10B cells at 37°C for 45 min 
 SW106 cells at 32°C for 45 min   
 SW106 for recombineering at 32°C for 2 h 
The cells then were centrifuged for 5 min at 2300 g and RT, most of the 
supernatant should be removed if possible (100-200 µl should be left in the tube, 
otherwise plate whole suspension). Subsequently the cells were resuspended, 
which appear hairy and fluffy, and the suspension was plated on agar plates 
containing the appropriate antibiotic: 
 BAC: chloramphenicol 
 Plasmid: ampicillin, kanamycin 
 BAC modification: kanamycin (introduction of neokanR) or blasticidin 
(cassette exchange from neokan
R
 to blasticidin in homozygous targeting) 
Finally, the plates were incubated overnight at 32°C/37°C. 
3.2.8 Recombineering 
To introduce the STOP- or the lacZ-box into the wild-type BACs CH242-248P18 
and PigI-170I3 for CFTR and CH242-21F3 for GGTA1, the bacterial 
recombination based method called recombineering was used. The procedure was 
performed according to the given recombineering protocols (Liu et al., 2003). 
For this project the E. coli strain SW106 was used, which facilitates a heat 
induced bacterial recombination by the λ-phage encoded proteins exo, bet and 
gam, which are transcribed by the λPL promoter. The promoter is repressed by 
cI857, so at 32°C the expression is blocked. Increasing the temperature to 42°C 
enables the transcription of exo, bet and gam. Because of the possibility to induce 
the recombineering machinery by a heating step, the strain has to be grown at 
32°C in regular LB medium (doubling time: approx. 50 min). The exo gene 
encodes a 5’-3’ exonuclease, producing single strand overhangs at linear DNA 
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fragments. Those overhangs are stabilized by the bet protein. The gam protein 
protects the introduced single-stranded DNA from degradation mediated by the 
E. coli RecBCD protein. The introduction of linear DNA fragments, which exhibit 
homology to DNA molecules contained in the SW106 cells, results, mediated by 
the recombination proteins, in the desired recombination between the homologous 
regions of the DNA molecules. Additionally, in SW106 bacterial cells an 
arabinose induced Cre recombinase is encoded, needed for targeted exchange or 
excision of antibiotic resistance cassettes, using the Cre-loxP system, in which the 
Cre recombinase exclusively mediates recombination between palindromic loxP 
sites. The bacterial strain itself contains no antibiotic resistance. For a more 
convenient handling of the BAC-constructs after the recombineering procedure, 
they were retransformed into the E. coli strain DH10B enabling cultivation in 
regular LB medium at 37°C. 
3.2.9 DNA isolation methods 
Several DNA isolation protocols, described below, have been used to isolate 
genomic, plasmid and BAC-DNA. DNA from small amounts of cells was isolated 
using the high-salt precipitation method. Genomic DNA isolation was performed 
according to a standard PCiA-based protocol or using the spermidine-method. 
BAC-DNA was prepared endotoxin-free following a modified protocol using a 
combination of the QIAgen DNA Maxi Kit (Qiagen, Hilden) and the E.Z.N.A
®
 
Tissue DNA Mini Kit (Peqlab, Erlangen). 
3.2.9.1 Genomic DNA isolation 
Genomic DNA from porcine ear cartilage tissue was isolated and purified 
according to the protocols either described by Sambrook (2001) (PCiA-method) 
or using the spermidine-method adapted from the lab protocol of Dr. Josef Platzer.  
Targeting experiments were performed with primary porcine kidney cells (pKC) 
as target cells. Several DNA isolation methods for genomic DNA were tested. 
This turned out to be challenging due to the small amount of available cells per 
targeted clone and in parallel the very high purity of the DNA required for 
subsequent qPCR application. In this experiment six conventional isolation 
methods (Phenol-Chloroform-Isoamylalcohol extraction, Kawasaki buffer 
isolation, high-salt precipitation, spermidine-purification, Gentra Puregene Cell 
Kit, Wizard
®
 genomic DNA-Purification Kit), five column-based isolation 
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methods (Nucleospin
®
 Tissue Kit, peqGOLD MicroSpin Tissue DNA Kit, Qiagen 
DNeasy Blood & Tissue Kit, QIAamp
®
 DNA Micro Kit, E.Z.N.A
®
 Tissue DNA 
Kit), one filtration-based (nexttec
TM
 DNA Isolation clean columns) and one 
isolation method based on magnetic particles were tested according to the 
suppliers protocol.  
PCiA-method  
The samples were minced with a scalpel and transferred to a reaction cup. 400 µl 
lysis buffer plus 20-30 µl Proteinase K (20 mg/ml) were added per sample and 
mixed by agitation. The samples were held o/N at 60°C. If the tissue was not 
completely digested after one night another 10-20 µl Proteinase K have been 
added and incubated for additional 3-4 hours. After the sample was centrifuged 
for 5 min at 16100 g and RT, the supernatant was transferred to a new tube, 
whereas undigested parts (hair etc.) should be retarded. 400 µl 4.5 M NaOAc were 
added to the tube which was then mixed by inverting it several times. Thereafter 
600 µl PCiA were added to each tube, which then were put onto the rolling device 
for gently and homogenous mixing of the solution. The tubes then were 
centrifuged for 5 min at 16100 g and RT. After the transfer of the resulting 
supernatant to a new tube the PCiA step was repeated. Then, 0.7 volumes of 
Isopropanol (approx. 650 µl) were added and mixed by inverting the tube several 
times. Subsequently, DNA was precipitating. This DNA fiber was washed in 70% 
EtOH two times and then transferred to a tube containing 70% EtOH, where it 
stayed ideally o/N. The 70% EtOH is removed again and the DNA pellet should 
be air-dried for 6-10 min. Finally the pellet was dissolved in an appropriate 
volume of T-buffer and the DNA concentration was measured using the 
spectrophotometer. 
Spermidine-method  
Tissue samples were placed in reaction tubes, 400 µl of the mastermix to lyse the 
tissue were added and then the tubes were incubated for a minimum of 3-4 hours 
at 60°C. After the sample was centrifuged for 5 min at 16100 g and RT, the 
supernatant was transferred to a new tube, whereas undigested parts (hair etc.) 
should be retarded. Then, 0.7 volumes of Isopropanol were added and mixed by 
inverting the tube several times. Subsequently, DNA was precipitating. This DNA 
fiber was washed in 70% EtOH two times and then transferred to a tube 
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containing 70% EtOH, where it stayed ideally o/N. The 70% EtOH was removed 
again and the DNA pellet should be air-dried for 6-10 min. Finally the pellet was 
dissolved in an appropriate volume of T-buffer and the DNA concentration was 
measured using the spectrophotometer. 
High-salt precipitation 
The sample was incubated for at least one hour at 60°C with 110 µl of the 
mastermix. 2 µl Proteinase K (20 mg/ml) were added and the mix was incubated 
for another hour at 60°C. After adding 30 µl NaCl (4.5 M) the mixture should be 
placed immediately on ice for 10 min. Then the sample was centrifuged at 
16100 g for 20 min and RT. The supernatant was transferred to a new reaction 
tube and mixed by inverting the tube gently with 0.7 volumes Isopropanol. After 
the centrifugation at 16100 g for 20 min and RT the supernatant was removed, the 
pellet was washed one or two times with 500 µl 70% EtOH. Subsequently, the 
DNA was left in 70% EtOH overnight. Finally, the 70% EtOH was removed, the 
pellet was air-dried for 6-10 min and then dissolved in 35 µl T-buffer. 
Kawasaki buffer isolation 
To lyse the cells 100 µl Kawasaki buffer (see 3.1.5) were added per each sample. 
After adding 5 µl Proteinase K (20 mg/ml) the sample was incubated for 1 h at 
55°C. The Proteinase K was inactivated by a heating step for 15 min at 95°C. 
Thereafter the tubes were put immediately on ice for several minutes. The 
samples then were centrifuged for 1 min at 16100 g and the supernatant was 
directly used for PCR. 
3.2.9.2 Plasmid DNA isolation 
Single colonies were picked from LB-agar plates with a sterile inoculating loop 
and transferred to 15 ml culture tubes containing 2.5-5 ml LB medium with the 
appropriate antibiotic. After an overnight incubation at 37°C in the shaking 
incubator the bacteria suspension was centrifuged for 10 minutes at 1300 g. 
Optionally, from the overnight cultures glycerol stocks to conserve the bacterial 
culture for subsequent inoculations have been made by mixing 900 µl 60% 
glycerol with 300 µl o/N culture. The DNA was isolated according to the protocol 
adapted from (Sambrook, 2001) (Volumes are capable for 2.5 ml bacteria culture; 
using 5 ml culture, a 1.5 fold amount of solutions is necessary, as is needed for 
BAC isolation). 
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The supernatant was discarded; the pellet then was resuspended in 750 µl STE 
and transferred to 1.5 ml (2.0 ml) reaction tubes. After centrifugation of the 
samples for 5 minutes at 4500 g and RT the supernatant was discarded, the pellet 
was resuspended in 200 µl plasmid A, 400 µl plasmid B were added, the 
suspensions was mixed 5-7 times and the samples were incubated for 5 min on 
ice. Then 300 µl plasmid C were added, the solution was mixed again 5-7 times, 
held on ice for 3 min followed by a centrifugation for 10 min at 16100 g and RT. 
The resulting supernatant was incubated with 4 µl RNaseA (20 mg/ml) for 45 min 
at 37°C. Thereafter, 300 µl PCiA were added per sample, which then was shaken 
for at least 1 min and then centrifuged for 2.5 min at 16100 g and RT. The 
aqueous phase was transferred to a new tube. 0.7 volumes (approx. 650 µl) iPrOH 
were added to precipitate the DNA, followed by a centrifugation for 10 min at 
16100 g and RT and a washing step of the pellet in 700 µl 70% EtOH, at least for 
a few hours, better o/N. The samples then were centrifuged for 2.5 min at RT and 
16100 g, the EtOH was removed, the pellet was air-dried for 6 min and finally 
dissolved in 55 µl T-buffer. The DNA concentration of each sample was 
determined by the spectrophotometer. 
BAC-DNA isolation by heating step for PCR screening 
A number of grown BAC colonies were picked from agar plates, were inoculated 
in 5 ml LB medium + antibiotic (kanamycin) and grown at 32°C overnight. 10 µl 
of the overnight culture were mixed with 20 µl T-buffer in PCR tubes. This 
mixture was heated up and denatured for 10 min at 95°C. After cooling the 
suspension down for 15 min at 4°C, the tubes were centrifuged for 5 min at RT 
and 1500 g. The supernatant (1 µl) containing the BAC-DNA was used for the 
screening PCR using primer pairs, selective for the wild-type sequence (in case of 
a random integration of the modified construct), and for the introduced sequence 
(STOP-box, lacZ reporter gene). 
BAC-DNA isolation (modified protocol; endotoxin-free) 
The BAC-DNA was prepared endotoxin-free to assure an optimal transfection rate 
in pKCs and pFFs. The modified protocol used represents a combination of the 
Endofree plasmid Maxi Kit using the QIAGEN-tips 500 and the buffer set 
(Qiagen, Hilden) and the E.Z.N.A.
®
 Endo-free Plasmid Midi Kit, using the ETR-
solution. BACs in SW106 cells are cultured at 32°C, in DH10B cells at 37°C.  
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A pre-culture of 3 ml LB medium supplied with the respective antibiotic was 
inoculated with the BAC of interest and left on the shaking incubator at 32°C 
(SW106)/37°C (DH10B) for at least 4 hours. After that a 100-200 ml o/N culture 
was inoculated. The o/N culture was centrifuged for 15 min at 4600 g and 4°C, 
the supernatant was discarded and the pellets resuspended in 10 ml P1 (+ RNase). 
After adding 10 ml P2 and a 5 min incubation at RT, 10 ml P3 (ice-cold) were 
added and incubated on ice for 15 min. Afterwards the samples were centrifuged 
for 30 min at 16100 g and 4°C, the supernatants were transferred to new tubes and 
0.1 volumes (approx. 3 ml) ETR solution were added. The tubes were inverted for 
mixing 7 times and then held on ice for 10 min. To enable the next centrifugation 
step, the solution had to be split into 15 ml tubes, which then were incubated for 
15 min at 42°C (water bath) and centrifuged for 10 min at 5000 g and RT. The 
supernatant was transferred to a new tube, 1 ml of prewarmed A. dest. was added 
and the previous centrifugation step was repeated, followed by the transfer of the 
supernatant to a 50 ml tube. 0.5 volumes of 100% EtOH were added and 
incubated for 2 min at RT. In the meantime the QIAtip 500 column was 
equilibrated by applying 10 ml QBT solution. The DNA solution was applied to 
the equilibrated column and entered the resin by gravity followed by a 2 times 
washing step with 30 ml QC solution. Afterwards the DNA was eluted with 15 ml 
QF solution, 10.5 ml iPrOH were added, the solution was then split into 15 ml 
tubes and centrifuged for 30-40 min at 16100 g and 4°C. Subsequently, the 
supernatant was discarded, the pellet was washed with 5 ml 70% EtOH overnight, 
the supernatant was removed on the next day and finally the pellet was 
resuspended in an appropriate volume of T-buffer. The DNA concentration was 
determined in a spectrophotometer. 
3.2.10 DNA sequencing 
DNA sequencing was achieved by capillary sequencing at the Helmholtz Center 
Munich. The DNA for sequencing was purified by PEG-precipitation and 
prepared for the sequencing service according to the following protocols. 
PEG-precipitation 
To achieve higher purities of plasmid DNA for sequencing, a precipitation step 
using PEG-MgCl2 was performed according to (Sambrook, 2001). A reaction mix 
containing equal amounts of plasmid DNA, PEG-MgCl2 and H2O (20 µl each) 
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was equilibrated for 10 minutes at RT. The mixture then was centrifuged for 20 
minutes at RT and 16100 g, the pellet was washed in 70% EtOH, air-dried and 
dissolved again in 20 µl T-buffer. 
Sequencing 
The sequencing was carried out according to the protocol of the Helmholtz Center 
sequencing service. The amount of DNA-template in ng was calculated as 
follows: DNA amount (ng) = (length of fragment in bp / 100) x 1.5. 
The DNA samples were diluted with A. dest. to the desired concentration. 
Constructs were sequenced using oligonucleotides termed T7 and M13, which are 
prone to sequence the fragments inserted into the multiple cloning site of the 
pGEM vector. Additionally DNA fragments were sequenced with self-designed 
primers or primers designed with the Primer Express software. The regular 
mastermix and the standard cycler protocol are given in table 3.5. 
Table 3.5:  Mastermix and cycling protocol for sequencing. 
Sequencing mix 
 
Sequencing cycler protocol 
4 µl  5x sequencing buffer 
 
95°C 1 min   
1 µl  BigDye 
 
95°C 5 sec   
1 µl  primer (10 µM stock) 
 
50°C 10 sec 40x 
2 µl  template 
 
60°C 4 min   
2 µl  A.dest. 
   
     
EtOH precipitation 
After adding 2.5 µl 125 mM EDTA and 30 µl 100% EtOH to the sequenced 
samples the solution was transferred to 1.5 ml tubes, which then were incubated 
on ice for 15 min. The samples then were centrifuged for 30 min at 16100 g and 
4°C. Thereafter the pellet was washed in 50 µl 70% EtOH (overnight). 
Subsequently the samples were centrifuged for 2.5 min at 16100 g and RT, the 
pellets were air-dried for 6 min and dissolved in 30 µl A. dest. Finally, the 
samples were transferred to a sequencing plate (ABgene
®
 96-well plate) and 
stored at -20°C until they were sent to the Helmholtz Center sequencing service. 
Data-analysis 
The electropherograms of the sequences were analyzed with the DNA sequencing 
chromatogram trace viewer FinchTV 1.3.1 and the biological sequence alignment 
editor BioEdit.  
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4 RESULTS 
4.1 Modification and preparation of BACs 
A total number of four different modification plasmid vectors (pCFTR-
STOP/lacZ and pGGTA-STOP/lacZ) were designed to introduce the desired 
alterations by recombineering into the respective BACs, carrying the target gene 
of interest (CFTR or GGTA1). The constructs pCFTR/GGTA-lacZ and their 
further application are described in 4.6. 
4.1.1 Searching for wild-type BACs 
For the CFTR gene, two different BACs, carrying the respective genomic 
sequence of interest, which is subsequently altered by recombineering (Copeland 
et al., 2001) with the respective modification vectors, were chosen. CH242-
248P18, including a pTARBAC1.3 backbone and PigI-170I3, supplied with a 
pBeloBACII backbone, were tested by a restriction digest (PvuII) for their 
integrity. The fragments on the agarose gel, when compared with the in silico 
pattern, give information if the supplied BACs actually contain the correct region 
of interest. CH242-248P18 was used for further experiments. 
The verification procedure concerning the BACs containing the GGTA1 gene 
(CH242-21F3 and CH242-372F22; both with pTARBAC1.3 backbones) was 
similar. The wild-type BACs were digested with PvuII and the resulting fragments 
were compared with the in silico pattern. Finally, BAC CH242-21F3 was used for 
further experiments. 
4.1.2 Design and construction of the modification vectors 
In order to obtain the complete knock-out of a desired gene, either RNA or protein 
synthesis have to be eliminated. In case of CFTR both, the RNA transcription and 
the protein translation start, are located in exon I. For the knock-out of the GGTA1 
gene, exon IV was targeted, eliminating the transcriptional and translational start 
as well. For this reason, a STOP-box containing a HIS3 (encodes 
imidazoleglycerol-phosphat dehydratase) yeast protein termination sequence as 
well as a SV40-pA (simian virus-polyadenylation) signal (Sauer, 1993) coupled to 
a neomycin/kanamycin resistance cassette (neokan
R
), was introduced behind the 
initial ATG codon of the respective exon by fusion PCR. The modification 
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vectors pCFTR-STOP and pGGTA-STOP were similarly designed and 
constructed. Restriction digests and ligations were carried out as described in 
methods 3.2.4 and 3.2.6, respectively. PCRs were performed according to the 
standard protocol in 3.2.1.1 with varying annealing temperature and elongation 
time, given in brackets. 
pCFTR-STOP and pGGTA-STOP 
The 2 kb floxed neomycin resistance cassette, lox
2
neo (NEO), derived from the 
vector pPNTlox
2
 was exchanged by a PGK (phosphoglycerate kinase) promoter 
driven, floxed 2.2 kb neomycin/kanamycin resistance (neokan
R
) cassette from 
pL452 via arabinose induced Cre-recombination. Neokan
R
 was cloned by 
NotI/BamHI into the pBSK II vector (pBSK-NEO). The 0.5 kb 3’arm-fragment 
was amplified from genomic pig DNA by conventional PCR using the primer 
pairs CFTR-3armf/CFTR-3armr (58°C annealing, 1 min elongation) and GGTA-
3armf/GGTA-3armr (58°C annealing, 1 min elongation). The amplified fragments 
were digested with NotI/NsiI and then ligated into the lox
2
neo-pBSK II vector 
(pBSK-3arm-NEO). The STOP-box, derived from pBS302, was cloned via 
BamHI into the pBSK II vector (pBSK-STOP). The 0.8 kb 5’arm-fragment was 
amplified from genomic BAC-DNA (CH242-248P18, CFTR; CH242-21F3, 
GGTA1) using primers CFTR-5armf/CFTR-STOPr and GGTA-5armf/GGTA-
STOPr, respectively (annealing 58°C, elongation 30 sec). In parallel, the STOP-
fragment was amplified from the pBS302 vector using the primer pair CFTR-
STOPf/STOPr and GGTA-STOPf/STOPr (annealing 58°C, elongation 1 min). 
The 5’arm- and STOP-PCR-fragments were eluted from an agarose gel and 
subsequently used as templates for a two-step-fusion-PCR using the flanking 
primers CFTR-5armf/STOPr and GGTA-5armf/STOPr according to the cycling 
protocol described in table 3.2. The PCR fusion-amplificates were directly 
digested with KpnI-BglII and then ligated into the KpnI-BglII digested pBSK-
STOP vector (pBSK-5arm-ATG-STOP). The resulting 5arm-ATG-STOP 
fragment was cloned by a HindIII-KpnI digest into the pBSK-3arm-NEO vector 
resulting in the modification vectors pCFTR-STOP and pGGTA-STOP 
(figure 4.1). The generated modification vectors subsequently were used to be 
introduced into the respective BAC mediated by recombination proteins in 
SW106 E. coli cells. 
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Figure 4.1: Illustration of the modification vector construction of pCFTR-STOP and 
pGGTA-STOP. 
Each modification construct consists of (i) a 5’-arm of homology and (ii) a 3’-arm of homology, 
amplified from genomic DNA by primer pairs indicated with yellow arrows, (iii) a floxed 
neomycin/kanamycin resistance (neokan
R
) cassette driven by a PGK (phosphoglycerate kinase) 
promoter and (iv) a STOP-box, containing a HIS3 (encodes imidazoleglycerol-phosphat 
dehydratase) yeast protein termination sequence as well as a SV40-pA (simian virus-
polyadenylation) signal. Primer pairs used to append the STOP-box directly to the ATG of the 
porcine gene of interest (CFTR or GGTA1) by a 2-step fusion PCR are indicated by green arrows. 
 
4.1.3 Modification of wild-type BACs  
The modification vector pCFTR-STOP and the respective wild-type BAC 
(CH242-248p18) were prepared according to the plasmid preparation protocol 
(adapted from Sambrook, 2001) described in 3.2.9.2. Thereafter, the isolated 
BAC-DNA was transferred to recombineering competent SW106 E. coli cells 
(500 ng BAC-DNA per aliquot) by electroporation. The bacterial suspension was 
plated after the electro-transformation step on agar plates containing the suitable 
antibiotic (kanamycin). Cells were grown overnight at 32°C. A resulting colony 
was picked, tested for the correct uptake of the BAC by conventional PCR and 
prepared as given in table 3.4 (SW106-recombineering). In parallel, the purified 
plasmid DNA was digested overnight (see 3.2.4) with KpnI/Cfr42I and the 
respective fragments were eluted from the agarose gel.   
Aliquots of the SW106 cells, containing the BAC of interest, were used for the 
electrotransformation step as described in 3.2.7.2. Two different amounts of 
linearized modification-fragment were used: 20 ng and 100 ng. After 2 hours 
recovery at 32°C (allowing activity of recombineering enzymes), the cells were 
plated on agar plates (containing kanamycin) and were incubated overnight at 
32°C. Clones appearing after recombineering on LB + Kan plates, were picked 
and prepared for screening PCR as described in 3.2.9.2 (heating step isolation). 
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The isolated BAC-DNA modified with the pCFTR-STOP constructs was screened 
with the primer pair CFTR-6456f/CFTR-7160r (annealing 60°C, elongation 
90 sec) for the wild-type sequence and with the primers CFTR-6456f/STOPr 
(annealing 54°C, elongation 90 sec) detecting the correct integration of the 
modification construct. BAC-DNA used for the GGTA1 approach, was screened 
after modification with the constructs pGGTA-STOP using the primers 
GGTAsf/GGTA5armr (annealing 56°C, elongation 90 sec) for the wild-type 
sequence and GGTAsf/STOPr (annealing 60°C, elongation 90 sec) for correct 
integration of the modification construct.  
The CFTR BAC modification approach resulted in 627 colonies from 4 agar 
plates (2 x 20 ng and 2 x 100 ng of linearized STOP fragment). 24 of them have 
been picked and analyzed by PCR as described above. 14 out of 24 clones could 
be dedicated as correctly modified. Colony 7 was used for further experiments. 
The GGTA1 BAC modification resulted in a total number of 182 colonies. Again 
24 colonies have been screened, of which 3 carried the correct modification. The 
results of the BAC modifications are shown in figure 4.2.  
 
Figure 4.2: Modification scheme for wild-type BACs by recombineering. 
Recombineering-competent SW106 cells containing the BAC of interest have been used for 
electrotransformation with the respective modification fragment, primarily excised from pCFTR-
STOP or pGGTA-STOP, respectively. The picture indicates a selective overview of the PCR-
screened modified BACs. In case of CFTR 14 out of 24 clones were screened positive (clone 7 
was used for further experiments), in case of GGTA1 3 out of 24 have been correctly modified 
(clone 10 was used for further experiments). Screening primers for the wild-type sequence are 
indicated by green arrows, for the knock-out sequence by red arrows. 
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For a more easy-handling, correctly modified BAC clones (in SW106 cells), 
termed p248-STOP or p21F3-STOP, respectively, were re-transformed into 
recombineering deficient E. coli strains (DH10B). The procedure was carried out 
similar to the electrotransformation described above. Aliquots of electrocompetent 
DH10B cells (produced as described in 3.2.7) were transformed with 20 ng as 
well as 100 ng of the respective BAC-DNA. The cell suspension was plated on 
agar plates containing the suitable antibiotic (kanamycin or chloramphenicol) and 
incubated overnight at 37°C. A number of the resulting colonies were picked, and 
prepared for screening PCR as well. The remaining screening steps were carried 
out equally as already described above. 
4.1.4 Preparation of the modified BACs for transfection approaches 
Finally, the correctly modified BAC-constructs were prepared for the transfection 
step into porcine kidney cells following the endotoxin-free isolation protocol 
described in 3.2.9.2. After DNA isolation, the constructs have been linearized 
with AscI as restriction enzyme of choice. The restriction digest was carried out 
according to the standard protocol for BAC digestion given in 3.2.4 using 
adequate amounts of enzyme for the amount of DNA to be digested. The number 
of BAC-DNA isolations per construct and the resulting amount of DNA, after 
linearization, is listed in table 4.1. 
Table 4.1:  Overview of BAC-DNA isolations per construct. 
p248STOP p21F3STOP 
 # isolation DNA amount [µg]   # isolation DNA amount [µg]  
1 27.4 1 9.0 
2 21.7 2 4.0 
3 15.0 3 5.5 
4 10.0 4 33.5 
5 14.0   
6 38.0   
7 42.8   
8 19.2   
9 34.6   
10 14.0   
11 18.0   
12 20,7   
13 17,6   
14 31.8   
   324.8  51.5 
 
Results     56 
4.2 Introduction of modified BAC-DNA into porcine primary 
cells 
The necessary cell culture work for this project, including (i) preparation of target 
cells, (ii) cell transfection, (iii) antibiotic-based selection for construct integrations 
into the cells, (iv) the microscopical screening for single cell clones and (v) the 
propagation of cell clones for DNA isolation and cryopreservation for nuclear 
transfer experiments was carried out under the direction of Dr. Annegret Wünsch 
at the Chair for Molecular Animal Breeding and Biotechnology.  
4.2.1 Preparation of target cells 
Two different target cell populations were established from different material 
according to an isolation protocol using Collagenase II for cell dissociation: (i) 
primary porcine fetal fibroblasts (pFF) obtained from a day 27 male pig fetus and 
(ii) primary porcine kidney cells (pKC) from approximately three months old 
male pigs. After verification of the cells for the correct karyotype (sus scrofa = 38 
chromosomes) and capability for nuclear transfer the primary cells were further 
cultured and transfected after two to three passages. As standard culture medium 
Dulbecco Modified Eagle Medium (DMEM) with 10-15% (v/v) fetal calf serum 
and additional supplements was used. Both cell populations were growing as 
monolayer on collagen-coated plates and detached using trypsin/EDTA. 
4.2.2 Transfection of target cells 
Transfection was performed via the electroporation based Nucleofector
®
 
(AMAXA
®
 Basic Nucleofector Kit Primary Fibroblasts, Lonza, Köln) according 
to the manufacturers protocol. In brief, 0.5-1 x 10
6
 target cells (pFF or pKC) were 
transfected after harvesting from the plates with circular or linearized BAC-DNA. 
DNAs p248STOP, p248lacZ, p21F3STOP, p21F3lacZ were isolated according to 
the protocol described in 3.2.9.2 and linearized, if needed, with AscI (see 3.2.4). 
4.2.3 Selection for construct integration and screening for single cell 
clones  
48 hours (except one time 24 hours) after transfection of the target cells, the 
selection for clones with integrated BAC-constructs carrying the neomycin 
resistance cassette was started. Different amounts of transfected cells (partly in 
combination with non-transfected wild-type cells) were seeded on 96-well plates 
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and cultured in regular growth medium supplemented with geneticin (G418) in 
the appropriate concentration (0.6 mg/ml for pFF, 1.2 mg/ml for pKC) for one 
week. Thereafter, the plates were screened for wells containing one colony of a 
single cell clone. Those single cell colonies were expanded to 30-90% confluence. 
Different strategies were faced: (i) after harvesting the cells with at least 90% 
confluence from the 96-well plates the cell pellets were frozen in a reaction tube 
for subsequent DNA-isolation (see 3.2.9.1) at -80°C, (ii) the cells were transferred 
to another 96-well plate when they were minimum 30% confluent to promote 
proliferation; after reaching confluence, they were harvested and frozen for DNA 
isolation (see above); (iii) to generate a backup sample for nuclear transfer, the 
cell colonies were split 1:2 on new 96-well plates; after reaching 90-100% 
confluence, the cells were removed by trypsinization from the plates. One aliquot 
was used for DNA isolation as needed for qPCR-screening, the other one was 
conserved as backup sample in cryopreservation medium (90% fetal calf serum + 
10% DMSO) at -80°C, enabling the reactivation of candidate clones for nuclear 
transfer. 
The CFTR knock-out approach included 23 AMAXA nucleofections using 
porcine kidney cells as target cells, resulting in 1151 clones for subsequent 
analysis (for a detailed overview see table 4.2).  
Table 4.2: Nucleofection overview for CFTR targeting. 
p248STOP # epos DNA [µg]  # cells (10
6
) # cells per well*  clones 
100309 2 10/10 1 2000 51 
270309 4 10/10/10/10 1 2000 164 
310309 2 10/4.7 0.74 2000 19 
200609 4 7/7/5.6/5.6 1 2000 83 
060709 5 5.6/5.7/7.6/7.6/2.5 1 2000 329 
300709 2 9/9 1 2000 59 
110809 2 5.6/5.6 1 2000 165 
120909 (A) 1 3.2 0.5 600 / 600 53 
120909 (B) 1 6.7 1 1300 / 1100 228 
total CFTR 23 168 8.24 
 
1151 
*transfected/wild-type 
 
In case of the GGTA1 gene knock-out using pKCs as target cells five transfections 
with the p21F3STOP construct resulted in 306 clones for further investigation 
(a detailed overview of the p21F3STOP transfections is listed in table 4.3). 
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Table 4.3: Nucleofection overview for GGTA1 targeting. 
p21F3STOP # epos DNA [µg]  # cells (10
6
) # cells per well* clones 
310309 3 6.4/3/3.9 0.74 2000 36 
120909(A) 1 4.5 1 2400/2400 150 
120909(B) 1 6.6 1 2400/2400 120 
total GGTA 5 24.4 2.74 
 
306 
* transfected/wild-type 
    
 
The genomic DNA of the generated cell clones was isolated followed by the 
screening for correct construct integration into the porcine genome of the somatic 
cell according to the LOWA-assay. 
4.3 Isolation of genomic DNA from cell clones 
After transfection of the target cells with the respective gene constructs for the 
targeting approach (p248-STOP or p21F3-STOP), single cell clones have been 
generated, preselected and screened for vector integration. Each of the single cell 
clones was propagated to confluence on a 96-well plate well, bearing the problem 
of very small amounts of primary cells (maximum of 8000-10000) available per 
clone. The isolated DNA is demanding appropriate purity for further qPCR-
application. Hence, several DNA isolation methods needed to be tested.  
In this experiment 13 different isolation methods, including six conventional 
isolation methods (Phenol-Chloroform-Isoamylalcohol extraction, Kawasaki 
buffer isolation, high-salt precipitation, spermidine-purification, Gentra Puregene 
Cell Kit, Wizard
®
 genomic DNA-Purification Kit), five column-based isolation 
methods (Nucleospin
®
 Tissue Kit, peqGOLD MicroSpin Tissue DNA Kit, Qiagen 
DNeasy Blood & Tissue Kit, QIAamp
® 
DNA Micro
 
Kit, E.Z.N.A
®
 Tissue DNA 
Kit), one filtration-based (nexttec
TM
 DNA Isolation clean columns) and one 
isolation method based on magnetic particles (MAXWELL® 16 cell LEV 
Purification Kit), were tested. In each case five samples containing 7500 pFFs 
(this amount complies with the average cell number grown in one well of a 
96-well culture plate) and five samples containing 3750 cells (reflecting cell 
clones growing not that good) were isolated according to the provided protocols. 
Due to the small amount of available cells, it was not possible to measure the 
resulting DNA concentration by a spectrophotometer as usual. Standard qPCR 
runs provided an insight, which isolation methods met the demands for further 
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approaches. In table 4.4 an overview of the 13 different methods regarding DNA-
yield and reproducibility of the qPCR results is shown. 
Table 4.4:  Overview of 13 different isolation methods. 
  DNA isolation method DNA-yield reproducibility 
conventional PCiA sufficient high SD 
 
Kawasaki low / 
 
High-salt precipitation sufficient yes 
 
Spermidine sufficient* / 
 
Puregene sufficient high SD 
 
Wizard
® 
low / 
column-based Nucleospin
® 
low / 
 
peqGOLD low / 
 
DNeasy low / 
 
QIAamp low / 
 
E.Z.N.A
®
 low / 
filtration-based Nexttec
TM 
sufficient high SD 
magnetic particles MAXWELL
®
 sufficient high SD 
* Agent interferes with SYBR green I detection in qPCR; SD: standard deviation 
 
In case of the conventional methods tested, the Kawasaki buffer isolation was not 
applicable for qPCR, due to insufficient DNA yield and purity. The isolation of 
DNA by spermidine for the SYBR green I assay was also not practicable, due to 
inhibiting effects correlating with the concentration of the DNA samples tested. 
The Wizard
®
 genomic DNA-Purification Kit yielded too low amounts of DNA, 
the initially used PCiA-method and the Gentra Puregene Cell Kit showed too high 
standard deviations when tested in qPCR applications. 
The five column-based methods and the filtration based method all resulted in a 
too high loss of DNA during the procedure, making them not feasible for this 
approach.  
The magnetic-beads-based method used, showed a very high variety in the 
binding capacity of the DNA to the magnetic particles, resulting as well in very 
high standard deviations during qPCR, whereas the high-salt precipitation method 
showed convincing results in the qPCR assay. Additionally, the easy-handling due 
to the requirement of nontoxic reagents for the isolation and the expedient time-
management pointed out the high-salt precipitation as method of choice. 
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4.4 Screening of cell clones for correct vector integration 
Due to the long homology regions, preparing BACs as ideal tools for targeting 
experiments, it is necessary to think of alternative methods to detect correct vector 
integrations in the porcine genome beside Southern blot technology and 
conventional PCR.  
4.4.1 LOWA-assay  
The ‘loss of wild-type allele’-assay (LOWA), known as a qPCR-based method to 
detect copy numbers of wild-type alleles of one target gene compared to 
respective reference genes throughout the genome, provides an excellent method 
to screen hundreds of clones for heterozygous as well as homozygous alterations 
(figure 4.3). Due to possible variations concerning the qPCR efficiency 
throughout different loci the search for appropriate reference genes and primer 
pairs was necessary. 
 
Figure 4.3: Schematic illustration of the LOWA-assay for CFTR/GGTA1 targeting. 
The copy numbers of the target gene and two selected reference genes (CFTR, GGTA1, HPRT) 
were detected by qPCR. Primer pairs were selected to detect wild-type alleles in each case, and the 
copy number ratio between the target gene and each reference gene was calculated. In wild-type 
cells or cells with random integration of the vector the ratio was 2:2. After targeted introduction of 
the vector construct, the ratio between the target gene and each reference gene was reduced to 1:2, 
indicating the loss of one wild-type allele for the desired DNA region. 
 
4.4.2 Optimization of qPCR conditions 
Several primer pairs for the target loci CFTR or GGTA1 as well as for four other 
reference genes (β-actin, ACTB; Hypoxanthine-phosphoribosyl-transferase, 
HPRT; porcine Leptinreceptor, lepR; Myelocytomatosis oncogene, MYC) have 
been designed (table 4.5) and purchased from Thermo Scientific (Ulm, Germany). 
All 31 primer pairs, either designed by hand or using the Primer Express
®
 
Software v2.0 (Applied Biosystems, Weiterstadt), have been initially tested by 
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conventional PCR, each showing bands on agarose gels at the desired size. The 
conventional PCR was carried out according to the protocol given in 3.2.1.1 with 
an annealing temperature of 60°C/63°C and elongation for 45 sec.  
Table 4.5:  Overview of the pre-tested primer pairs for qPCR optimization. 
GGTA1 CFTR HPRT ACTB lepR MYC 
2377f/2758r 6752f/118r 781i2f/943i2r 237f/390r 3059f/3119r 41f/307r 
3423f/3640r 6822f/7199r 834i2f/987i2r 1059f/1219r 1452f/1616r 633f/761r 
3323f/3516r 359f/564r 3133i4f/3297i4r 
  
286f/425r 
10f/149r 402f/621r 374i5f/528i5r 
  
949f/1051r 
126f/492r 1772f/2060r 3088f/3425r 
   
131f/297r 986f/1132r 4152f/4478r 
   
232f/424r 46f/172r 4578f/4744r 
   
 
696f/853r 657f/788r 
   
7 8 8 2 2 4 
 
In order to evaluate the appropriate primer pairs for the subsequent qPCR 
application to test the targeted cells for events of homologous recombination by 
the LOWA-assay, several conditions have to be kept. Thus, (i) the amplificate 
should show sizes ranging between 150 to 500 bp, (ii) the run conditions relating 
to extension temperature and primer concentration should be at least similar 
throughout the compared genes (iii) the PCR efficiency should amount to almost 
100% marked by a slope of -3.322 of the standard curve and (iv) the correlation 
factor (R
2
), obtained by a standard curve, should not be less than 0.99.  
In an initial qPCR approach, genomic DNA from porcine fetal fibroblasts (pFF) 
has been isolated by PCiA extraction, diluted with T-buffer to concentrations of 
125 ng, 12.5 ng and 1.25 ng (a no template control, NTC, was also added) and 
tested at run conditions of 60°C extension temperature and a primer concentration 
of 0.25 µl per 12.5 µl total volume per sample. Promising primer pairs then were 
tested in additional qPCR-set-ups by increasing the annealing temperature to 63°C 
and the primer concentration to 0.5 µl or 0.75 µl per 12.5 µl mastermix total 
volume.  
Optimization of the evaluated 31 primer pairs revealed for the LOWA-assay: the 
CFTR gene has been detected with primer pair CFTR402f-CFTR621r at run 
conditions of 60°C extension temperature and 0.25 µl primer per 12.5 µl (0.2 µM) 
total volume per PCR mix and the reference genes of choice (HPRT, GGTA1) 
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have been detected with the primer pairs HPRT834i2f-987i2r with 63°C and 
0.25 µl primer (0.2 µM) and GGTA3423f-GGTA3640r with 63°C and 0.75 µl 
primer (0.6 µM), respectively (table 4.6).  
Table 4.6:  Overview of the primer pairs for qPCR representing the best candidates 
for target and reference gene. 
gene primer fragment length in bp run conditions slope R
2
 
ACTB 1059f/1219r 160 0.2 µM/63°C -3,266 0,999 
HPRT 834i2f/987i2r 153 0.2 µM/63°C -3,206 0,995 
GGTA1 3423f/3640r 217 0.6 µM/63°C -3,404 0,997 
CFTR 402f/621r 219 0.2 µM/60°C -3,374 0,997 
lepR 3059f/3119r 60 0.2 µM/63°C -3,231 0,997 
MYC 41f/307r 266 0.2 µM/63°C -2,904 0,991 
 
949f/1051r 102 0.2 µM/60°C -2,794 0,963 
 
The amplification plots and the associated dissociation curves for the three chosen 
primer pairs are shown in figure 4.4. For the GGTA1 approach target gene and 
reference gene were simply switched (CFTR now reference gene and GGTA1 
evaluated as target gene). 
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Figure 4.4: Amplification plots and dissociation curves. 
The primer pairs CFTR402f-621r, GGTA3423f-3640r and HPRT834i2f-987i2r were tested in an 
initial qPCR approach using isolated pFF DNA diluted to concentrations of 125 ng, 12.5 ng and 
1.25 ng. The screenshots represent the amplification plots on a logarithmic scale and the respective 
dissociation curves as an output of the ABIPrism 7000 detection system. The amplification plots 
indicate a serial 10-fold dilution as the single DNA curves cross the threshold (indicated by the 
light green horizontal line) every 3 cycles, representing a valid result for further proceeding with 
this PCR primer pair. The peaks of the dissociation or melting curve demonstrate a particular type 
of molecule (the amplicon) dissociating at a particular temperature. NTCs (no template controls) 
should display an almost flat line without any or too high peaks, otherwise primer dimer formation 
according to secondary structures might affect the amplification reaction.   
 
The thermal profile of the qPCR performance consists of (i) an initial activation 
step at 50°C for 2 min, followed by (ii) an initial denaturation step at 95°C for 
10 min completed by (iii) a 40 cycle repeat of denaturation at 95°C for 15 sec and 
primer annealing and extension at 60°C (for CFTR) and 63°C (HPRT, GGTA1) 
respectively, for 1.5 min (illustrated in figure 4.5). 
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Three stages including an initial activation step (for UNG) for 2 min at 50°C, an initial 
denaturation step for 10 min at 95°C and a 40 cycle repeat of denaturation for 15 sec at 95°C and 
primer annealing and elongation for 90 sec at 60°C (in case of CFTR) and 63°C (in case of 
HPRT/GGTA1). After the last cycle the samples again were heated from 60°C to 95°C to obtain a 
dissociation curve of the PCR amplicons. 
 
4.4.3 Routine setup for qPCR screening 
Different PCR conditions for three different genes required the correlation of the 
copy numbers from three separated PCR runs. Thus, all screening experiments 
were conducted on three different plates each detecting CFTR, GGTA1 or HPRT, 
respectively. One Microamp
TM
 optical 96-well plate contains the following 
samples: (i) genomic pig DNA at positions A1-H2 with concentrations of 10000, 
7500, 5000, 2500, 500, 250, 50 and 25 copies pipetted in duplicates representing a 
standard curve, (ii) a triplicate of genomic pig DNA at positions H9, 10 and 11 in 
a concentration of around 5000 copies working as a calibrator between the three 
plates of one evaluation set, (iii) a no template control (NTC) at position H12 
representing a negative control for the system and (iv) a maximum of 38 clones 
pipetted in duplicates (illustrated in figure 4.6). 
Figure 4.5: The qPCR thermal profile used for cell clone screening. 
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Figure 4.6:  Routine setup for qPCR screening. 
Standard dilutions for the standard curve in the given concentrations (assuming that 100 ng of 
porcine DNA is equivalent to 15000 copies), a calibrator and a no template control (NTC) are set 
on a Microamp
TM
 optical 96-well detection plate. It is possible to evaluate 38 different clones 
(duplicates) per setup. Plates are held on ice during pipetting, samples are added using filter tips. 
 
4.4.4 Clone determination 
The template number of the clones was calibrated for each amplicon using a male 
porcine genomic DNA with a defined copy number (~5000 copies). The 
calibrated copy numbers were compared by calculating the ratios GGTA1/CFTR, 
HPRT/CFTR and GGTA1/HPRT. For visual illustration later on, the 
GGTA1/HPRT ratio was omitted. In the case of random integration the number of 
the CFTR target locus was assumed to be the same as for the reference genes, 
thus, the calculated ratios should be around 1.0 whereas in the case of successful 
targeting, there would be only one remaining wild-type CFTR copy per diploid 
genome, changing the ratios with the CFTR copy number as divisor near 2.0.  
Of course, this presumption of the copy number ratios is only valid for identical 
PCR efficiencies for all detected genes with a respective PCR efficiency of 100%. 
For this reason, it was necessary to adjust the mathematical calculation to 
determine positive cell clones as follows. The qPCR raw data was analyzed by the 
calculation of the copy number ratios of each reference gene divided by the target 
gene copy number. Clone DNA was pipetted in duplicates (as described in 4.4.3), 
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the mean value (MV) as well as the two times standard deviation (2 SD) of each 
clone were determined. Clones exceeding the value of the 2 SD of the mean value 
of all ratio values per setup-plate were termed as ‘candidates’. Assuming a normal 
distribution of the ratio values, clones are termed as candidates with a statistical 
likelihood of 97.5%. An illustrated example of the candidate evaluation is given in 
figure 4.7-A. Those candidates are confirmed as correctly targeted in a second 
qPCR run using a different set of clones to ensure a different background situation 
(figure 4.7-B). 
 
Figure 4.7: Illustrated example of the candidate evaluation. 
The copy number ratios of each reference gene divided by the target gene copy number are used 
for calculating the mean value (mv; indicated by continuous lines) and the two times standard 
deviation (2 SD; indicated by dotted lines) among the investigated clone DNA. Clones exceeding 
the 2 SD-value are termed ‘candidates’. (A) Assuming a normal distribution of the ratio values, 
CFTR 1100 and CFTR 1101, represent correctly targeted candidates with a statistical likelihood of 
97.5%. (B) The candidates are verified in a second qPCR setup, using different background clones. 
 
Clones showing calibrated copy numbers below 30 (cn < 30) and standard 
deviations of their ratio values higher than 0.5 (SD > 0.5) in any of the 4 values 
were termed ‘not determinable’ and not considered for further processing. 
Additionally, not detectable wells due to pipetting errors or too low DNA 
amounts, leading to clones which were not evaluable also were summarized in 
this category.  All other samples meeting the quality criteria (cn > 30, SD < 0.5) 
were used for the final targeted clone evaluation. 
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4.4.5 LOWA-screening results 
The LOWA-results for the CFTR screening were summarized in table 4.7 and for 
the GGTA1 screening in table 4.8. 
Table 4.7: CFTR knock-out screening. 
p248STOP # epo DNA [µg] # clones positive clones confirmed 
100309 2 20 51 0 0 
270309 4 40 164 1 1 
310309 2 14.7 19 0 0 
200609 4 25.2 83 1 1 
60709 5 29 329 7 6 
300709 2 18 59 1 0 
110809 2 11.2 165 2 0 
120909 2 9.9 281 9 6 
total pKC 23 168 1151 21 14 
 
The 23 transfections of pKCs with different amounts of endotoxin-free prepared 
and linearized p248STOP-DNA resulted in the generation of 1151 single cell 
clones. After isolation of the clone DNA and evaluation of 31 clone sets (each 
consisting of one target gene plate and two reference gene plates) for qPCR-
screening, 1034 of those clones were categorized as ‘determinable’.  14 out of 21 
candidate clones were finally confirmed as correctly targeted after a second 
qPCR-validation. This led to a targeting efficiency of 1.35%. 
Table 4.8: GGTA1 knock-out screening. 
p21F3STOP # epo DNA [µg] # generated clones candidates confirmed 
310309 3 13.3 36 0 0 
120909 2 11.1 269 11 8 + 1mc* 
total pKC 5 24.4 305 11 8 + 1mc* 
* mc: mixed clone  
 
A total number of five electroporations using endotoxin-free prepared and 
linearized p21F3STOP DNA resulted in the generation of 305 neomycin resistant 
clones which were evaluated in eight clone sets. 230 clones were determinable 
from which 8 out of 11 candidates could be validated as correctly targeted. One 
candidate, marked as mixed clone, showed less prominent qPCR confirmation 
properties, presumably mediated by a mixed population, containing targeted and 
non-targeted cells. Nevertheless, this clone was used for nuclear transfer as well. 
The targeting efficiency in this case, assuming the mixed clone as positive 
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candidate, was 3.91%. The illustrations of the correctly targeted clones for each 
targeting approach are shown in figure 4.8 for CFTR and 4.9 for GGTA1. Only 
clones subsequently used for SCNT have been considered. Finally, the correctly 
targeted clones were thawed, cultured and prepared for nuclear transfer. 
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Figure 4.8: Illustration of clone sets for CFTR. 
CFTR1002, 1019, 1025, 1100, 1101 and 1064 exceed the 2 SD-value, indicated by dotted lines, 
therefore considered as correctly targeted candidates. All clones are demonstrated in a first 
evaluation and a second confirmation run. MV: mean value, 2 SD: two times standard deviation, 
continuous line: mean value, dotted lines: MV plus 2 SD, orange boxes: candidates after a first 
qPCR evaluation, green boxes: verified candidates in a second evaluation on a different clone set, 
to ensure different background situations. Only clones, subsequently used for further proceeding 
have been considered. 
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Figure 4.9: Illustration of clone sets for GGTA1. 
GGTA 65, 91, 131, 140, 218 and 250 exceed the 2 SD-value, indicated by dotted lines, therefore 
considered as correctly targeted candidate. All clones are illustrated in a first evaluation and a 
second confirmation run. MV: mean value, 2 SD: two times standard deviation, continuous line: 
mean value, dotted lines: MV plus 2 SD, orange boxes: candidates after a first qPCR evaluation, 
green boxes: verified candidates in a second evaluation on a different clone set, to ensure different 
background situations. Only clones, subsequently used for further proceeding have been 
considered. 
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An overview of the candidate clones, regarding their copy number ratios (cnr), the 
mean value (MV) detected on the respective clone set and the ratio of both of 
them to visualize the change of the copy number ratios after correct targeting by 
dividing cnr/MV, is shown in table 4.9. 
Table 4.9: Overview of candidate clones for SCNT. 
candidate MV H/C MV G/C cnr H/C cnr G/C cnr/MV (H/C) cnr/MV (G/C) 
CFTR1002 1.00 0.80 2.30 1.68 2.30 2.09 
  0.69 0.98 1.06 1.59 1.54 1.62 
CFTR1019 1.00 0.80 2.01 1.41 2.02 1.76 
  0.69 0.98 1.70 2.14 2.46 2.18 
CFTR1025 1.18 1.25 2.34 2.22 1.98 1.78 
  0.69 0.98 1.20 2.14 1.74 1.73 
CFTR1064 1.38 1.07 2.56 1.60 1.92 1.49 
  0.72 0.96 1.50 1.96 2.08 2.04 
CFTR1100 0.69 0.98 1.35 1.84 1.96 1.88 
 
0.64 0.88 1.15 1.37 1.80 1.56 
CFTR1101 0.69 0.98 1.20 1.66 1.74 1.70 
 
0.64 0.88 1.30 1.40 2.03 1.59 
       candidate MV H/G MV C/G cnr H/G cnr C/G cnr/MV (H/G) cnr/MV (C/G) 
GGTA65 0.85 1.24 2.45 2.17 2.88 1.75 
  0.92 1.12 2.27 2.56 2.47 2.06 
GGTA91 0.92 1.12 1.87 2.44 2.03 1.97 
  1.00 1.77 1.95 3.44 1.95 1.94 
GGTA131 0.83 1.11 1.69 2.12 2.04 1.91 
  1.00 1.18 1.62 2.15 1.62 1.82 
GGTA140 0.83 1.11 2.53 2.05 3.04 1.85 
  1.00 1.18 2.04 2.28 2.04 1.93 
GGTA218 1.00 1.77 1.73 3.24 1.73 1.83 
  0.67 1.00 1.22 1.71 1.82 1.71 
GGTA250* 1.00 1.18 1.72 1.68 1.72 1.42 
  0.67 2.45 1.14 3.35 1.70 1.37 
MV: mean value; C: CFTR; G: GGTA1; H: HPRT; cnr: copy number ratio; cnr/MV: ratio 
between cnr and MV; * indicates mixed clone; 
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4.5 Generation of the respective porcine animal model 
4.5.1 Nuclear transfer and embryo transfer experiments 
Nuclear transfer (NT) and embryo transfer (ET) technologies were carried out by 
Dr. Mayuko Kurome and Dr. Barbara Keßler at the Chair for Molecular Animal 
Breeding and Biotechnology. Practical techniques therefore are just briefly 
summarized below. 
In vitro matured (IVM) oocytes, treated according to the protocol for oocyte 
maturation (reviewed in Kurome et al, 2006) were used for the somatic cell 
nuclear transfer (SCNT) experiment. After in vitro maturation, oocytes showing 
extrusion of the first polar body were actually used for enucleation. In the case of 
the targeting approach using the p248STOP- and p21F3STOP-constructs, pairs or 
triplets of selected pKCs were pooled and used as nuclear donor cells after cell 
cycle synchronization by serum starvation for 48 hours. Single donor cells were 
inserted into the perivitteline space of the enucleated oocytes. The membranes of 
oocyte and donor cell were fused by an electric pulse, followed by the activation 
of the oocyte mediated by a direct pulse. Reconstructed oocytes were cultured for 
one or two days until they have been used for ET. Six to seven months old estrus 
synchronized gilts were used as recipients for embryo transfer. The reconstructed 
embryos, cultured for two days after NT, were transferred laparoscopically to the 
right oviduct of the synchronized gilt. In case of CFTR 3 NT/ET experiments 
resulted in the establishment of two pregnancies, with an overall outcome of 
seven fetuses and five piglets. A total number of three NT/ET experiments using 
correctly targeted cell clones modified with the p21F3STOP construct, led to the 
establishment of two pregnancies with an overall outcome of ten fetuses, three 
alive piglets and one still born. The results of the NT/ET experiments for the 
STOP constructs (p248STOP, p21F3STOP) are illustrated in table 4.10. Finally, 
the gained fetuses and piglets were rescreened for the assumed targeted deletion 
of the CFTR and GGTA1 gene, respectively. 
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Table 4.10: Results of NT/ET experiments for targeting approaches. 
p248STOP cell pool maturation 
rate 
#NT 
embryos 
fused 
oocytes 
embryos 
transferred 
pregnancy outcome* 
041209 1019, 1100 142/173 121 103 93 1 7f 
111209 1002, 1101 143/161 116 107 105 1 5p 
220110 1025, 1064 93/138 85 75 66 0 0 
p21F3STOP cell pool maturation 
rate 
#NT 
embryos 
fused 
oocytes 
embryos 
transferred 
pregnancy outcome* 
290110 65, 91, 131 111/186 98 83 79 0 0 
110210 140, 218 105/158 100 82 82 1 3p/1sb 
170210 250
**
, 218 158/178 139 110 110 1 10f 
*f: fetus; p: piglet; sb: still born; **indicates a mixed population 
 
4.5.2 Evaluation of fetuses and piglets 
4.5.2.1 CFTR results 
Three NT/ET experiments (shown in table 4.10) have been performed, resulting in 
the establishment of two pregnancies. The NT1 pregnancy was terminated at 
day 59, allowing the evaluation of the kidney-tissue samples of the seven obtained 
fetuses for correct targeting. The NT2 pregnancy delivered five piglets 
(#9978-#9982) at term, from which ear tips have been taken. Kidney DNA from 
fetuses and DNA from ear cartilage tissue of the piglets was isolated according to 
the protocols given in 3.2.9.1. Subsequently, the isolated, purified DNA was 
tested by qPCR regarding its CFTR-heterozygosity. 
4.5.2.1.1 Fetus verification 
The isolated fetus DNA was added to a set of pKC cell clones, isolated by high-
salt precipitation and obtained from the CFTR targeting before, providing a 
comparable background situation. The plates were simultaneously prepared as 
known from the LOWA-evaluation of the targeted CFTR clones described in 4.4.3 
and 4.4.4. Fetus one was not confirmed as targeted, whereas fetus two to seven 
were confirmed as correctly heterozygously targeted. The results of the LOWA-
evaluation of the fetal kidney cell DNA are shown in figure 4.10. An overview of 
the obtained fetuses, regarding their copy number ratios (cnr), the mean value 
(MV) detected on the respective clone set and the ratio of both of them to 
visualize the change of the copy number ratios after correct targeting by dividing 
cnr/MV, is shown in figure 4.11. 
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Figure 4.10: qPCR confirmation of the 7 heterozygous knock-out fetuses. 
From kidney samples primary pKCs were isolated, cultured, the DNA was isolated by high-salt 
precipitation and used for LOWA-screening by qPCR. Fetus 1 was slightly below the 
predetermined 2 SD-values. Fetuses 2-7 were verified, as their copy number ratios exceed the 
2 SD-value, to be heterozygous knock-outs. Background was given by high-salt isolated pKC-
clones obtained from the CFTR targeting.  
 
 
Figure 4.11: Evaluation of the CFTR-fetuses. 
The copy number ratios of each fetus were related to the whole plate mean value of copy number 
ratios obtained from the respective clone set by dividing those values. For a correct targeting, the 
result should be around 2.00. Due to clone set variability a range of 1.60 to 2.90 is considered. 
MV: mean value; C: CFTR; G: GGTA1; H: HPRT; cnr: copy number ratio; cnr/MV: ratio between 
cnr and MV. 
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4.5.2.1.2 Piglet verification 
The isolated ear fibroblast DNA of the five obtained piglets was analyzed with the 
LOWA-assay for a heterozygous allele status. The results of the qPCR-evaluation 
are shown in figure 4.12. All animals reflected copy number ratios indicating a 
successful heterozygous targeting of the CFTR gene. As background, DNA 
isolated by high-salt precipitation from clones used for the GGTA1 approach had 
been used. The CFTR heterozygous knock-out litter including the animals 
#9978-#9982 is shown in figure 4.13-A. Surprisingly, all animals established a 
malformation of the forelegs, shown in figure 4.13-B. With increasing age those 
malformations decreased, not impairing the animals’ welfare. Animal #9978 
suffered from a congenital atresia ani (figure 4.13-C). After an unsuccessful 
surgery, implicating the total lack of the rectum, the animal was euthanized on 
day six. Animal #9981 died with the age of four months of cystitis and rupture of 
the bladder, but, as assumed, not due to consequences of its CFTR-heterozygosity. 
 
Figure 4.12: qPCR confirmation of the 5 CFTR
-/+
 piglets. 
From ear tissue fibroblasts were isolated, cultured, the DNA was purified by high-salt precipitation 
and used for LOWA-screening by qPCR. All 5 piglets were verified as heterozygous knock-outs. 
The copy number ratios of each piglet were related to the whole plate mean value of copy number 
ratios obtained from the respective clone set by dividing those values. For a correct targeting, the 
result should be around 2.00. Due to clone set variability a range of 1.70 to 2.20 is considered. 
MV: mean value; C: CFTR; G: GGTA1; H: HPRT; cnr: copy number ratio; cnr/MV: ratio between 
cnr and MV. 
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The CFTR heterozygous knock-out litter (#9978-#9982) is shown in (A). Malformations of the 
forelegs are demonstrated in (B). The congenital atresia ani of piglet #9978 is indicated in (C). 
 
4.5.2.1.3 Production of homozygous animals and outlook 
The residual three boars (#9979, #9980, #9982) were used to establish additional 
heterozygous pigs which subsequently are going to be used for interbreeding to 
obtain homozygous knock-outs. Mating results of the heterozygous animals with 
wild-type German landrace sows are shown in table 4.11. 
Table 4.11: Mating results of CFTR
+/-
 boars. 
CFTR
-/+
 boar litter male/female hemizygous knock-out 
# 9979 170411 7/7 1/3 
# 9980 140311 8/0 2/0 
# 9982 141211 6/3 4/2 
  
21/10 7/5 
 
The results are in line with the expected Mendelian distribution. Animal #9981, 
which was euthanized, due to cystitis and bladder rupture with the age of four 
months, was used to establish a heterozygous kidney cell line to target the second 
Figure 4.13: Piglets derived from the NT-2 experiment. 
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CFTR allele. For this reason the floxed neokan
®
 cassette was exchanged through 
arabinose induced Cre-mediated excision by a blasticidin resistance (bsr
®
) 
cassette. CFTR
-/+
 cells have been nucleofected with the targeting vector, carrying 
the bsr
®
 resistance gene, subsequently were preselected by blasticidin S. A total 
number of 213 resistant colonies have been generated, 173 have been screened 
using the LOWA-assay and two of them could be determined as CFTR
-/- 
(carried 
out by Dr. Nikolai Klymiuk and Anne Richter). One of those homozygous 
knock-out clones was used for SCNT. An overall number of 348 embryos were 
transferred to four synchronized gilts, two pregnancies were established and the 
delivery at term resulted in litters of nine and two piglets, respectively. Two 
piglets were still born, all the others were alive, but had to be euthanized after a 
maximum of 37 hours (for further information read Klymiuk et al., 2011). 
4.5.2.2 GGTA1 results  
Three NT/ET experiments (table 4.10) have been performed. NT2 (GGTA140, 
GGTA218) delivered three alive and one still born piglets at term. The pregnancy 
resulting from NT3 (GGTA250, GGTA218) was terminated at day 58, allowing 
the evaluation of the kidney-tissue samples of the ten obtained fetuses for correct 
targeting. From the piglets (#9987-#9990), ear tips have been taken. DNA has 
been isolated according to the protocol described in 3.2.9.1, except for #9990, as it 
was not possible to isolate DNA from the last (still born) piglet. Kidney DNA 
from fetuses also was isolated as described in 3.2.9.1. Subsequently, the isolated, 
purified DNA was tested by qPCR regarding its GGTA1-heterozygosity. 
4.5.2.2.1 Fetus verification 
The isolated fetus DNA was evaluated by adding it to sets of pKC cell clones, 
isolated by high-salt precipitation and obtained from the GGTA1 targeting before, 
providing a comparable background situation. The plates were equally prepared as 
described in the LOWA-evaluation of the targeted GGTA1 clones (4.4.3 and 
4.4.4) Fetus 6, 8 and 9 were not confirmed as targeted, whereas fetus 1, 2, 3, 4, 5, 
7 and 10 were confirmed as GGTA1
-/-
. The results of the LOWA-evaluation of the 
fetal kidney cell DNA are shown in figure 4.14. 
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Figure 4.14: qPCR confirmation of the 10 GGTA1-fetuses. 
DNA, isolated by high-salt precipitation, gained from pKCs of the fetal kidney samples, was used 
for LOWA-evaluation. Copy number ratios of fetus 6, 8 and 9 were below the predetermined 
2 SD-values. Fetuses 1-5, 7 and 10 were verified, as their copy number ratios exceed the 2 SD-
value, to be heterozygous knock-outs. Background was given by high-salt isolated pKC-clones 
obtained from the GGTA1 targeting.  
An overview of the obtained fetuses, regarding their copy number ratios (cnr), the 
mean value (MV) detected on the respective clone set and the ratio of both of 
them to demonstrate the change of the copy number ratios after correct targeting 
by dividing cnr/MV, is shown in figure 4.15. 
 
Figure 4.15: Evaluation of the GGTA1-fetuses. 
The copy number ratios of each fetus were related to the whole plate mean value of copy number 
ratios obtained from the respective clone set by dividing those values. For a correct targeting, the 
result should be around 2.00. Due to clone set variability a range of 1.60 to 2.60 is considered. 
MV: mean value; C: CFTR; G: GGTA1; H: HPRT; cnr: copy number ratio; cnr/MV: ratio between 
cnr and MV 
 
4.5.2.2.2 Piglet verification 
DNA of the three live born piglets was isolated from the taken ear tips and 
subsequently analyzed by the LOWA-assay for a heterozygous allele status. The 
results of the qPCR evaluation are shown in figure 4.16. All produced animals 
could be determined, regarding their copy number ratios, as heterozygously 
targeted for the GGTA1 gene. As background, DNA isolated by high-salt 
precipitation from clones used for the GGTA1 approach before had been used. An 
overview of the copy number ratio change as an indication of correct targeting is 
given in figure 4.16 as well. 
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Figure 4.16: qPCR confirmation of the 3 heterozygous GGTA1
-/+
 piglets. 
From ear cartilage tissue fibroblasts were isolated and cultured, the DNA was purified by high-salt 
precipitation and used for LOWA-screening by qPCR. All 3 piglets were verified as heterozygous 
knock-outs. The copy number ratios of each piglet were related to the whole plate mean value of 
copy number ratios obtained from the respective clone set by dividing those values. For a correct 
targeting, the result should be around 2.00. Due to clone set variability a range of 1.70 to 2.20 is 
considered. MV: mean value; C: CFTR; G: GGTA1; H: HPRT; cnr: copy number ratio; cnr/MV: 
ratio between cnr and MV. 
 
4.5.2.2.3 Outlook 
Boar #9988 was euthanized with the age of three months to obtain a GGTA1
-/+
 
kidney cell line, which subsequently can be used for the targeting of the second 
GGTA1 allele. In order to perform a homozygous targeting, the neokan
R 
cassette 
from one allele is exchanged by a blasticidin (bsr
®
) resistance cassette, enabling 
the preselection of nucleofected clones with the bsr
®
 targeting vector, by 
blasticidin S. After generation of homozygous knock-out clones finally the 
neokan
R
 and the bsr
®
 cassette are going to be removed by arabinose-induced Cre-
mediated cassette excision utilizing the lox sites of the respective cassette. 
Resulting clones are going to be used for NT/ET experiments to obtain GGTA
-/-
 
animals without any antibiotic resistance background. Additionally, the generation 
of GGTA
-/-
 animals can be achieved by breeding. 
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4.6 Reporter gene strategy: a side project 
In order to evaluate if BAC vectors are suitable tools for additive gene transfer, a 
side project was pursued in the context of this doctoral thesis. One possibility to 
determine the distribution of one gene of interest is to construct an expression 
vector which substitutes the respective gene by a reporter gene, visualizing the 
activity of the endogenous promoter. On that account, the lacZ gene (encoding β-
galactosidase) was introduced, similar to the STOP-box, behind the ATG of exon 
I and IV of the CFTR and the GGTA1 gene, respectively. Thus, the lacZ reporter, 
terminating the transcription by a bGH-pA (bovine growth hormone-
polyadenylation) signal, is transcribed instead of the respective gene. The 
modification vectors pCFTR-lacZ and pGGTA-lacZ were similarly designed and 
constructed. Restriction digests and ligations were carried out as described in 
3.2.4 and 3.2.6, respectively. PCRs were performed according to the standard 
protocol shown in 3.2.1.1 with varying annealing temperature and elongation 
time, given in brackets. 
4.6.1 Design and construction: pCFTR-lacZ and pGGTA-lacZ 
The 2 kb floxed neomycin resistance cassette, lox
2
neo (NEO), derived from the 
vector pPNTlox
2
 was exchanged by a PGK (phosphoglycerate kinase) promoter 
driven, floxed 2.2 kb neomycin/kanamycin resistance (neokan
R
) cassette from 
pL452 via arabinose induced Cre-recombination. Neokan
R
 was cloned by 
NotI/BamHI into the pBSK II vector (pBSK-NEO). The 0.5 kb 3’arm-fragment 
was amplified from genomic pig DNA by conventional PCR using the primer 
pairs CFTR-3armf/CFTR-3armr (58°C annealing, 1 min elongation) and GGTA-
3armf/GGTA-3armr (58°C annealing, 1 min elongation). The amplified fragments 
were digested with NotI/NsiI and then ligated into the lox
2
neo-pBSK II vector 
(pBSK-3arm-NEO). The lacZ-fragment, derived from the pSV-β-Galactosidase 
Control Vector (Promega, Mannheim) was cloned via NcoI/XbaI into the 
bGHpA/pGEM vector (kindly provided by Marlon Schneider) (pGEM-lacZ). The 
0.5 kb 5’arm-fragment was amplified from genomic BAC-DNA (CH242-248P18, 
CFTR; CH242-21F3, GGTA1) using primers CFTR-5armf/CFTR-lacZr and 
GGTA-5armf/GGTA-lacZr, respectively (annealing 58°C, elongation 30 sec). In 
parallel, the lacZ-fragment was amplified from the pSV-β-Galactosidase Control 
Vector using the primer pair CFTR-lacZ/lacZr and GGTA-lacZf/lacZr (annealing 
58°C, elongation 1 min). The 5’arm- and the lacZ-PCR-fragment were eluted 
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from an agarose gel and subsequently used as templates for a 2-step-fusion-PCR 
using the flanking primers CFTR-5armf/lacZr and GGTA-5armf/lacZr according 
to the cycling protocol described in table 3.2. The PCR fusion-amplificates were 
directly digested with KpnI/EcoRV and then ligated into the KpnI/EcoRV 
digested pGEM-lacZ vector (pGEM-5arm-ATG-lacZ). The resulting 
5arm-ATG-lacZ fragment was cloned by a SalI/KpnI digest into the pBSK-3arm-
NEO vector resulting in the modification vectors pCFTR-lacZ and pGGTA-lacZ 
(figure 4.17). The resulting plasmids have been used for the modification of the 
respective BACs by recombineering. 
 
 
Figure 4.17: Construction of the pCFTR-lacZ and pGGTA-lacZ modification vectors. 
The modification vectors for the introduction of the lacZ gene into the porcine genome contain (i) 
a 5’-arm of homology and a (ii) 3’-arm of homology, amplified from genomic DNA by primer 
pairs indicated with yellow arrows, (iii) a floxed neomycin/kanamycin resistance (neokan
R
) 
cassette driven by a PGK (phosphoglycerate kinase) promoter and (iv) the lacZ reporter, 
terminating the transcription by a bGH-pA (bovine growth hormone-polyadenylation) signal, 
which subsequently is transcribed instead of the respective gene. Primer pairs to fuse the reporter 
gene to the respective ATG are indicated with blue arrows. 
 
4.6.2 Modification of wild-type BACs 
The modification vectors pCFTR-lacZ and pGGTA-lacZ and the respective wild- 
type BACs (CH242-248p18 and CH242-21F3) were prepared according to the 
plasmid preparation protocol (adapted from Sambrook, 2001) described in 3.2.9.2. 
Thereafter, the isolated BAC-DNA was transferred to recombineering competent 
SW106 E. coli cells (500 ng BAC-DNA per aliquot) by electroporation. The 
bacterial suspension was plated after the electro-transformation step on agar plates 
containing the suitable antibiotic (kanamycin). Cells were grown over night at 
32°C. A resulting colony was picked, tested for the correct uptake of the BAC by 
conventional PCR and prepared as given in table 3.4 (SW106-recombineering). In 
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parallel, the purified plasmid DNA was digested overnight (read 3.2.4) with 
KpnI/Cfr42I and the respective fragments were eluted from the agarose gel. 
Aliquots of the SW106 cells, containing the BAC of interest, were used for the 
electrotransformation step as described in 3.2.7.2. Two different amounts of 
linearized modification-fragment were used: 30 ng and 100 ng. After two hours 
recovery at 32°C (allowing activity of recombineering enzymes), the cells were 
plated on agar plates (containing kanamycin) and were incubated overnight at 
32°C. Clones appearing after recombineering on LB + Kan plates, were picked 
and prepared for screening PCR as described in 3.2.9.2 (heating step isolation). 
The isolated BAC-DNA modified with the pCFTR-lacZ construct was screened 
with the primer pair CFTR-6456f/CFTR-7160r (annealing 60°C, elongation 
90 sec) for the wild-type sequence and with the primers CFTR-6456f/lacZr 
(annealing 54°C, elongation 90 sec) detecting the correct integration of the 
modification construct. BAC-DNA used for the GGTA1 approach, was screened 
after modification with the construct pGGTA-lacZ using the primers 
GGTAsf/GGTA5armr (annealing 56°C, elongation 90 sec) for the wild-type 
sequence and GGTAsf/lacZr (annealing 60°C, elongation 90 sec) for correct 
integration of the modification constructs. The CFTR BAC modification approach 
resulted in 214 colonies from 4 agar plates (2 x 30 ng and 2 x 100 ng of linearized 
lacZ-fragment). 24 of them have been picked and analyzed by PCR as described 
above. 4 out of 24 clones could be dedicated as correctly modified. Colony 2 was 
used for further experiments. The GGTA1 BAC modification resulted in a total 
number of 83 colonies. Again 24 colonies have been screened, of which 3 carried 
the correct modification. The results of the BAC modifications are shown in 
figure 4.18. 
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Figure 4.18: Modification scheme for wild-type BACs by recombineering. 
SW106 cells containing the BAC of interest have been used for electrotransformation with the 
respective modification fragment, primarily excised from pCFTR-lacZ or pGGTA-lacZ, 
respectively. The picture indicates a selective overview of the PCR-screened modified BACs. In 
case of CFTR 4 out of 24 clones were screened positive (clone 2 was used for further 
experiments), in case of GGTA1 3 out of 24 have been correctly modified (clone 16 was used for 
further experiments). Screening primers for the wild-type sequence are indicated by green arrows, 
for the knock-out sequence by red arrows. 
 
Correctly modified BAC clones (in SW106 cells), termed p248-lacZ or 
p21F3-lacZ, respectively, subsequently were re-transformed into recombineering 
deficient E. coli strains (DH10B) to allow incubation steps at regular 37°C. The 
procedure was carried out similar to the electrotransformation described above. 
Aliquots of electrocompetent DH10B cells (produced as described in 3.2.7) were 
transformed with 20 ng as well as 100 ng of the respective BAC-DNA. The cell 
suspension was plated on agar plates containing the suitable antibiotic (kanamycin 
or chloramphenicol) and incubated overnight at 37°C. A number of the resulting 
colonies were picked, and prepared for screening PCR as well. The remaining 
screening steps were carried out equally as already described above. 
4.6.3 Preparation of the modified BACs  
In the next step, the correctly modified BAC-DNA was prepared endotoxin-free 
according to the given protocol (3.2.9.2) to be transfected into porcine kidney 
cells (pKC) or primary fetal fibroblasts (pFF). Prior nucleofection, the constructs 
have been linearized, if necessary, with AscI as restriction enzyme of choice. The 
restriction digest was carried out according to the standard protocol for BAC 
digestion given in 3.2.4 using adequate amounts of enzyme for the amount of 
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DNA to be digested. The number of BAC-DNA isolations per construct and the 
resulting amount of DNA is listed in table 4.12. 
Table 4.12: Overview of endotoxin-free BAC isolations 
p248lacZ p21F3lacZ 
 # isolation DNA amount [µg]   # isolation DNA amount [µg]  
1 17.7 1 12.3 
2 55.0 2 11.0 
3 10.8     
 
83.5 
 
23.3 
 
4.6.4 Introduction of BAC-DNA into target cells 
In order to replace CFTR and GGTA1 by introducing the lacZ reporter gene into 
the porcine genome under the control of the respective endogenous promoter, 
additive gene transfer was the method of choice. An overview of the experiments 
carried out with the constructs p248lacZ (CFTR) and p21F3lacZ (GGTA1) 
respectively is given in table 4.13. 
Table 4.13:  Overview of nucleofection experiments using p248lacZ and p21F3lacZ. 
p248lacZ # epos cell line DNA DNA [µg] # cells (10
6
) 
200609 1 pKC circular 9.6 1 
220609 2 pKC circular 9.6/4.8 1 
300709 1 pKC circular 10 1 
241009 1 pFF linear 5 1 
p21F3lacZ # epo cell line DNA µg DNA # cells (10
6
) 
200609 1 pKC circular 0.52 1 
300709 1 pKC circular 10 1 
241009 1 pFF linear 5 1 
 
The transfected cells were cultured for 48 hours prior the selection using 
antibiotic containing medium (geneticin; G418) was started. Overall the 
selection was done for 9 days including one passaging step and media change 
every other day. After reaching 60-80% confluence the cell clones were mixed 
and frozen in cryopreservation medium and stored in liquid nitrogen.  
For nuclear transfer the cells were thawed and cultured in starvation medium 
for 48 hours.   
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4.6.5 Nuclear and embryo transfer experiments 
After thawing cell aliquots and culturing in starvation medium NT was performed 
as described in 4.5.1. The results of the additive NT/ET experiments are shown in 
table 4.14. 
Table 4.14: Overview of NT/ET experiments for the lacZ-constructs. 
p248lacZ cell 
type 
epo maturation 
rate 
#  NT 
embryos 
fused 
oocytes 
embryos 
transferred 
# piglets 
240709 (c) pKC 200609 182/265 157 128 112 0 
140809 (c) pKC 300709 183/318 162 140 134 0 
041209 (l) pFF 241009 132/156 131 120 119 3 (#9975-9977) 
150910 (l) pFF 241009 102/194 92 87 87 0 
160910 (l) pFF 241009 114/161 105 99 99 0 
141010 (l) pFF 241009 216/325 201 191 178 5 (#1180-#1184) 
181110 (l) pFF 241009 189/259 98 91 91 6 (#1202-#1207) 
p21F3lacZ cell 
type 
epo maturation 
rate 
#  NT 
embryos 
fused 
oocytes 
embryos 
transferred 
# piglets 
210809 (c) pKC 300709 194/267 172 142 129 0 
(c): circular; (l): linear 
     
4.6.6 Outlook 
A total number of three established pregnancies resulted in the delivery of 14 
piglets. Further characterization and proceeding of the resulting outcome was not 
part of this doctoral thesis, because the main focus was addressed to the 
establishment of targeted gene knock-outs. The aim of this experiment was to get 
an insight into the spatial expression of the respective genes throughout the body, 
never been observed before. Therefore genotyping of the respective piglets and 
expression studies by RT-PCR will have to be performed. Organ sections for lacZ 
staining, to determine the expression will be performed by our cooperation 
partners at the Department of Veterinary Pathology, Faculty of Veterinary 
Medicine, Freie Universität Berlin. 
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5 DISCUSSION 
Different strategies to produce large transgenic animal models have been 
established within the last decades, as PMI (Hammer et al., 1985), SMGT or viral 
transgenesis (Hendrie et al., 2005; Smith et al., 2005). With the development of 
vectors derived from the adeno-associated virus (AAV) it became possible to 
introduce also targeted mutations into the host genome. The very low possible 
packaging size of only 5 kb (Muzyczka, 1992; Hirata et al., 2000) and licensing 
requirements and orders to be allowed to work with AAV vectors make their use 
inappropriate for this project. Additionally, ZFNs have already been applied to 
introduce targeted mutations into the porcine genome (Watanabe et al., 2010; 
Hauschild et al., 2011). Pigs in particular represent ideal tools for the generation 
of various disease models, such as cystic fibrosis and could serve as organ donors 
in xenotransplantation. With this project both areas were linked by the 
establishment of a new technology enabling the targeted knock-out of two distinct 
genes, CFTR and GGTA1. As a side-project also additive gene transfer, utilizing 
BAC-based vectors for the introduction of the lacZ reporter gene into the porcine 
genome at the given loci, was used.  
5.1 Generation of modified BACs for cell transfection 
In previous studies, several strategies to overcome the low targeting efficiency in 
porcine primary cells, such as gene trapping, negative selection and adeno-
associated viral vectors have been reported (Lai et al., 2002; Jin et al., 2003; 
Rogers et al., 2008). It was stated that random integration of DNA constructs 
occurs 1000 to 100000 times more frequently than by HR and in particular the 
targeting efficiency of somatic cells is about two orders of magnitude lower than 
in murine ESCs (Schwartzberg et al., 1990; Arbones et al., 1994). An appropriate 
way to increase the targeting efficiency is represented by an increase of the 
homologous regions of the vector construct (Scheerer et al., 1994). Generally, 
conventional targeting vectors are prone to carry 20 kbp as a maximum genomic 
insert size. In contrast, BACs are reported to be capable to carry large, regularly 
200 to 300 kbp, genomic regions of interest (Shizuya et al., 1992). It is said that 
inserts cloned and maintained in BACs show low frequency of chimerism and 
much higher stability compared to YACs (Monaco et al., 1994). Additionally, 
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BACs have also been used to increase the HR frequency in targeting approaches 
using ESCs to establish various mouse models (Valenzuela et al., 2003; Yang and 
Gong, 2005; Barakat et al., 2011). Effective targeting efficacies of up to 28% 
have been observed (Yang and Seed, 2003). Several different modification 
protocols to introduce desired alterations into BACs, independent of cloning 
strategies based on restriction enzymes, driven by homologous recombination 
have been reported (Yang et al., 1997; Jessen et al., 1998; Zhang et al., 1998). In 
this project BAC modification was carried out according to the defective λ-phage- 
mediated recombineering protocol established by Copeland and colleagues 
(2001). Several different BACs have been purchased and screened by restriction 
digests, whether they really carry the genomic region of interest. BAC 
RP44-360A14, assumed to contain the CFTR gene, had to be rejected after 
comparison of the restriction digest pattern and the in silico pattern. Two 
additional BACs carrying the CFTR gene have been purchased and verified. BAC 
CH242-248P18 was used for further experiments, due to the higher yield of DNA 
obtained when prepared according to the regular plasmid isolation protocol 
(PCiA), compared to PigI-170I3. For the GGTA1 locus BAC CH242-372F22 was 
also confirmed by restriction digest. In order to target the desired locus and 
introduce the alteration by homologous recombination the design and construction 
of an adequate DNA vector was necessary. This study aimed to obtain a complete 
knock-out of two distinct genes (CFTR and GGTA1), meaning that by the 
manipulation of the transcription or translation start, RNA or protein synthesis are 
eliminated. In a first step plasmid-based vectors have been generated to modify 
the respective BACs by recombineering. In case of CFTR both, RNA transcription 
and the protein translation start are localized in exon I. In order to knock-out the 
GGTA1 gene, exon IV was targeted. For this reason, modification vectors, 
containing a STOP-box, comprising a HIS3 yeast protein termination sequence 
and a SV40 pA signal (Sauer, 1993) to be introduced downstream of the 
respective start codon, have been constructed. The STOP-box is coupled to a 
floxed neomycin/kanamycin resistance cassette under the control of a mPGK and 
T7 promoter (to enable the switch between prokaryotic and eukaryotic expression 
systems) also containing a bGH polyadenylation site. This vector component 
assures the possibility for an antibiotic-mediated pre-selection for construct 
integration into target cells. The neomycin/kanamycin resistance cassette is often 
used for positive selections and is well established in our lab (van der Weyden et 
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al., 2002). Possible interference of the selection cassette with the expression of the 
surrounding genes is prevented by the addition of both-sided loxP sites, which 
enable the removal of the cassette via arabinose-induced Cre recombinase-
mediated excision (Sauer et al., 1988). In case of the reporter gene approach, the 
lacZ gene was linked to the described neomycin/kanamycin resistance cassette. 
Another strategy to enrich targeted cell clones, positive-negative selection, usually 
achieving a two- to ten-fold enrichment of targeted cells, was also considered. 
Due to the fact, that the overall efficiency of this method might be reduced, 
because of damage or loss of the negative selection cassette, which becomes even 
more likely with increasing length of homologous arms provided by BACs, this 
idea was condemned (Hanson and Sedivy, 1995). Promoter-trap as an additional 
enrichment method, where the transcription of a selection cassette is driven by the 
endogenous promoter of the target gene, requires a transcriptionally active target 
gene in somatic cells (Marques et al., 2006). Hence, the promoter-trap strategy 
was not suitable for this project, as it is known that CFTR is described as a silent 
locus in porcine fetal fibroblasts (Williams et al., 2003). Homologous arms of 
0.5 kb length were added on both sides to the STOP-box- or lacZ-antibiotic 
resistance region to enable HR, although they needed to be as short as 40-50 bp 
using the recombineering methodology according to the Copeland-protocol. 
However, it was reported that 0.1-0.3 kb homologous arms increase efficiency and 
specificity. Single arm homologous recombination, as it was used in GENSAT 
projects, is possible but adding a second homologous arm to the construct enables 
a targeting without including the vector backbone (Hollenback et al., 2011). The 
modification rate of the BACs with the respective modification vector complied 
with the expectations, as they ranged from 12.5% to 58.3% correctly modified 
BAC clones. This implicates that on average only a limited number of colonies 
(less than 10) has to be screened for positive integration to obtain one correctly 
modified clone (Sparwasser et al., 2004). One additional advantage of BAC 
vectors, especially if randomly integrated, is that the positional effects, where the 
host sequences surrounding the location of transgene integration are able to 
influence the expected expression pattern, are overcome by their large cloning 
capacity. Moreover, the inclusion of all necessary regulatory elements, as present 
on BACs, guarantees optimal expression levels in the produced transgenic 
animals, independent of the integration position (Giraldo et al., 2001). The 
introduction of the lacZ-constructs in both approaches yielded a lower amount of 
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colonies and also a lower amount of positively modified BAC clones after PCR 
screening. This might be due to a little higher salt-concentration of the lacZ 
modification vector DNAs, compared to STOP-approaches, used for 
electrotransformation into the BAC-containing SW106 E. coli cells, implicated by 
a shorter, but still sufficient, time constant (Hollenback et al., 2011).  
5.2 BAC-DNA isolation and cell transfection  
The DNA of the correctly modified BACs was isolated according to a protocol 
using several components of two different commercially available kits. The buffer 
set and the QIAGEN-tips 500 of the Endofree plasmid Maxi Kit and the ETR-
solution of the E.Z.N.A.
®
 Endo-free Plasmid Midi Kit in combination achieved 
the best results regarding DNA yield, purity and transfection efficiency, although 
it was reported elsewhere that column-based BAC-DNA isolation should be 
avoided due to detrimental influence to the integrity of large BACs (Sparwasser et 
al., 2004). Nevertheless, in this approach the impact of column-based purification 
seemed not to affect the DNA quality adversely, as it was possible to generate 
transgenic pigs subsequently. An endotoxin-free preparation strategy was chosen, 
because it is stated that endotoxins, known as cell-membrane components of 
gram-negative bacteria such as E. coli, are released during the lysis step of 
plasmid purification. They are known to be extremely toxic, as potent stimulator 
of the mammalian immune system, and therefore they are held to be responsible 
to significantly reduce transfection efficiencies (Budryk et al., 2001). The amount 
of DNA obtained from several isolations varied from 10.0 µg to 42.8 µg for 
p248STOP, from 4.0 µg to 33.5 µg for p21F3STOP (table 4.1), from 10.8 µg to 
55.0 µg for p248lacZ and from 11.0 µg to 12.3 µg for p21F3lacZ (table 4.12). All 
in all, the DNA yield of BAC-DNA was satisfying but this relatively high 
variability among different isolations, of course might be ascribed to the initial 
volume of BAC overnight culture (100 or 200 ml), but also might be explained by 
the binding capacity of the column. In some cases an overload of the column was 
quite obvious, implicated by the very slow entering of the DNA solution to the 
resin and the subsequent elution, indicating that utilizing a column-based isolation 
method didn’t affect DNA quality but, in some cases, might affect DNA yield. 
Additionally, it was observed that it has been important to start the BAC-DNA 
isolation with the inoculation of a 3 ml pre-culture, leaving it at least four hours 
on the shaking incubator before an overnight culture was inoculated. Omitting this 
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pre-culture step on account of time problems always resulted in a lower BAC-
DNA yield. Initially, it was tried out to resuspend the DNA pellet directly in a 
suitable amount of AMAXA nucleofection buffer, not to influence the 
transfection procedure by changing the nucleofection components using regular 
T-buffer. But this did not work very efficiently, as the pellet did not dissolve in 
AMAXA buffer. Furthermore, the DNA pellet was dissolved in an appropriate 
volume of T-buffer. In general, it really took very long until the pellet completely 
was dissolved, promoted by incubation at 42°C in the water bath. Due to time 
reasons, the DNA concentration might have been measured in some cases without 
complete dissolution of the DNA pellet also explaining the variable amounts of 
DNA obtained. Prior to nucleofection of the pFFs or pKCs with the endotoxin free 
prepared BAC-DNA, construct linearization was performed. An initial experiment 
was set up to determine the transfection efficiency in pFFs using whether circular 
(supercoiled) or linearized p248STOP DNA. The results (data not shown in the 
results) were in accordance with the literature, as with linearized DNA a higher 
amount of cell clones with stable construct integrations could be obtained 
(linearized 1 and 2 resulted in 31 and 74 cell clones compared to circular 1 and 2 
resulting in 11 and 12 cell clones). It is also reported that the initial uptake of 
linear DNA, usually used if stable construct integration is needed, is lower 
compared to supercoiled DNA, which is mainly used for transient gene transfer 
(according to the handbook of the AMAXA nucleofector kit).   
Since until now true ESCs have only been isolated from mouse, cultured somatic 
cells are most commonly used as donor cells in SCNT. Viable offspring have been 
produced utilizing fetal fibroblasts (Hyun et al., 2003), adult fibroblasts (Brunetti 
et al., 2008) and somatic cumulus cells (Polejaeva et al., 2000). In this project, 
porcine fetal fibroblasts (pFFs) were used as donor cell source for SCNT for 
initial approaches, as they are routinely used in our lab. Also additive gene 
transfer approaches have been performed using pFFs. Additionally, in the 
meantime another promising donor cell line isolated from kidney samples of three 
month old male pigs (Niere m) has been established. These primary kidney cells 
(pKCs) feature comparable proliferation properties to fibroblasts, convenient 
isolation and modification characteristics and senescence is evolved at a later time 
point compared to pFFs (personal communication with Dr. Annegret Wünsch). 
BAC-DNAs were routinely linearized, if needed, with AscI and nucleofected with 
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the same program and nucleofection solutions established by the provider for 
primary mammalian fibroblasts. The transfection itself and the generation of 
single cell clones are not further discussed, because they were carried out by Dr. 
Annegret Wünsch and her team.  
5.3 Isolation of genomic DNA from cell clones 
Due to the low expected targeting efficiency, numerous single cell clones have to 
be generated. In order to limit extensive cell culture work and to be aware of long-
term cultures of primary cells, as the target cells do have a finite lifespan (Jeon et 
al., 2011), we aimed to isolate DNA from only small amounts of cells for qPCR 
application. The generated single cell clones have been expanded in 96-well 
plates. Therefore a maximum amount of 8000 to 10000 cells per clone, limited by 
the growing surface of one well, could be obtained for subsequent DNA isolation. 
The isolation methods should meet pre-determined demands, such as applicability 
for very small amounts of available cells, achieving acceptable yields of high 
quality DNA to be suitable for subsequent qPCR, in a time-saving and not too 
cost-extensive manner, because once established, this method is going to be 
adapted to the routinely performed lab protocols, to be reproducibly used by 
anyone. Additionally, the possibility for an automated sample proceeding is 
aspired. Firstly, in particular due to the time factor and the reproducibility, 
commercially available kits based on DNA isolation via binding to silica 
membranes offered by different providers (Macherey & Nagel, Dueren; Peqlab, 
Erlangen; Qiagen, Hilden; Omega Bio-tek, Norcross) have been considered. 
Comparing the standard protocols of five different column-based commercial kits 
(Nucleospin
®
 Tissue Kit, peqGOLD MicroSpin Tissue DNA Kit, Qiagen DNeasy 
Blood & Tissue Kit, QIAamp
® 
DNA Micro
 
Kit, E.Z.N.A
®
 Tissue DNA Kit) 
indicated relatively similar proceeding steps. The kits were selected due to 
different reasons. Because the peqGOLD and E.Z.N.A
®
 kit have been used in 
previous experiments, they have already been available in the lab. Nucleospin
® 
and both QIAGEN Kits (DNeasy and QIAamp
®
) have been selected because they 
were told to be applicable even with very small amounts of cells for isolation 
(presumable amount from 10
2
 to 10
7
 cells). All kits started with a lysing step of 
the cell pellet, primarily suggested to be washed in PBS, whereas the incubation 
time with the respective lyse buffer, in all cases except the E.Z.N.A
®
 Tissue DNA 
Kit (lysing protease is called OB protease) supplemented with Prot K varied from 
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as short as 10 minutes to a maximum of 1-3 hours. Cultured cells are reported to 
have high levels of RNA, particularly liver and kidney cells due to their 
transcriptional activity. Using column-based kits a RNase A digestion in all cases 
except in the QIAamp protocol was suggested, avoiding co-purification of RNA 
with DNA. In the QIAamp protocol adding RNase A is omitted because the 
addition of carrier RNA is intended to achieve better binding properties of the 
DNA to the column membrane (Shaw et al., 2009). In principle, the cells are lysed 
by Prot K to gain access to the DNA. By the addition of a chaotropic salt, in all 
cases guanidinium chloride or guanidine thiocyanate, a hydrophobic environment 
is created, promoting the DNA binding to the silica membrane of the column and 
the denaturation of proteins, therefore inactivating nucleases. Proteins, 
metabolites and other contaminants do not bind to the membrane and are removed 
in the subsequent washing steps. The DNA, bound to the silica membrane, is 
eluted applying low salt buffer (T-buffer). The supplied elution buffers had not 
been used due to possible inhibitory effects of the supplemented EDTA in 
subsequent qPCR applications as it was described by Huggett and colleagues 
(Huggett et al., 2008). The elution volume was also one critical point, because 
elution from the silica membrane requires in general a higher volume (50-200 µl 
in the tested kits), accompanied by an undesired dilution effect of the inherently 
small amount of DNA, keeping in mind, that the qPCR mastermix is restricted to 
the addition of 2 µl sample. Only in the QIAamp and peqGOLD kit a satisfying 
elution with only 20 µl of T-buffer has been promised. Due to the small amount of 
starting material, a DNA concentration determination using a spectrophotometer 
was not possible. After isolating five trial samples of 7500 and 3750 pFF cells, 
respectively according to the given protocols per each kit, the obtained DNA was 
tested in qPCR. In all cases, Ct-values (cycle threshold; point at which 
fluorescence crosses the defined threshold) of 27 to 33 have been measured, 
indicating too less amounts of DNA to obtain determinable measuring results. 
Afterwards, a semi-automated purification system provided by Promega 
(MAXWELL
®
 16 DNA purification Kit) was tested. Samples are purified using 
paramagnetic particles, providing a mobile solid phase that optimizes capture, 
washing and elution of DNA. The isolation procedure is carried out by the 
MAXWELL
®
 16 Instrument, containing magnetic particle handlers, required for 
the processing of liquid and solid samples, for the transport of the magnetic 
particles through the purification reagents and for mixing during the processing. 
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The cell lysis is also achieved by Prot K and DNA binding to the magnetic 
particles and protein denaturation is promoted by guanidine thiocyanate. Initially, 
also five pFF samples (7500 and 3750 cells) as already tried out with the column-
based kits, were proceeded. A critical point of the MAXWELL system was the 
predefined elution volume of 300 µl T-buffer. Hence, several different elution 
amounts have been tried out, ending up with 35 µl T-buffer. As satisfying results 
could be achieved by subsequent qPCR tests, indicated by Ct-values ranging 
between 23 to 25, it was decided to use this system for the isolation of generated 
single cell clones (pFF) transfected with the p248STOP construct. Finally, after 
isolation of 230 clones and evaluating the qPCR results (data not shown) the 
disadvantages of this method became quite obvious. The qPCR results exhibited 
high standard deviations in between the duplicate samples, maybe as a result of a 
varying binding capacity of the DNA to the particles or due to the downscaling of 
the elution volume. In many eluted samples residues of the paramagnetic particles 
remained, assumed to be responsible for the detected variability by influencing the 
SYBR green detection, concordant with literature (Cheong et al., 2008). 
Furthermore, this system would have been very cost extensive, because not only 
the kit reagents but also the instrument itself would have to be bought. As a 
consequence, the MAXWELL purification system was condemned. Moreover, a 
filtration-based method, the nexttec
TM
 isolation system was evaluated. This 
method  promised a one-step purification procedure in which proteins, detergents 
and low molecular weight compounds are retained by the nexttec
TM
 sorbent, 
whereas the DNA is so to speak filtered and passed through the clean column. 
Cell lysis is also achieved by Prot K digestion. The nexttec system allows a really 
fast proceeding and facilitates high throughput isolation due to the possibility of 
adapting it to a 96-well format. Although the amount of the obtained DNA was 
not that low compared to the column-based isolation methods mentioned, the 
reproducibility between different samples was insufficient. Finally, six 
conventional methods, two of them commercially available kits provided by 
Qiagen and Promega, have been compared. The protocol of the Gentra Puregene 
Kit allows cell lysis in a very short centrifugation step of only 10 sec in the 
presence of an anionic detergent (such as SDS), Prot K and a DNA stabilizer 
(such as EDTA), which limits the activity of intracellular DNases. An optional 
RNase step can also be added. Contaminants like proteins are removed by salt 
precipitation, and DNA is precipitated with alcohol (isopropanol) and dissolved in 
Discussion 100 
T-buffer. The salt precipitation step is suggested to be supported by a five minutes 
incubation step on ice. Because a low DNA yield was expected, glycogen as DNA 
carrier was added during isopropanol precipitation, as suggested. The dissolving 
volume is recommended to be 50 µl, but as there is no elution from any DNA-
binding material required, it is somehow freely adjustable, depending on the 
requirements. Hence, 35 µl have been chosen as in all the other conventional 
isolation methods, to obtain comparable results. In general 1-2 x 10
6
 cells are used 
as starting material for DNA isolation using this Kit, but it is indicated that also 
small numbers of cells (100-10000) can be proceeded. The Wizard isolation Kit, 
designed for cell amounts of 1-8 x 10
6 
works in a very similar way but there are 
slight differences: according to the protocol, there is no DNA stabilizer 
supplemented, there is no Glycogen addition suggested, cell lysis is carried out 
without Prot K and the salt precipitation is not carried out while incubating the 
sample on ice. All other steps, including salt precipitation of the proteins and 
contaminants, RNase digestion and DNA precipitation by isopropanol are 
identically performed to the Puregene Kit. In this case, the DNA is suggested to 
be dissolved in 100 µl T-buffer, but as already mentioned, 35 µl have been 
applied. In both kits the rehydration step of the cell pellet should be carried out for 
at least one hour at 65°C. The isolated DNA samples of both kits (again five times 
7500/3750 pFF cells) have been tested in qPCR. Surprisingly, although the 
proceeding was very similar, the Wizard kit achieved very low DNA yield, 
insufficient for the following approaches. This might be due to an insufficient cell 
lysis, according to the Wizard protocol, in which Prot K addition is omitted. Using 
the puregene kit, sufficient amounts of DNA could be obtained, in particular 
evaluating the 7500 cell aliquots. Nevertheless, the qPCR-tests of the isolated 
3750 cell aliquots were evidently accompanied by raised standard deviations in 
between the different samples. However, this method was considered to be used 
for further proceeding. The Kawasaki-buffer isolation method was tried out 
according to a protocol obtained from Dr. Marc Boelhauve, generally applied to 
isolate DNA from blastomeres of bovine embryos. Though, the isolated DNA 
subsequently was only used for conventional PCR tests. Cells are lysed in the 
presence of ProtK, KCl and Tween as a detergence, promoted by incubation at 
55°C for one hour. After centrifugation the supernatant was directly used for 
qPCR testing. This method yielded insufficient amounts of DNA, varying in 
between the distinct isolated samples. The spermidine method, routinely used in 
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the lab for genomic DNA isolation, particularly for isolation from mouse tail or 
porcine ear tips, was evaluated next whether to be suitable for small amounts of 
starting material. In order to lyse the cells a cutting buffer containing EDTA, 
DTT, NaCl and spermidine was mixed with Prot K and SDS. DNA was 
precipitated by isopropanol. The qPCR tests demonstrated the spermidine method 
to be a potential candidate for further isolations, as the DNA yield was sufficient 
and standard deviations were not that high. Due to the very fast and efficient DNA 
isolation an additional test has been performed. A pre-defined standard curve, as it 
was used subsequently for the LOWA-assay, was tested in qPCR with DNA 
isolated by the spermidine method. As a result, a kind of inhibitory effect to the 
SYBR green I-mediated qPCR test was observed, because the more sample DNA 
was added, the less fluorescence, indicated by very low Ct-values, was detectable. 
This effect might be related to the reported inhibitory effect of polyamines, such 
as spermidine, to DNA polymerases (Ahokas et al., 1993). Although the method 
was promising at a first sight it had to be abolished. The PCiA method is also used 
in daily lab routine, applied for the isolation of genomic DNA of mouse tails or 
porcine ear tips. Lysing the cells is also achieved by Prot K digestion in 
combination with SDS. DNA was stabilized by EDTA. Contaminants are 
extracted using PCiA and DNA is precipitated using isopropanol. The high-salt 
precipitation originally was employed for the DNA extraction of spermatogonial 
cells (protocol provided by Dr. Marc Boelhauve). Cells are lysed by a buffer 
combination containing EDTA, SDS, DTT and Prot K. Proteins and contaminants 
were removed through a precipitation step using highly concentrated NaCl, 
supported by incubation on ice. DNA was precipitated with isopropanol. The 
qPCR tests with isolated pFF-DNA resulted in sufficient DNA amounts for both 
isolation methods, but better results in DNA yield have been achieved by the 
PCiA method. Though, higher standard deviations, mainly observed with the 3750 
pFF cell aliquots, occurred with PCiA extraction, probably due to phenol residues, 
proved to influence qPCR adversely (Cankar et al., 2006). In conclusion, the 
puregene kit, the PCiA method and the high-salt precipitation seemed to meet the 
demands regarding DNA yield. The PCiA method was mainly rejected, because it 
is quite laborious, the phenol extraction is a quite critical, error-prone step, as 
transferring just little phenol to the aqueous, DNA containing phase, might result 
in undesired qPCR variability. Not to forget, if possible, working without toxic 
reagents (like phenol) is always preferable. In a final decision step, although the 
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puregene kit achieved sufficient results regarding DNA yield and showed a 
convincing time-saving proceeding, the high-salt precipitation was pointed out as 
method of choice, combining a not too laborious, easy to handle and comparably 
low-priced method with sufficient DNA yield, isolated from starting material as 
less as 3000 cells, and reproducible results in between distinct samples. 
5.4 Targeted clone verification via qPCR 
The decision to use BACs as targeting vectors was accompanied by one hurdle. 
Due to the large regions of homology provided by BACs, making them a very 
promising tool for HR-based targeting, the screening of the transfected cell clones 
was quite difficult. Conventional long-range PCR or Southern blotting were not 
applicable. It is described that the targeting efficiency increases with the length of 
the homologous vector arms, but in practice, homologous arms longer than 5 kb 
represent a problem for Southern blot analysis (Hofemeister et al., 2011). In order 
to detect the number as well as the chromosomal localization of BAC integrants, 
FISH analysis could be used (Cao et al., 2011). For both methods, which are 
known to be quite laborious and time-consuming, the amount of DNA obtainable 
from the generated cell clones would be insufficient. Hence, the ‘loss of wild-type 
allele’-assay was utilized for determining targeted cell clones (Valenzuela et al., 
2003). The resulting targeting efficiencies, produced by a non-viral vector system, 
of 1.35% in case of CFTR, and 3.91% for GGTA1, are competitive compared to 
literature (Dai et al., 2002; Lai et al., 2002; Jin et al., 2003; Klymiuk et al., 2010), 
although effective targeting efficacies of up to 28% have been observed, using 
murine ESCs (Yang and Seed, 2003).   
5.5 Evaluation of fetuses and piglets 
Using candidate clones transfected with the p248STOP construct, three NT/ET 
experiments have been performed. A total number of 264 embryos have been 
transferred resulting in the establishment of two pregnancies comprising an 
outcome of seven fetuses, obtained after pregnancy termination at day 59, and five 
piglets. Furthermore, for the establishment of GGTA1
+/-
 pigs, three NT/ET 
experiments, using candidate clones, transfected with the p21F3STOP construct 
have been performed. For this purpose, 271 embryos have been transferred, two 
pregnancies have been established, one of them terminated to obtain ten fetuses, 
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the other delivered three alive and one stillborn piglet at term. The obtained 
fetuses all looked normally developed, although obviously fetus #1 and fetus #7 in 
the CFTR approach and fetus #4 and fetus #5 in the GGTA1 approach appeared 
smaller compared to the other respective littermates. This growth variation is 
described in literature as accessory phenomenon of SCNT (Cho et al., 2007). 
Evaluation of the CFTR-fetuses revealed that fetus #1 could not be determined as 
correctly targeted, also reflected by the calculated copy number ratio related to the 
whole plate mean value of 1.27 (G/C) and 1.24 (H/C) shown in figure 4.11. In 
case of the GGTA1-fetuses, fetus #6 (cnr/MV 1.79 (H/G) and 1.29 (C/G)), fetus 
#8 (cnr/MV 1.80 (H/G) and 1.46 (C/G)) and fetus #9 (cnr/MV 1.79 (H/G) and 
1.24 (C/G)) have not been correctly targeted (summarized in figure 4.15). This 
results were surprising, as with SCNT in general 100% of the offspring is 
transgenic (Wolf et al., 1998). One possible explanation could be the aberrant 
transfer of a cumulus cell instead of the candidate fibroblasts or kidney cells 
(personal communication with Dr. Barbara Keßler), which might be true for the 
CFTR approach with only one negative fetus out of five. In contrast, to explain 
three untargeted GGTA1-fetuses another possibility has to be taken under 
consideration. Candidate clone GGTA250 was previously described as a mixed 
clone, indicated by an elevation of the copy number ratio change as required to be 
determined as correctly targeted clone, but compared to the other candidate clones 
the increase was not that convincing. One reason could be found in cell culture, 
where a cell could be wrongly identified as single cell clone although it was a 
mixed colony of targeted and non-targeted cells. Furthermore, the cloning team is 
choosing the donor cells by hand, deciding by morphological characteristics, 
regarding for example size and surface structure, which might lead to the transfer 
of untargeted donor cells not differing from targeted cells in their shape (personal 
communication with Dr. Annegret Wünsch and Dr. Mayuko Kurome). The 
obtained piglets, in both approaches, all have been ratified as correctly 
heterozygously targeted. CFTR
+/-
pigs all established malformations of the 
forelegs, described in literature as contracted tendons, sometimes occurring with 
SCNT. It was also described that this kind of malformation is neither transferred 
to the offspring derived from affected founder animals (Prather et al., 2004) nor 
cloning this animal resulted in 100% affected clones (one of 4 pigs suffered from 
contracted tendon as well)(Park et al., 2002), indicating that the obtained affected 
CFTR
+/- 
pigs nevertheless could be utilized for further mating or for re-cloning 
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after targeting the second allele to obtain homozygous knock-out pigs. Pig #9978 
suffered from anal atresia, representing a rarely recognized congenital disorder in 
neonatal pigs, with an estimated incidence of 0.1 to 1.0% (Hori et al., 2001). 
Although atresia ani was also reported to occur in cloned pigs in another study, it 
is rarely seen in other reports related with pig somatic cell cloning (Walker et al., 
2002). For this reason, it is hard to estimate the possibility that anal atresia is 
directly related to SCNT, as it also occurs in normal piglets (Lee et al., 2005). The 
GGTA
+/-
 pigs didn’t show any abnormalities. The achieved pregnancy rates (66% 
in both cases) and delivery rates (100% in both cases) are regularly observed in 
our lab, also being competitive regarding to literature (Vajta et al., 2007).  
5.6 Outlook 
Especially in cystic fibrosis, one of the most common, genetically inherited 
disorders with recessive outcome, which is caused by mutations in the CFTR 
gene, adequate models mirroring the human phenotype are required. Although a 
CFTR-lacking porcine model already has been generated by Rogers and co-
workers (Rogers et al., 2008), which might not be available to be internationally 
used due to sanitary restrictions, it was decided to generate a second CFTR
-/- 
knock-out pig, evolving another genetic background. In mice, it was shown that 
differences in their genetic background, accompanied by phenotypical changes, 
are providing insight to mechanisms of the disease (Wilke et al., 2011). In the 
context of this doctoral thesis, an alternative method, utilizing modified BACs for 
targeting CFTR heterozygously, has been established. Further, but not as a part of 
this project, it was possible to apply the established technique to target the second 
CFTR allele, in order to generate homozygous knock-out pigs, resembling the 
pathological aberrations in human CF. The generated pigs demonstrated tight 
phenotypic similarities to the CF pigs produced via AAV-mediated gene transfer 
in the group of Rogers, with one exception: the meconium obstruction was located 
in the large intestine, compared to a localization oral and aboral to the ileocaecal 
junction described by Meyerholz and colleagues (2010). This newly generated 
porcine CF model can be applied for investigating CF disease mechanisms and for 
the development of novel treatment strategies (Klymiuk et al., 2011). 
Additionally, CFTR
-/-
 animals can also be produced by breeding. 
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Xenotransplantation represents a way out of the availability imbalance of donated 
human organs and the demand for transplantation. One major obstacle, xenograft 
rejection, could be overcome by the genetic modification of the porcine genome. 
In a first step hyperacute rejection, mainly mediated by natural antibodies directed 
against the α1,3-Gal epitope, synthesized by the α-1,3-galactosyltransfrease, 
encoded by GGTA1, has to be circumvented. For this purpose several different 
porcine models with targeted deletions of the GGTA1 gene have been produced 
(reviewed in Klymiuk et al., 2010). Among this porcine models, different  
strategies to inactivate GGTA1 have been pursued, including the targeting of exon 
IV, which contains the endogenous translation initiation codon or exon IX, which 
comprises the majority of the coding region for the catalytic domain (Katayama et 
al., 1998). The novel BAC-based targeting method, established in this project, 
was reproducibly adapted to generate GGTA1
-/-
 pigs, inactivating GGTA1 by 
targeting exon IV. With the transient transfection of a Cre recombinase containing 
plasmid, it is possible to remove the floxed neokan resistance, not being used in 
any other GGTA1 knock-out model before. Further, the GGTA1
-/-
 pigs have 
already been used in further experiments, being not a part of this thesis, to target 
the second GGTA1 allele. This was achieved by the exchange of the neokan 
resistance by a blasticidin resistance. In the near future, after generation of 
homozygous knock-out clones in cell culture, both resistance cassettes, which are 
reported to possibly interfere with the surrounding genes (Pham et al., 1996), are 
going to be removed through Cre-mediated cassette excision. Furthermore, 
GGTA
-/-
 pigs without any antibiotic resistance, required for preclinical and clinical 
xenotransplantation, also preferable for further animal care and treatment, can be 
produced by SCNT. This reflects a time saving strategy compared to conventional 
breeding, which can be used to produce additional GGTA1
-/-
 animals as well. 
In order to evaluate if BAC vectors are suitable tools for additive gene transfer, 
knowing that they comprise all necessary regulatory elements (Giraldo and 
Montoliu, 2001), a side project was pursued in the context of this doctoral thesis. 
The lacZ reporter, terminating the transcription by a bGH-pA signal, introduced 
behind the ATG codon of exon I and IV respectively, is transcribed instead of the 
respective gene. Until now, it was possible to generate 14 piglets (CFTR), still 
needed to be determined by genotyping and regarding their lacZ expression. 
Sections of different organs, mainly relevant for CF-phenotypes, such as lung, 
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pancreas, kidney and many more, can be investigated for CFTR distribution by 
lacZ staining.  
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6 SUMMARY 
Establishment of BAC-targeting in porcine primary cells 
The establishment of large animal models is of increasing interest, due to the 
inadequacy of rodent model organisms regarding special requirements, in 
particular their suitability as models for human diseases. Above all, the pig has 
become an important resource in biomedical research, covering many areas as 
expedient model. Advantageous characteristics, such as similarities to human in 
size, physiques, anatomy, physiology, metabolism, organ development and 
disease progression as well as beneficial properties like a standardized 
environmental situation, the well established reproductive technology and 
advanced techniques of genetic modification of the porcine genome, represent 
ideal prerequisites to be used as animal model for both, human diseases and 
xenotransplantation. The aim of this study was the establishment of a method 
enabling the introduction of targeted genome alterations, mediated by BAC-based 
vector constructs, so far not described being applied in large animal mutagenesis. 
For this purpose the targeted knock-out of the CFTR (cystic fibrosis 
transmembrane conductance regulator) gene, responsible for the development of 
cystic fibrosis if mutated, and the GGTA1 (α-1,3-galactosyltransferase) gene, 
playing a major role in hyperacute rejection of xenografts, were pursued. BACs 
(bacterial artificial chromosomes) are described as circular molecules that are 
capable to carry large (up to 300 kb) genomic regions of interest, offering all 
necessary regulatory elements and an increased region of homology to elevate the 
targeting efficiency. Plasmid based modification vectors, containing a STOP-box 
and a neokan resistance cassette for positive selection, have been constructed to 
modify the respective BACs by recombineering. The DNA of the resulting 
correctly altered BAC clones, was prepared endotoxin-free, linearized, and used 
for nucleofection into porcine fetal fibroblasts (pFFs) or primary porcine kidney 
cells (pKCs). The propagated single cell clones provided only small amounts of 
cells for subsequent qPCR evaluation through the ‘loss of wild-type allele’-assay. 
Therefore 13 different isolation methods, regarding DNA yield and quality, have 
been compared, pointing out high-salt precipitation as the most suitable method 
among them. In case of CFTR a targeting efficiency of 1.35%, for GGTA1 3.91%, 
has been achieved. Correctly targeted candidate clones were used for nuclear 
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transfer (NT) followed by embryo transfer (ET) to synchronized gilts. Three 
NT/ET experiments were carried out, resulting in two established pregnancies in 
each targeting approach. One pregnancy was terminated after 59 (CFTR) and 58 
(GGTA1) days respectively, and fetuses were recovered for qPCR validation of 
the correct heterozygous targeting. For CFTR six out of seven, in case of GGTA1 
seven out of ten could be ratified as correctly targeted. The other pregnancies 
delivered five correctly targeted CFTR
-/+
 piglets (#9978-#9982) and three 
correctly targeted GGTA1
-/+ 
animals (#9987-#9989). All CFTR
-/+
 animals 
established contracted tendons of the forelegs, but not influencing the welfare of 
these animals, maybe as side effect of SCNT, and one out of these suffered from a 
congenital anal atresia. The GGTA1
-/+ 
animals could be characterized as vital and 
normally developed. As a side project, in order to evaluate the suitability of BACs 
for additive gene transfer as well, the lacZ reporter gene was introduced to be 
transcribed, under the control of the endogenous promoter, instead of the 
respective gene, allowing the determination of CFTR and GGTA1 expression and 
localization in the pig. Seven NT/ET experiments resulted in a total number of 14 
piglets, still needed to be determined by genotyping and regarding their lacZ 
expression. 
These results indicate that the use of BAC vectors combined with SCNT provides 
a suitable strategy for the production of genetically modified pigs, represented by 
the successful targeting, achieving competitive targeting efficiencies, of two 
distinct genes and the additive introduction of the reporter gene lacZ into the 
given loci. 
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7 ZUSAMMENFASSUNG 
BAC-Targeting Etablierung in porcinen Primärzellen. 
Die Etablierung von Großtiermodellen gewinnt immer mehr an Bedeutung, da 
Nager als Modellorganismen in Bezug auf gewisse Anforderungen, vor allem ihre 
Eignung als Krankheitsmodelle, nicht immer ausreichend geeignet sind. Das 
Schwein im Besonderen stellt mittlerweile eine wichtige Ressource in der 
Biomedizin dar, indem es eine Vielzahl von Bereichen als zweckdienliches 
Modell abdeckt. Vorteilhafte Charakteristika, wie etwa die große Ähnlichkeit zum 
Menschen in Größe, Körperbau, Anatomie, Physiologie, Stoffwechsel, 
Organentwicklung und Krankheitsverlauf, aber auch günstige Eigenschaften einer 
standardisierten Umgebungssituation, die gut etablierte Reproduktionstechnologie 
und die weiterentwickelten Techniken zur genetischen Modifikation des 
Schweinegenoms, stellen ideale Voraussetzungen zur Nutzung, sowohl als 
Krankheitsmodell als auch als Modell für die Xenotransplantation, dar. Diese 
Studie verfolgt das Ziel eine Methode zur Einbringung gezielter 
Genomveränderungen zu entwickeln. Dies soll mittels BAC (bakterielle 
artifizielle Chromosomen) Vektoren erreicht werden, deren Anwendung in der 
Großtiermutagenese bisher noch nicht beschrieben wurde. Deshalb wurde ein 
gezielter Knockout des CFTR (cystic fibrosis transmembrane conductance 
regulator) Gens, dessen Mutation für die Entstehung von Mukoviszidose 
verantwortlich gemacht wird, und des GGTA1 (α-1,3-Galactosyltransferase) Gens, 
das eine grundlegende Rolle in der hyperakuten Abstoßungsreaktion von 
Xenotransplantaten spielt, angestrebt. BACs sind zirkuläre Moleküle, die große 
genomische Regionen von Interesse (bis zu 300 kb) tragen können und somit 
gleichermaßen alle benötigten regulatorischen Elemente beinhalten, sowie eine 
größere homologe Region zur Erhöhung der Targetingeffizienz mittels homologer 
Rekombination verfügbar machen. Plasmid-basierte Modifikationsvektoren, die 
eine STOP-Box und eine Neokan Resistenzkasette zur positiven Selektion tragen, 
wurden konstruiert, um BACs mittels Recombineering-Technologie entsprechend 
zu verändern. Die DNA der ordnungsgemäß veränderten BAC-Klone wurde frei 
von Endotoxinen vorbereitet, linearisiert, und zur Nukleofektion in porcine fetale 
Fibroblasten (pFF) oder porcine primäre Nierenzellen (pKC) verwendet. Aus den 
hochgezogenen Einzelzellklonen konnte nur mit geringen DNA-Mengen 
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gerechnet werden, die folglich mittels des qPCR-basierenden „Verlust des 
Wildtypallel“-Assays ausgewertet werden sollten. Deshalb wurden 13 
verschiedene DNA-Isolationsmethoden, bezüglich Ausbeute und Qualität, 
verglichen, wobei die Hochsalz-Fällung als Methode der Wahl ermittelt werden 
konnte. Targetingeffizienzen von 1.35% für CFTR und 3.91% für GGTA1 wurden 
erzielt. Die ordnungsgemäß veränderten Kandidatenzellklone wurden für den 
Kerntransfer verwendet, gefolgt von Embryotransfers auf synchronisierte 
Jungsauen. Drei NT/ET Experimente resultierten in jeweils zwei Trächtigkeiten 
pro Targetingansatz, wobei jeweils eine davon nach 59 (CFTR) und 58 (GGTA1) 
Tagen abgebrochen wurde. Die gewonnen Föten wurden in weiterer Folge mittels 
qPCR auf ein korrektes heterozygotes Targeting hin untersucht. Im Falle des 
CFTR-Ansatzes konnten sechs aus sieben und für GGTA1 sieben aus zehn Föten 
als korrekt getargetet bestätigt werden. Die verbleibenden Trächtigkeiten ergaben 
fünf  korrekt veränderte CFTR
-/+
 Ferkel (#9978-#9982) und drei korrekt 
getargetete GGTA1
-/+
Schweine
 
(#9987-#9989). Bei allen CFTR
-/+
 Ferkeln konnte 
eine Sehnenkontraktion der Vorderläufe festgestellt werden, die aber keine 
weiteren Einschränkungen in der Lebensqualität der Ferkel brachte und 
möglicherweise als Nebenerscheinung des Kerntransfers mit somatischen Zellen 
gewertet werden muss. Eines von diesen Ferkeln litt zusätzlich an einer 
Analatresie. Im Falle der GGTA1
-/+
 Schweine konnten alle als vital und normal 
entwickelt beschrieben werden. Als Nebenprojekt, um die Eignung von BACs 
auch im additiven Gentransfer zu ermitteln, wurde das Reportergen lacZ in die 
beschriebenen Genloci eingeführt, um unter der Kontrolle des jeweiligen 
endogenen Promoters transkribiert zu werden, und so Rückschlüsse auf die 
Expression und Lokalisierung des CFTR beziehungsweise GGTA1 Gens ziehen zu 
können. Aus sieben NT/ET Experimenten konnten insgesamt 14 Ferkel gewonnen 
werden, die allerdings noch bezüglich ihrer lacZ-Expression genauer untersucht 
werden müssen. 
Anhand dieser Ergebnisse konnte gezeigt werden, dass BAC-Vektoren in 
Kombination mit SCNT eine geeignete Methode zur Erstellung genetisch 
modifizierter Schweine bieten. Dies konnte durch das erfolgreiche Targeting, im 
Rahmen wettbewerbsfähiger Targetingeffizienzen, zweier verschiedener Gene 
und der additiven Einbringung des lacZ-Reportergens in die vorgegebenen 
Genloci, hervorgehoben werden. 
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